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ABSTRACT 
Low vitamin D is associated with an increased risk of autoimmune diseases, whose pathology 
might involve TReg and Th17 dysregulation. Thus, understanding how vitamin D modifies 
CD4+ T cell responses holds therapeutic potential. I therefore investigated the effect of 
1,25(OH)2D3, the active form of vitamin D, upon human CD4
+ T cell differentiation.  
 
1,25(OH)2D3 acted directly upon human CD4
+ T cells, suppressing inflammatory cytokines 
(IL-17, IL-21, IFN and IL-22) whilst enhancing regulatory markers (CTLA-4, CD25, FoxP3 
and IL-10). Consistently, 1,25(OH)2D3-treated T cells suppressed division of naive T cells 
stimulated by dendritic cells (DCs). Strong up-regulation of CTLA-4 by 1,25(OH)2D3  
reduced B7 expression by DCs, suggesting that enhanced CTLA-4 could be important 
mechanistically in 1,25(OH)2D3-modified immunity. Furthermore, pro-regulatory effects of 
1,25(OH)2D3 were maintained under inflammatory conditions and modest suppression of 
established IL-17 by 1,25(OH)2D3 was observed, supporting ability of 1,25(OH)2D3 to control 
T cell phenotype at inflammatory sites. DCs could also efficiently convert 25(OH)D3 to drive 
1,25(OH)2D3-modified T cell responses, which might be important in-vivo, given the low 
level of 1,25(OH)2D3 in serum. 
 
Whether dysregulation of the TReg/T17 balance or response to 1,25(OH)2D3 was associated 
with disease outcome in early synovitis patients was also studied. Although the TReg/T17 ratio 
did not stratify with outcome, T cell responses to 1,25(OH)2D3 were observed in all patients, 
suggesting that their VDR signalling is intact and that 1,25(OH)2D3  might be useful in the 
treatment of synovitis.  
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1 INTRODUCTION 
1.1 Role of the immune system 
The prime responsibility of the immune system is to protect the body from infection by 
pathogenic organisms ranging from viruses, through unicellular bacteria, to multi-cellular 
parasites (Bettelli et al., 2006). It also serves to rid the body of altered self-cells, the 
uncontrolled division of which can lead to cancer. To achieve such functions, the immune 
system is comprised of several organs and many cell types, which communicate through cell 
surface and soluble molecules such as cytokines and chemokines. Immune defence operates at 
two levels: the innate and adaptive. The former, which involves both cellular and molecular 
mechanisms, is constitutively present and deals non-specifically with the invading pathogen. 
By contrast, the latter, which involves the activation and differentiation of antigen specific 
CD4+ or CD8+ T lymphocytes and antibody secreting B lymphocytes is a delayed response 
tailored to the pathogen. CD8+ T cells recognise endogenous antigen displayed as linear 
peptides by Class I Major Histocompatibility (MHC) antigens on the surface of all body cells. 
As such, CD8+ T cells deal with the removal of virally infected or altered self-cells. 
Conversely, CD4+ T cells recognise processed exogenous antigens that have been taken up 
primarily by professional antigen presenting cells (APCs), including monocytes, dendritic 
cells (DCs), macrophages and B lymphocytes and presented to them by MHC class II 
molecules. Therefore, CD4+ T cells are important in responses to bacterial, fungal and 
parasitic pathogens. The adaptive immune response also displays the feature of memory. This 
ensures that subsequent infection by the same pathogen is dealt with quickly, usually before 
symptoms develop (Delves and Roitt, 2000a).  
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The essential role of the immune system in protection from disease is clear, since 
abnormalities that cause the loss of its activity result in recurrent infections and severe cases 
of immunodeficiency can lead to death. Equally, inappropriate, excessive activation of 
immune responses can result in debilitating and life threatening autoimmune diseases in 
which the immune system attacks normal self-cells. Thus, the immune system might be 
viewed as a double-edged sword, which whilst serving to protect has the potential to harm. 
Maintaining a balanced immune state is therefore essential and is the key to the prevention 
and treatment of immune disease. By deciphering the molecular and cellular basis of immune 
reactions, and identifying factors that can shift the position of immune homeostasis, potential 
therapeutic targets for immune-related diseases can be determined.  
 
In recent years, a number of environmental factors including dietary vitamins have been 
studied in the context of immunity and seen to affect its balance (Benson et al., 2007; Elias et 
al., 2008; Quintana et al., 2008; Sun et al., 2007; Veldhoen et al., 2009; Veldhoen et al., 
2008a; Xiao et al., 2008). Such information could be useful in the design of prophylactic 
therapies as well as treatments for active disease. Vitamin D is one such factor, which despite 
its longstanding association with calcium and phosphate homeostasis and the avoidance of 
childhood rickets and osteoporosis, has been shown to have immunological effects, 
influencing both innate and adaptive systems (Adams and Hewison, 2008; Holick, 2007). This 
project is particularly concerned with the effect of 1,25-dihydroxyvitamin D3 (1,25(OH)2D3), 
the active form of vitamin D, upon CD4+ T cell differentiation to the T helper 17 (Th17) & 
and inducible TReg  (iTReg) effector lineages.  
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To put the work of this project in context, subsequent paragraphs within this section overview 
the principles behind T cell activation and differentiation, focussing upon the factors required 
for iTReg and Th17 development and their roles in health and disease. Lastly, an overview of 
vitamin D metabolism and evidence that suggests its involvement in the regulation of innate 
and adaptive immune networks is provided.  
 
1.2 T cell activation  
1.2.1 Antigen recognition and co-stimulation signals 
T cell activation, as illustrated in figure 1.1, requires the induction of two signals within the T 
cell. The first stems from the engagement of the T cell receptor (TCR) variable domains with 
the linear peptide antigen displayed by an MHC class II molecule at the surface of an APC. 
All of the TCRs expressed by a single T cell have the same antigen specificity but as a 
consequence of gene rearrangement within the variable domain during T cell development, 
approximately 1010 unique antigen specificities can be generated, which is sufficient to cater 
for the diversity of pathogen motifs. The random nature of the process, however, results in the 
formation of self-reactive T lymphocytes (Delves and Roitt, 2000b). Extensive autoimmune 
attack is avoided as these cells are largely removed in the thymus at the negative selection 
stage and those cells that escape are suppressed in the periphery by tolerance mechanisms. 
(Delves and Roitt, 2000a). 
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Figure 1-1. The immune synapse 
Figure 1.1. The immune synapse. Major Histocompatibility complex (MHC) II 
molecules on antigen presenting cells (APCs) display processed linear antigen to 
CD4+ T cells. The variable domains of the T cell receptor (TCR)  and  chains form 
the antigen binding groove and CD4 co-receptor binds to an invariant site on the 
MHC II molecule. The CD3 co-receptor, whose component  chains (,, and )
contain intracellular immunoreceptor tyrosine based activation motifs (ITAMs), 
mediates intracellular signalling following antigen recognition by the TCR (signal 1). 
Interaction of co-stimulatory CD28 with its B7 ligands, CD80 or CD86, is also 
required for T cell activation (signal 2). CD28 family member, CTLA-4, is induced 
upon T cell activation to inhibit T cell activation.  Abbreviations: IgV domain (V), IgC 
domain (C).
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Figure 1-2. Signalling pathways activated upon T cell receptor ligation
Figure 1.2. Signalling pathways activated upon T cell receptor ligation. Upon 
TCR-antigen-MHCII engagement the TCR-CD3 complex associates with CD4. p56Lck
that is bound to the cytoplasmic tail of CD4 phosphorylates the ITAMs of the CD3 
chains, creating a docking site for tyrosine kinase, ZAP-70, that in turn 
phosphorylates a series of adaptor molecules including LAT, SLP-76 and Vav-1. 
Mitogen activated protein kinase (MAPK) and Phospholipase C (PLC) pathways 
are induced leading to the activation of transcription factors AP-1, NFAT and NFB
and a change in gene expression (red arrows indicate phosphorylation involvement). 
The expression of IL-2 is one early response, required to instigate T cell proliferation. 
Activation of the small G protein, Rho/Rac-GTPase, results in cytoskeletal 
remodelling that is essential for migration of the T cell and its closer interaction with 
its target cell. 
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Signal transduction cannot extend directly from the TCR due to the lack of appropriate motifs 
within its short cytoplasmic tails. Instead signal transduction is achieved through the six chain 
CD3 co-receptor with which the TCR associates (Delves and Roitt, 2000b). Transcription 
factors AP-1, NF-AT and NF-B are activated downstream of CD3 signalling to induce T cell 
activation. One early response is the induction of cytokines such as interleukin-2 (IL-2), 
which is important for the initiation and maintenance of T cell proliferation (figure 1.2) 
(Razzaq et al., 2004).  
 
The second signal, defined as a co-stimulatory signal is apparently required to prevent clonal 
anergy, in which the T cell is incapable of proliferation and IL-2 secretion (Schwartz, 1996). 
It stems from the engagement of the transmembrane receptor molecule, CD28 with its cognate 
B7 ligand, either CD80 (B7-1) or CD86 (B7-2) expressed by the APC. Downstream responses 
to CD28 stimulation are the induction of glucose metabolism, high IL-2 production, T cell 
proliferation and resistance to apoptosis (reviewed in (Carreno and Collins, 2002; Lenschow 
et al., 1996)). The importance of CD28 co-stimulation is seen in the phenotype of the CD28 
knock out mouse, which has decreased sensitivity to antigen, reduced IL-2 production and a 
lack of maintained T cell proliferation (Shahinian et al., 1993). Additionally, immunoglobulin 
concentrations are much lower in CD28-deficient mice compared to wildtype controls and 
CD28-deficient mice show defects in isotype class switching and germinal centre formation 
(Ferguson et al., 1996; Lucas et al., 1995). Likewise, CD80 and CD86 knockout mice show 
defects in humoral and cellular immune responses (Borriello et al., 1997). The biological 
significance of the two CD28 ligands, which have strong structural homology (reviewed in 
(Collins et al., 2005)), is not known but their conservation across species (Collins et al., 2005) 
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argues for redundancy in the system or that the two ligands have distinct functions. In-vitro 
evidence supports the later, since resting T cells when stimulated with anti-CD3 in the 
presence of CD80 or CD86 alone show differences in cytokine production and the expression 
of surface molecules (Odobasic et al., 2008).  
 
1.2.2 CTLA-4 mediated suppression of T cell activation 
Induction of the CD28 family member, cytotoxic T-lymphocyte associated-4 (CTLA-4), is 
one response that lies downstream of T cell activation. CTLA-4 expression is evident as early 
as six hours and reaches its maximum level by 36 hours (Lindsten et al., 1993). In addition to 
TCR signalling, CD28 and IL-2 independently and additively enhance CTLA-4 expression 
(Alegre et al., 1996). Although, CTLA-4 shares 30% homology with CD28, they have 
opposite roles, as CTLA-4 is required to suppress T cell activation rather than to promote it. 
This function is evident from the fact that CTLA-4 knockout mice die from 
hyperlymphoproliferative disorders (Tivol et al., 1995; Waterhouse et al., 1995). Thus, 
together, the phenotypes of CD28 and CTLA-4 knockout mice highlight the importance of 
both stimulatory and suppressive immune mechanisms for survival.  
 
In contrast to CD28, CTLA-4 is localised primarily in intracellular vesicles (Egen and 
Allison, 2002; Linsley et al., 1996) but in response to TCR activation it is trafficked to the cell 
surface, towards the sites of TCR activation. New protein is not synthesised (Schneider et al., 
1999) but the extent of surface expression is dependent upon the strength of the TCR signal 
(Egen and Allison, 2002). This mechanism therefore allows for balance in the strength of 
stimulatory and inhibitory signals. CTLA-4 exocytosis might depend upon the activities of 
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GTPase ADP-ribosylation factor 1 and phospholipase D (Mead et al., 2005). By contrast, 
endocytosis of CTLA-4 from the plasma membrane involves binding of the 2 chain of AP-2 
clathrin associated adaptor complex to the phosphotyrosine motif YVKM, within the 
cytosolic tail of CTLA-4 (Shiratori et al., 1997). Interestingly, the same YVKM motif could 
be the means by which CTLA-4 delivers a cell-intrinsic negative signal, since tyrosine 
phosphatases such as Syp (Marengere et al., 1996) and SHP-1 (Guntermann and Alexander, 
2002) can be recruited to it and might in turn inactivate components of the TCR signalling 
cascade. Since AP-2 2 binds to the YVKM motif in the absence of phosphorylation it 
appears that the phosphorylation status of a single tyrosine could determine whether CTLA-4 
delivers a negative signal or whether it is internalised (Shiratori et al., 1997). The clathrin 
adaptor protein complex, AP-1, can also associate with the YVKM motif of CTLA-4. 
However, in contrast to AP-2, AP-1 and CTLA-4 associate predominately within the golgi 
compartment, although binding to AP-1 may also regulate the distribution of CTLA-4 to 
lysosomal compartments. Thus, by directing excess CTLA-4 to the lysosomes for 
degradation, AP-1 might be a homeostatic regulator of intracellular CTLA-4 (Schneider et al., 
1999).  
 
Consistent with its high homology to CD28, CTLA-4 interacts with CD80 and CD86 and in 
agreement with the role of CTLA-4 in suppressing B7-CD28 co-stimulatory signals, mice 
triply deficient for CD80, CD86 and CTLA-4 did not show the autoimmune phenotype of 
CTLA-4 knockout mice (Mandelbrot et al., 1999). The affinity of CTLA-4 for both CD80 and 
CD86 is greater than the affinity of CD28 for both ligands (Carreno et al., 2005; Carreno and 
Collins, 2002; van der Merwe et al., 1997) (figure 1.3). Therefore, absence of CTLA-4 prior 
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to simulation is important to permit CD28-driven T cell activation but when CTLA-4 is 
subsequently expressed, its high affinity for CD80 and CD86 enables it to efficiently suppress 
CD28-mediated co-stimulation. In addition, during the course of stimulation, CD80 
expression by the APC is increased relative to CD86. Because the CTLA-4/CD28 relative 
affintiy is greater for CD80 than CD86, this change in the CD80/CD86 ratio could help to 
maximise the efficiency of CTLA-4-mediated suppression. These differences in binding 
affinities and temporal patterns of B7 expression could contribute to differences in T cell 
responses following stimulation by CD80 or CD86 alone (Lenschow et al., 1996; Odobasic et 
al., 2008). As well as simply competing with CD28 for binding to B7, in-vitro and in-vivo 
data by others in my lab (Qureshi et al., manuscript in preparation) strongly suggest a 
mechanism of transendocytosis, in which engagement of B7 with CTLA-4 leads to 
internalisation of the ligand by the T cell and its subsequent lysosomal degradation. Such a 
mechanism is clearly consistent with the continual cycling of CTLA-4 between the plasma 
membrane and intracellular compartments upon TCR stimulation. In addition, by this model, 
one CTLA-4 expressing cell could suppress itself and neighbouring cells rather than itself 
only, as the model of binding competition suggests.  
 
1.2.3 Other CD28 and B7 family co-stimulatory systems 
The CD28/CTLA-4–CD80/CD86 co-stimulatory system represents the first and best 
understood of several CD28 family-B7 co-stimulatory systems, which over the past decade 
have been identified and become recognised participants in the regulation of T cell activation. 
Other CD28 family receptors expressed by leukocytes include: inducible co-stimulator 
(ICOS), programmed cell death-1 (PD-1) and B and T lymphocyte attenuator (BTLA), and 
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other B7 ligands include: ICOS-L (B7-H2), PD-L1 (B7-H1), PD-L2 (B7-DC), B7-H3 and B7-
H4 (Carreno et al., 2005). Both haematopoietic and non-hematopoietic cells express these 
ligands. The importance of these molecules in the regulation of T cell activation and their 
roles as either inducers or inhibitors has been confirmed through knockout mice studies in 
which immunosuppressive or autoimmune disorders developed respectively in their absence 
(reviewed in (Carreno et al., 2005; Carreno and Collins, 2002)). Figure 1.3 summarises the 
distribution and binding partners of CD28 receptor and B7 ligand family members. Although, 
the precise functions and relative requirements of these co-stimulatory receptors and ligands 
is not yet known, their differential expression patterns might allow for finer regulation of T 
cell activation than is possible through the CD28/CTLA-4-CD80/CD86 system alone. 
Heterotypic binding, has also been seen within this family of ligands and receptors, for 
example between CD80 and the PD-1 ligand, PD-L1 (Butte et al., 2007). Conceivably, such 
alternative interactions could permit even finer tuning of T cell activation. 
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Figure 1-3. CD28 receptor family members and their B7 ligands 
 
Figure 1.3. CD28 receptor family members and their B7 ligands. A)  CD28 family 
receptors and their B7 family ligands have conserved structures: The receptors are 
single pass transmembrane proteins with a single IgV motif in their extracellular IgV 
domain. The B7 ligands have one IgV and one IgC motif in their extracellular domain. 
Interaction between the ligands and receptors is largely via their IgV motifs. Both co-
stimulatory () and co-inhibitory () interactions are seen. With the exception of 
CD28 and CD86 and ICOS-L expression is not constitutive (C) but is induced upon 
activation (I). Receptors are expressed by T cells, although PD-1 is also expressed 
on monocytes and B cells. B7 ligands are expressed by DCs, B cells and monocytes, 
although expression by non-haematopoietic cells is also observed for some ligands 
(*). B) CD28 and CTLA-4 both bind to CD80 and CD86 but their binding affinities are 
different. The order of their binding affinities is shown.  
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T cell differentiation 
The role of CD4+ T cells in the adaptive immune response is to orchestrate the activities of 
other effector cells whose reactions in turn kill the pathogen. They achieve this in the main by 
soluble factors including cytokines and chemokines that they release and it is according to 
their cytokine profile that CD4+ T cells are classified into differentiation lineages (figure 1.4). 
Mossmann and Coffman introduced the concept of T cell differentiation over twenty years 
ago. They proposed a binary model wherein a naive CD4+ (Th0) cell can differentiate into one 
of two terminal effector fates: T helper 1 (Th1) or T helper 2 (Th2) (Mosmann and Coffman, 
1989). Th1 cells release interferon gamma (IFN) and tumour necrosis factor (TNF), through 
which they instigate delayed-type-hypersensitivity responses effective in the clearance of 
intracellular pathogens as well as virally infected or cancerous cells. Aberrant activation of 
these cells is associated with inflammatory disease. By contrast, Th2 cells release cytokines 
including IL-4, IL-5, IL-9, IL-10 and IL-13 that induce B cell antibody class switching to IgE, 
mast cell proliferation and degranulation, and eosinophilia. These reactions facilitate the 
killing of extracellular parasites such as helminths (Bettelli et al., 2007; Harrington et al., 
2005; Park et al., 2005). Aberrant activities of these cells in response to innocuous antigens 
are associated with allergy and asthma.   
 
Much work has been done to determine the signals that govern the differentiation of CD4+ T 
cells into each type. These studies have led to the hypothesis that polarisation is primarily 
controlled at the level of the APC, which matures to a particular phenotype following its 
direct activation through detection of pathogen products by Pattern Recognition Receptors 
(PRRs) or the detection of tissue factors that are released from neighbouring cells in response 
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to their detection of the pathogen. As such, the terms DC1 and DC2 have been assigned to 
mature DCs that direct the development of Th1 and Th2 cells respectively (Kaiko et al., 2008; 
Rissoan et al., 1999). However, how particular pathogens promote each type of T cell 
response is still poorly understood. 
 
1.2.4 Th1 and Th2 differentiation  
An environment enriched in DC and macrophage derived IL-12, type 1 interferons (IFN and 
IFN) and potentially IL-18 (Kaiko et al., 2008) favours Th1 development, as IL-12 signals 
through signal transducer and activator of transcription factor 4 (STAT4) to drive IFN 
expression. This in turn signals through STAT1 to promote T-bet expression, the Th1 
signature transcription factor. T-bet fixes the Th1 phenotype by itself driving IFN and IL-12 
receptor expression (figure 1.5). By contrast, IL-4, which might be released by natural killer 
T cells, eosinophils and mast cells, drives Th2 development. Through STAT6, IL-4 induces 
GATA-3, the hallmark Th2 transcription factor. GATA-3 induces Th2 associated cytokines 
and suppresses IL-12R2, thereby desensitizing T cells to pro-Th1 conditions. Similarly, 
during Th1 development, T-bet down-regulates IL-4. In addition to GATA-3, the transcription 
factor c-MAF supports Th2 differentiation by inducing IL-4 expression (figure 1.5) (Dong, 
2006).  
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1.2.5 Other CD4+ T helper cell lineages 
In recent years, it has become apparent that the binary model of CD4+ T cell differentiation is 
not sufficient. Rather, as shown in figure 1.4, the CD4+ T cell differentiation map now 
includes inducible TRegs (iTReg), T helper 17 (Th17), T follicular helper (Tfh) (Vogelzang et al., 
2008), T helper 9 (Th9) (Veldhoen et al., 2008b) and T helper 22 (Th22) (Trifari et al., 2009) 
effector T cells. The increased availability of fluorophores and cytokine staining reagents may 
well lead to the discovery of additional subsets with specific cytokine and cell surface protein 
expression patterns and subsequently to the designation of additional CD4+ lineages. Of the 
newer CD4+ lineages, the immunoregulatory iTReg and pro-inflammatory Th17 cells are the 
best studied.  
 
The cytokines required for iTReg and Th17 differentiation in humans and mice are largely 
resolved and their significance in health and disease is being studied. Their potential to be 
reciprocally regulated by a number of exogenous factors makes them particularly attractive 
therapeutic targets for the restoration and maintenance of immune homeostasis. Since this 
study is concerned with the differentiation of CD4+ T cells to the iTReg and Th17 lineages, the 
following paragraphs overview the history of their discoveries, function and differentiation.  
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Figure 1.4. CD4+ T cell classes. Naive CD4+ T cells activated in the periphery 
differentiate into effector CD4+ T cells that by their release of certain cytokines direct 
an immune response that is tailored to a particular pathogen. Cytokines present at 
the time of antigen presentation (indicated on arrows) are largely responsible for the 
lineage chosen as they control the expression and activities of lineage transcription 
factors (indicated in nuclei). The effector classes presently defined include: T helper 1 
(Th1), T helper 2 (Th2), T helper 17 (Th17), T helper 9 (Th9) and T helper 22 (Th22).  
CD4+ T cells also differentiate into regulatory T cells (TReg). The hallmark cytokines of 
each lineage are coloured the same as the cell that releases them. Dysregulation of 
CD4+ T cell activities leads to disease. Functions of the CD4+ T cell lineages in 
immune homeostasis and disease are detailed in like-colour boxes above or beneath 
them.  Pale boxes indicate pathogens cleared by the cells. Dark boxes list diseases 
associated with the T cell lineage. 
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Figure 1-5. Cross regulation in Th1 and Th2 differentiation 
 
Figure 1.5. Cross regulation in Th1 and Th2 differentiation. Cytokines in the 
environment at the time of naïve T cell activation are largely responsible for the 
differentiation pathway chosen. Cross regulation ensures the efficient expansion of 
one lineage. In Th1 differentiation, IL-12, produced by the APC, induces the activation 
of signal transducer and activator of transcription 4 (STAT4) that induces IFN 
transcription and expression. IFN feeds back positively, activating transcription 
factor T-bet via STAT1. T bet promotes IFN production and inhibits Th2 cytokine 
expression via GATA-3. Th2 differentiation is promoted in an IL-4 rich environment. 
IL-4 signals via STAT6 to increase expression of the Th2 lineage transcription factor, 
GATA-3. GATA-3 drives the expression of Th2 cytokines but suppresses T-bet and 
therefore Th1 development. IL-4 expression is also promoted by transcription factor c-
Maf.  
 
Introduction 
17 
 
1.2.6 Regulatory CD4+ T cells (TRegs) 
The concept of a suppressor cell was introduced in the 1970s (Gershon and Kondo, 1970), 
however its potential existence lost presidency as researchers struggled to define the 
molecular identity of these cells. In 1995 Sakaguchi et al. showed that CD4+ T cells, which 
constitutively expressed the IL-2 receptor  chain, CD25, had immunosuppressive functions 
both in-vivo and in-vitro (Sakaguchi et al., 1995). Since then, the existence of a regulatory T 
cell subset (TReg) has become widely accepted and their importance in both health and disease 
acknowledged. It is now believed that TRegs potently suppress the proliferation or functions of 
CD4+, CD8+, NK cells, NK-T cells, DCs and B cells (Cederbom et al., 2000; Piccirillo and 
Shevach, 2001; Seo et al., 2002; Thornton and Shevach, 1998; Trzonkowski et al., 2004). 
Furthermore, it is recognised that suppression of T cell responses is independent of antigen 
specificity (Marie et al., 2005), although TRegs require antigen stimulation to function.  T cells 
with regulatory capacity have been identified in both the CD4+ and CD8+ divisions (Jiang and 
Chess, 2006; Kaiko et al., 2008) but most work has focussed on those from the former class, 
for which two subsets, the natural (nTRegs) and iTRegs, are defined. Together, these cells 
account for 5-10% of peripheral CD4+ cells (Marie et al., 2005; Thompson and Powrie, 2004) 
but to what extent they use similar mechanisms is not established. 
 
nTRegs develop in the thymus during the early stages of foetal and neonatal T cell 
development. Although the TCR repertoire of nTRegs is as varied as that of naive T cells and 
there is some overlap, in general, it is skewed towards the recognition of self-antigen. This 
implies a major role for nTRegs in protection from autoimmunity (Hsieh et al., 2006; Jordan et 
al., 2001; Sakaguchi et al., 2003). Consistent with this, depletion of nTRegs led to the 
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development of a variety of autoimmune disorders such as thyroiditis, gastrititis, orchitis, 
oophoritis, Type 1 diabetes (T1D) and inflammatory bowel disease (IBD) which could be 
prevented by provision of normal CD4+CD25+ T cells (reviewed in (Piccirillo, 2008)). 
However, nTRegs also provide tolerance to commensual bacteria, innocuous environmental 
antigens and provide foeto-maternal tolerance during pregnancy (reviewed in (Piccirillo, 
2008; Sakaguchi, 2004; Sakaguchi et al., 2006)).  
 
The highly conserved forkhead/winged helix transcription factor, FoxP3, has been defined the 
master regulator of the TReg lineage. This follows identification that loss of the FoxP3 protein 
due to a natural X-linked mutation in the foxP3 gene accounts for the lethal Scurfy phenotype 
of mice, in which CD4+ T cells are hyperactive and show enhanced cytokine production 
(Fontenot et al., 2003; Khattri et al., 2003). Likewise, in humans, the rare disease, immune 
dysfunction, polyendocrinopathy, enteropathy, X-linked (IPEX) syndrome, that is 
characterised by autoimmune diseases, allergies, hyper IgE production and many 
haematological and infectious diseases, occurs as a result of mutations in the foxP3 gene 
(Bennett et al., 2001; Gambineri et al., 2003; Sojka et al., 2008). Furthermore, FoxP3 is 
expressed at high levels by both murine and human TRegs and over expression of FoxP3 
converted naive T cells to a regulatory phenotype (Hori et al., 2003), suppressed diabetes in 
NOD mice (Jaeckel et al., 2005) and delayed disease in CTLA-4-/- mice (Khattri et al., 2003). 
Indeed, FoxP3 is presently the most reliable marker for TRegs in both rodents and humans 
(Ziegler, 2006). However, whilst dual expression of CD25 and FoxP3 clearly delineates TRegs 
in mice, this may not be true in humans, since CD25 is expressed on pro-inflammatory as well 
as anti-inflammatory cells (Kleinewietfeld et al., 2009) and human CD4+CD25-  T cells up-
regulate FoxP3 transiently upon activation (Allan et al., 2007). To aid the purification of TReg 
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cells for functional assays, additional biomarkers are being investigated. Whilst a number 
have been proposed, including high expression of glucocorticoid induced tumour necrosis 
factor receptor (GITR), IL-2R (CD122), CD103 and low levels of CD45RB, CD127 and 
CD49d (Liu et al., 2006b; Seddiki et al., 2006; Vignali et al., 2008) they too are present on 
activated T cells. Nonetheless, it is now considered that negative selection for CD49d-CD127- 
cells, provides an acceptably pure, untouched TReg population from peripheral human blood 
that is devoid of CD25+ effector cells (Kleinewietfeld et al., 2009).  
 
The importance of FoxP3 in TReg function, might be that it establishes the molecular 
programme of these cells. This it achieves through interaction with a range of other 
transcription factors including NFAT, AML-1 (acute myeloid leukaemia-1)/Runx-1 (runt 
related transcription factor- 1) the histone-acetyltransferase (HAT)/histone deacetyltransferase 
(HDAC) complex and NF-B. Following activation, NFAT complexes with AP-1 and NF-B 
to promote the expression of genes such as Il-2, Il-4 and ctla-4 (reviewed in (Piccirillo, 
2008)).  
 
In addition, to FoxP3, IL-2 appears to play a significant role in nTReg development, since mice 
deficient for IL-2, IL-2R (CD25) or IL-2R (CD122) show similar symptoms to Scurfy 
mice, dying from severe lymphoproliferative and autoimmune disorders and hyper-reactivity 
to commensual microbes (Malek et al., 1984; Malek et al., 2002; Wolf et al., 2001). Likewise, 
CD25 deficiency in humans results in a disease similar to IPEX (Caudy et al., 2007). 
However, it seems that IL-2 is necessary for maintenance of nTRegs in the periphery rather 
than their induction in the thymus, since T cells from IL-2 deficient mice expressed FoxP3 
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and suppressed T cell proliferation in vitro, even though reduced numbers of these cells were 
found in-vivo (Fontenot et al., 2005). It is possible that other common-gamma chain cytokines 
substitute for IL-2 in the thymus, since common  chain-deficient mice showed complete 
absence of FoxP3+ nTRegs. In particular, a role for IL-15 is suggested as TReg production is 
greatly reduced in IL-2 and IL-15 double deficient mice or in mice deficient in IL-2R, which 
is required for both IL-2 and IL-15 signalling (Burchill et al., 2007; Soper et al., 2007). In 
addition, a role for IL-7 in nTReg development has been proposed, although the finding that 
IL-7 deficient mice have normal numbers of nTRegs suggests that IL-7 might be redundant in 
nTReg development (Liston and Rudensky, 2007). Lastly, strong co-stimulation through 
CD28-B7 is required for nTReg induction. This might be to induce sufficient IL-2 but a cell 
intrinsic requirement for CD28 is also suggested (Bennett et al., 2001; Tai et al., 2005).  
 
In contrast to nTRegs that are released from the thymus as active self-antigen specific 
suppressor cells, iTRegs develop in the periphery from CD4
+CD25- T cells. Initial evidence for 
the existence of iTRegs was the finding that FoxP3
+ T cells expressing CD25, CTLA4 and 
GITR that had suppressive activity could be isolated from lymphopenic mice that had 
received polyclonal CD4+CD25- T cells (Curotto de Lafaille, 2004). It is now contended that 
various other types of CD4+ iTRegs exist, including IL-10 and TGF expressing Tr1 that do not 
stably express FoxP3 (reviewed by (Battaglia et al., 2006)) and TGF expressing Th3 (Chen 
et al., 1994). In addition, CD4+ T cells that expressed LAG-3 but had low CTLA-4, FoxP3 
and GITR expression have been identified and might represent another iTReg class but 
distinctions between iTReg classes are still not clear (reviewed in (Lan et al., 2005)).  Since 
iTRegs derive from conventional T cells, their TCRs should be specific to non-self antigens 
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(Hsieh et al., 2006; Pacholczyk et al., 2006). Thus, iTRegs might be responsible for establishing 
tolerance to commensuals, and innocuous antigens, rather than providing tolerance to self 
alongside their nTReg counterparts. Therefore, iTRegs may be particularly important at mucosal 
sites such as the gut. However, it has been shown that TRegs can transfer tolerance (Qin et al., 
1993), thus, iTRegs may mediate suppression following nTReg stimulation to self-antigen and 
thus provide protection from autoimmunity. Differentiating between the functions of nTRegs 
and iTRegs has been hampered by the lack of distinguishing markers (Curotto de Lafaille and 
Lafaille, 2009). In addition, much work on the features of iTRegs has utilised in-vitro generated 
iTRegs, which may not truly reflect the properties of in-vivo induced iTRegs. Indeed, it is 
contended that in-vitro induced TRegs might not be as suppressive as nTRegs, with human in-
vitro generated iTRegs requiring several rounds of stimulation to become suppressive (Curotto 
de Lafaille and Lafaille, 2009; Horwitz et al., 2008b; Shevach et al., 2008).  By contrast, in-
vivo generated iTRegs are considered effective suppressors (Apostolou and von Boehmer, 2004; 
Cobbold et al., 2004; Mucida et al., 2005). Consistent with distinct behaviours for nTRegs and 
in-vitro induced iTRegs, gene expression analysis revealed that iTRegs lack a component of the 
nTReg signature genes (Hill et al., 2007). In addition, in-vitro generated iTRegs lack 
demethylation of the conserved TReg cell specific demethylated region (TSDR) region, located 
upstream of exon 1 of the foxp3 gene, which is demethylated in nTRegs (Floess et al., 2007). 
By contrast, efficient demethylation of this locus was observed in in-vivo generated iTRegs 
(Polansky et al., 2008), which further supports the view that in-vitro and in-vivo generated 
iTRegs might not be mirror images of each other. However, it is possible that respective 
analysis at six days versus three weeks post antigen exposure in these studies could explain 
the discrepancy. Nonetheless, lack of TSDR demethylation might account for the instability 
of FoxP3 expression in in-vitro generated iTRegs. Another recently identified distinction 
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between natural and induced TRegs is the selective expression of Helios, a member of the 
Ikaros transcription factor family, in the former group (Thornton et al., 2010). 
 
The conditions under which iTRegs differentiate in-vivo are not clearly defined, indeed multiple 
micro-environments could be employed (Curotto de Lafaille and Lafaille, 2009). However, it 
is well established that both mouse and human  iTRegs can develop in-vitro by TCR 
stimulation in the presence of TGF and IL-2 and in contrast to nTReg development co-
stimulation might not be required (Apostolou and von Boehmer, 2004; Kretschmer et al., 
2005). This might explain why presentation of antigen by immature DCs promotes TReg 
development (Wakkach et al., 2003). TGF signalling involves receptor dependent 
phosphorylation of receptor associated Smads (2 or 3) followed by their heterodimerisation 
with the co-Smad, Smad4 to form a complex that binds to regulatory elements in its target 
genes and interacts with other DNA binding factors to control gene expression (O'Shea et al., 
2009). Consistent with the requirement of TGF for iTReg development, recent ChIP analysis 
of the foxP3 locus identified a Smad3 binding site in an enhancer site upstream of the FoxP3 
ATG start site (Tone et al., 2008; Xu et al., 2010). Binding of Smad3 at this site was found to 
precede its recruitment to the promoter region where it completed the assembly of an 
enhanceosome complex. Whilst Smads 2, 3 and 4 all appear to have non-redundant function 
in iTReg development, deficiency in any single gene does not impair nTReg function and only 
mildly affects nTReg numbers (Malhotra et al., 2010; Martinez et al., 2009; Takimoto et al., 
2010; Yang et al., 2008c). This is perhaps consistent with the fact that TGF is required for 
peripheral maintenance but not the induction of nTRegs (Marie et al., 2005). The importance of 
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TGF in TReg development is further evident, as deficiencies in TGF lead to pathologies 
similar to those associated with foxp3 deficiency (Marie et al., 2005) and (Chen et al., 2003). 
 
1.2.7 Suppressive mechanisms employed by TRegs 
Since their discovery, much work has been done to identify the mechanisms by which TReg 
cells suppress the functions of their target cells. Most studies have employed in-vitro assays. 
Direct effects of TRegs upon responder T cells versus indirect effects via APCs have been 
investigated with APC free and APC present systems respectively. In the former, suppression 
typically required high TReg to responder ratios and low concentrations of the stimulation 
reagent. Direct mechanisms suggested include, IL-2 consumption, release of inhibitory 
cytokines such as IL-10, TGF and the novel cytokine, IL-35, direct granzyme A and perforin 
or granzyme B mediated cytolysis or the induction of cell cycle arrest and apoptosis by 
soluble or cell surface galectin-1 (figure 1.6) (Shevach, 2009). However, contention 
surrounds many of the mechanisms proposed. For example, although IL-2 consumption by 
TRegs is an appealing mechanism, given that IL-2R chains (CD25, CD122 and CD132) are 
expressed at high levels by TRegs, the suggestion that exogenous IL-2 could not overcome 
suppression of IL-2 mRNA transcription by CD4+CD25-  T cells co-cultured with 
CD4+CD25+ T cells might imply that IL-2 consumption is not a critical mechanism (Thornton 
et al., 2004). Furthermore, blocking CD25 did not affect suppression by human TReg cells 
when TCR and CD28 signals were sufficiently strong (Tran et al., 2009). The importance and 
mechanism of TGF mediated suppression is likewise not clear: suppression by TGF could 
involve soluble or cell-contact mechanisms, since latent TGF has been detected on the 
surface of resting and activated CD25+ T cells, coupled to the latency-associated peptide 
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(LAP) (Andersson et al., 2008; Nakamura et al., 2001). However, most in-vitro studies have 
failed to inhibit suppression with anti-TGF, thus questioning its role. Conversely, in-vivo 
studies suggest a non-redundant role for TGF in suppression of IBD. Whilst it might be that 
TRegs are not the source of TGF (reviewed in (Shevach, 2009)), mice with a T cell specific 
defect in TGF production or processing developed IBD-like symptoms (Li et al., 2007; Pesu 
et al., 2008), therefore supporting the involvement of T cell produced TGF. The story for IL-
10 is similar to that of TGF, as in-vitro studies have generally failed to demonstrate its 
requirement in TReg mediated suppression (Shevach, 2009), whilst in-vivo studies again 
demonstrate importance of IL-10 secretion by TRegs (Belkaid, 2007; McGeachy et al., 2005). 
Ultimately, in-vitro suppression needs to be interpreted cautiously.  
 
Several indirect, APC mediated suppression mechanisms have also been proposed that in 
general involve suppression of antigen presentation or co-stimulatory capacities. 
Accumulating evidence from both in-vitro and in-vivo work suggests that the high constitutive 
expression of CTLA-4 by TRegs contributes greatly to their suppressive action (Friedline et al., 
2009; Kolar et al., 2009; Onishi et al., 2008; Read et al., 2006; Schmidt et al., 2009; Tivol et 
al., 1995; Waterhouse et al., 1995; Wing et al., 2008; Zheng et al., 2008b).  Importantly, 
CTLA-4 blockade or deletion of CTLA-4 in TRegs, prevented the down regulation of CD80 
and CD86 seen when TRegs were co-cultured with DCs (Onishi et al., 2008; Wing et al., 2008). 
Furthermore, selective deletion of CTLA-4 from TRegs induced systemic autoimmunity (Read 
et al., 2006). Although the biochemical nature of ex-vivo suppression awaits clarification, 
mechanisms by which CTLA-4 regulates T cell activation, including competition with CD28 
for B7 engagement and transendocytic depletion of B7, as described previously, are probably 
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involved. It has also been suggested that the engagement of CTLA-4 with CD80/86 leads to 
induction of indoleamine 2,3-dioxygenase (IDO) by the DC (Grohmann et al., 2002). IDO 
catabolises tryptophan to pro-apoptotic metabolites, such as kinurenins, that might in turn 
suppress the activation of responder T cells. However, there is little clear in-vivo or in-vitro 
evidence for the function of IDO in TReg mediated suppression (Shevach, 2009). Through 
their expression of LAG-3, a CD4 homologue that binds to MHC class II with high affinity, 
TReg cells might suppress DC maturation and stimulatory capacity (Liang et al., 2008). Yet 
another mechanism of suppression could involve the ability of TRegs to limit ATP induced 
induction of CD86, since TRegs, express the ectoenzyme, CD39, which hydrolyses ATP to 
ADP and AMP (Borsellino et al., 2007). ATP is released from damaged cells and might 
therefore be at high concentration at sites of inflammation. By metabolising ATP, TRegs would 
help to reduce the ATP-enhanced stimulatory capacity of the APC. Lastly, imaging studies 
suggest that TRegs, which are more mobile than naive cells outcompete them for clustering 
around DCs (Onishi et al., 2008). In addition, TRegs, reduced the time of association between 
DCs and T effector cells in-vivo (Tadokoro et al., 2006). Consistent with these findings, TRegs 
suppressed the clustering of diabetogenic TCR-transgenic T cells in pancreatic lymph nodes, 
thus reducing their chance of activation (Tang et al., 2006). One molecule that might favour 
the interaction of DCs with TRegs versus effector T cells is neuropillin (Nrp-1), since it is 
preferentially expressed on TRegs and enhances their interactions with dendritic cells during 
antigen recognition (Sarris et al., 2008). A role for leukocyte function-associated antigen-1 
(LFA-1) in this mechanism is also proposed (Onishi et al., 2008). Taken together, the in-vitro 
studies imply that TRegs employ a multitude of suppressive mechanisms, however, whether 
they are all relevant in-vivo and whether others exist, remains to be established.  
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Understanding how, when and where TRegs function could be important therapeutically, given 
that deregulation of TReg frequencies, defective TReg function or effector cell resistance to TReg 
suppression is implicated in a number of diseases. These include: chronic infections and 
cancer as well as autoimmune conditions such as, type 1 diabetes (T1D), multiple sclerosis 
(MS), rheumatoid arthritis (RA), psoriasis, inflammatory bowel disease (IBD) and systemic 
lupus erytheromatosus (SLE) (reviewed in (Buckner, 2010; Piccirillo, 2008)). However, it 
would appear that with the exception of IPEX syndrome, human diseases do not obviously 
reveal a general deficiency of TReg numbers. Indeed, for T1D and MS, most studies indicate 
that the frequency of TRegs in the peripheral blood of patients does not differ from that of 
healthy controls, whilst in RA and IBD mixed results have been obtained, including reports of 
increased and decreased frequencies. Most studies, however agree that TReg frequencies are 
increased at the disease site. Although, counterintuitive, the demonstration that TReg 
suppressive function is less effective in the listed autoimmune conditions, with the exception 
of IBD, could explain the finding. Given that activated T cells express markers of TRegs, 
including FoxP3 (Walker et al., 2003), it might be hypothesised that the apparent enrichment 
of CD25+FoxP3+ cells at inflammatory sites represents an accumulation of activated effector 
T cells. However, the fact that these cells could exert suppressive effects, albeit defective in 
some cases, might argue against this hypothesis. The accumulation of TReg cells as well as 
effector cells at inflammatory sites could be explained instead by the fact that they share the 
expression of some chemokine receptors that are responsible for homing to inflamed sites 
(Lim et al., 2006). Examples include CCR4, associated with skin homing (Campbell et al., 
1999), CCR6 that could home cells to an inflamed joint (Hirota et al., 2007) and 47 that 
directs T cells to the gut (Hamann et al., 1994). In addition, IFN inducible CXCR3, that is 
expressed by Th1 cells as well as CD8
+, NK and NKT cells to direct their movement to 
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inflamed sites, has been detected along with T-bet on a subset of FoxP3+ cells at sites of Th1 
inflammation (Koch et al., 2009). Although, it is difficult to establish a causative link between 
TReg cells and inflammatory disease, their involvement is supported by the fact that depletion 
of TRegs in animal models exacerbates disease supports their involvement. Furthermore, some 
clinically effective treatments such as anti-TNF (infliximab) in RA (Ehrenstein et al., 2004), 
IFN in MS (Venken et al., 2008) and corticosteroids in SLE (Suarez et al., 2006) were able 
to increase TReg cell frequencies. Whether local defects in TReg function are the cause or 
consequence of the inflammation in these conditions is presently not understood but it will be 
important to determine the mechanisms involved. It will also be important to identify if 
dysregulation of TRegs results from cell intrinsic or extrinsic environmental factors. If 
environmental factors are to blame, adoptive transfer of ex-vivo cultured TRegs in therapy 
might not be particularly successful. In this regard, it has been shown that FoxP3+ TRegs can be 
converted to inflammatory effector populations, including Th1 and Th17 (Beriou et al., 2009; 
Koenen et al., 2008; Zhou et al., 2009b), the outcome being determined by the 
microenvironment (Zhou et al., 2009b). Understanding the involvement of TReg cells in 
response to infection could have implication in the design of vaccination strategies, as it is 
generally the case that TRegs (CD4
+FoxP3+ cells) are present at increased frequencies in 
response to bacterial, parasitic or viral infection (reviewed by (Curotto de Lafaille and 
Lafaille, 2009)). Their presence could therefore impede successful vaccination. Likewise, the 
action of TRegs could prevent the success of cancer immunotherapy. Strategies to limit TReg 
responses locally might therefore aid the success of vaccination treatments.  
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Figure 1-6. Mechanisms of suppression by regulatory T cells (TRegs) 
 
Figure 1.6. Mechanisms of suppression by regulatory T cells (TReg). TReg 
suppression mechanisms can be classified as direct and indirect, APC-mediated. A) 
Direct mechanisms include 1) dominant use of pro-survival IL-2 as TRegs express high 
levels of IL-2R. Insufficient IL-2 at the effector T cell could lead to its apoptosis. 2) 
Production of granzyme B and perforin by the TReg permits killing of effector T cells by 
cytolysis. 3) Expression of suppressive cytokines by the TReg could inhibit activation 
of the effector T cell and /or promote its differentiation to an inducible TReg. 4) 
Molecules such as galectin-1 or TGF expressed on the surface of TRegs could 
suppress effector T cells by cell-cell contact signalling. B) Indirect mechanisms could 
involve 1) high CTLA-4 expression by the TReg. CTLA-4 could reduce co-stimulatory 
signals by i) competing with CD28 for binding CD80/86,  ii) reducing CD80/86 
expression, possibly by trans-endocytosis. CTLA-4 engagement with CD80/86 might 
also lead to indoleamine 2,3-dioxygenase (IDO) activation and the breakdown of 
tryptophan to kinurenins that could cause apoptosis of the T cells (2).  3) CD39 
expressed by TRegs hydrolyses ATP to AMP, thereby reducing ATP- induced DC 
maturation. 4) LAG-3 binding to MHC-II reduces DC maturation and its antigen 
presenting capacity. 5) Enhanced duration of TReg association with DCs, maybe 
through Nrp-1, reduces the opportunity for T effector cells to associate with DCs and 
become stimulated.   
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Th17 cells were defined a novel CD4
+ lineage in 2005 on the basis that they require different 
transcription factors and polarising cytokines to Th1 and Th2 cells for their development. They 
were named according to their hallmark cytokine, IL-17, which as described below has many 
targets and can therefore instigate a wide range of inflammatory responses. However, Th17 
cells can also release other pro-inflammatory cytokines including IL-17F, IL-21, IL-22, TNF 
and IL-6, which either support the development of the Th17 lineage or feed into the 
inflammatory response (Kaiko et al., 2008).  
 
1.2.8 The IL-17 cytokine 
IL-17 (also known as IL-17A) was originally identified by a subtractive hybridisation screen 
in a rodent T cell library (Rouvier et al., 1993) and is the founding member of a group of 
cytokines including: IL-17A, IL-17B, IL-17C, IL-17D, IL-25 (IL-17E) and IL-17F, which 
were discovered later by sequence alignment. Although pro-inflammatory responses are 
suggested for most members (with the exception of IL-17E), IL-17A and IL-17F are the best 
characterised and are both expressed by Th17 cells (Gaffen, 2009). Both IL-17A and IL-17F 
exist as covalent homodimers but they can also form heterodimers. Indeed, IL-17A-IL-17F is 
produced more abundantly in-vitro by peripheral blood mononuclear cells than IL-17A 
homodimer (Wright et al., 2007). IL-17A, IL-7F and the heterodimer signal through the same 
receptor, which is a heteromeric complex of the single-transmembrane domain proteins IL-
17RA and IL-17RC (Kuestner et al., 2007; Wright et al., 2008). Interestingly, although IL-
17A and IL-17F share a common receptor, the phenotypes of IL-17A and IL-17F knockout 
mice suggest that they have distinct functions (Ishigame et al., 2009; Yang et al., 2008b). It 
would appear that IL-17A contributes more strongly to autoimmunity than IL-17F. This might 
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reflect the different affinities of the IL-17RA and IL-17RC subunits for IL-17A and IL-17F 
and/or the greater strength of signalling induced by IL-17A (Ishigame et al., 2009; Yang et al., 
2008b).  
 
IL-17RA is expressed ubiquitously (Moseley et al., 2003), with particularly high expression in 
hematopoietic tissues. The majority of IL-17 induced responses are described for non-
hematopoietic cells, including epithelial and endothelial cells and fibroblasts, although 
macrophages and dendritic cells also respond to IL-17 (Dong, 2008; Gaffen, 2009; Miossec et 
al., 2009; Park et al., 2005; Shen and Gaffen, 2008). In general a pro-inflammatory response 
has been seen, involving expression of pro-inflammatory cytokines such as IL-1, IL-6, 
TNF, G-CSF and GM-CSF and the production of chemokines including CCL2, CCL7, 
CCL20, CXC-chemokine ligand 1 (CXCL1) and CXC8 (IL-8). From in-vivo studies, the 
recruitment and activation of neutrophils following induction of IL-8 and GM-CSF appears to 
be an early hallmark of the IL-17 response (reviewed in (Dong, 2008; Kolls and Linden, 
2004; Park et al., 2005)). IL-17 further enhances innate immune responses by inducing 
cyclooxygenase (COX) and inducible Nitric Oxide synthase (iNOS) expressions for 
respective generation of the inflammatory mediators prostaglandin E2 (PGE2) and nitric 
oxide (NO). In addition, it promotes acute phase protein production and antimicrobial 
peptides (reviewed by (Shen and Gaffen, 2008)). Matrix metalloproteinases (MMPs) are also 
released in response to IL-17, leading to extracellular matrix destruction that can facilitate cell 
movement (Shen and Gaffen, 2008). In bone, matrix destruction by MMPs would contribute 
to bone re-sorption. Osteoclastogenesis could be further enhanced by IL-17 as it promotes 
RANKL expression on osteoblasts (Nakashima et al., 2000). RANKL engagement with 
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osteoclast RANK leads to osteoclast activation and bone re-sorption. T and B cells also 
express RANKL (Kong et al., 1999) and higher levels of RANKL have been found on Th17 
cells than other subsets (Sato et al., 2006), although whether they engage with osteoclasts has 
not been confirmed (Miossec et al., 2009). Interestingly, very few IL-17 regulated genes are 
reported for lymphocytes. Furthermore, they are distinct from those induced by IL-17 in other 
cell types (Gaffen, 2009).  
 
The pro-inflammatory responses to IL-17 are similar to responses to stimuli such as Toll Like 
Receptor ligands (TLRLs) and IL-1 receptor signalling, both of which utilise NF-B 
pathways. Consistent with a role for NF-B in the regulation of IL-17 responses, NF-B 
binding sites are found in the promoters of IL-17 target genes (Shen et al., 2006) and IL-17 
was able to activate the p50 and p65 components of the canonical NF-B pathway (Shen and 
Gaffen, 2008). In addition, bioinformatics has revealed a conserved motif in the cytoplasmic 
domains of the IL-17R family members that is homologous to the Toll/IL-1R (TIR) domain 
present in TLRs (Novatchkova et al., 2003). This motif could permit the docking of 
intracellular adaptors involved in the NF-B signalling pathway, such as MYD88 (myeloid 
differentiation primary response protein-88) (Gaffen, 2009). Thus, NF-B signalling appears 
to contribute to IL-17 responses. Besides NF-B, IL-17A might signal via mitogen activated 
protein kinase pathways (MAPK), since ERK (extracellular signal-related kinase) and p38 
MAPK were phosphorylated following IL-17 stimulation (Shen and Gaffen, 2008). MAPK 
pathways are implicated in mRNA stabilisation by inhibiting mRNA destabilising proteins 
(reviewed by (Shen and Gaffen, 2008)). Several chemokines and cytokines regulated by IL-17 
contain 3‟destabilising motifs and IL-17 increases their transcript levels. Thus, IL-17 might 
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regulate cell responses by controlling mRNA stability. Similar to NF-B binding sites, 
binding motifs for CCAAT/enhancer binding proteins (C/EBP) are over-represented in the IL-
17 target gene promoters (Shen et al., 2006) and a functional role for C/EBP promoter binding 
has been demonstrated in the regulation of IL-17 target, IL-6 (Ruddy et al., 2004). There are 
also suggestions that JAK-STAT signalling might mediate some IL-17 responses (Kao et al., 
2004; Subramaniam et al., 1999), although secondary effects from STAT signalling cytokines 
such as IL-6, released upon primary response to IL-17, could explain the data from 
pharmacological JAK inhibition studies. Lastly, PI3Kinase signalling may contribute to IL-17 
signalling, as IL-17 responses in lung epithelial cells were associated with elevated lipid and 
AKT phosphorylation and could be inhibited by PI3Kinase specific inhibitors (Huang et al., 
2007). Taken together, a range of signalling systems might co-operate to regulate IL-17 
responses in target cells.  
 
Since the discovery of IL-17, a range of cell types have been found to express it. CD4+  T 
cells are the best characterised source but it is also expressed by CD8+ T cells, Natural Killer 
cells (NK), invariant NK T cells (iNKT),  T cells, neutrophils, eosinophils, Lymphoid tissue 
inducer cells (LTi) and mast cells (Dong, 2008; Hueber et al., 2010).  
 
1.2.9 Evidence for Th17 cells as a novel T helper cell lineage 
The initial studies that led to the conclusion that T helper cells expressing IL-17 represent a 
distinct lineage from Th1 and Th2 cells were conducted in mice. Interestingly, the first studies 
that spurred this consideration did not focus on IL-17 itself but involved analysis of the effects 
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of IL-12 family cytokines, IL-12 and IL-23, upon the establishment of autoimmune disease 
(reviewed in (Dong, 2008; Kaiko et al., 2008). The importance of IL-12 and by inference 
IFN secreting Th1 cells in autoimmune pathology had been concluded previously from the 
observation that neutralising antibodies to IL-12p40 could alleviate autoimmune disease in 
mouse models. However, in 2000, IL-12p40 was found to complex with p19, an IL-12p35 and 
IL-6 related molecule, to form the novel cytokine IL-23. Like IL-12, IL-23 is expressed by 
activated DCs and monocytes but signals through a unique receptor that is a complex of IL-
12R1 with IL-23R (Oppmann et al., 2000). p19 and p35 deficient mice were thus used to 
determine if IL-12 and/or IL-23 are responsible for the autoimmune phenotype of IL-12p40 
depleted mice. p19 deficient mice were less susceptible to autoimmune disease than p35 
deficient mice, suggesting that IL-23 rather than IL-12 is responsible for the autoimmune 
condition (Murphy et al., 2003; Oppmann et al., 2000). Subsequently, IL-23 was shown to 
induce IL-17 but not IFN expression (Murphy et al., 2003) and the co-expression of IL-17 
and IFN was not observed. Thus, the concept that IL-17 producing T cells are a distinct 
lineage grew.  
 
To test whether Th17 cells are distinct from Th1 or Th2 cells, the involvement of Th1 and Th2 
associated cytokines was studied in the context of IL-17 production. Two groups reported that 
inhibition of IFN and IL-4 enhances IL-17 production. These studies made use of 
neutralising antibodies and mice deficient in IFN or IFNR (Harrington et al., 2005; Park et 
al., 2005). Analysis of the roles of Th1 and Th2 associated transcription factors in the 
generation of IL-17 producing cells further confirmed that Th17 cells are a distinct lineage. 
Firstly, whilst T cells from STAT4 and STAT6 deficient mice did not express IFN and IL-4 
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respectively, the frequency of IL-17 expressing cells was not altered (Harrington et al., 2005; 
Park et al., 2005). Secondly, STAT1 and T-bet deficiencies increased the frequency of IL-17 
expressing cells, consistent with the hypothesis that IFN suppresses IL-17 expression 
(Harrington et al., 2005). That Th2 and Th17 cells represent separate lineages was similarly 
confirmed through observation that c-Maf over-expression increases IL-4 but reduces IL-17 
and IFN (Park et al., 2005).  
 
1.2.10 Cytokines critical for Th17 development 
The finding that STATs 1 and 4 are not required for Th17 development came as a surprise 
given that IL-23 signals through STATs 1, 3, 4 and 5. However, in contrast to IL-12, which 
mainly signals through STAT4 homodimers, IL-23 makes less use of STAT4 and might 
signal through STAT3 homodimers to promote Th17 development (Lankford and Frucht, 
2003). Consistent with this hypothesis, following IL-23 stimulation, IL-17 was increased in 
suppressor of cytokine signalling-3 (SOCS3) deficient cells (Chen et al., 2006) and over-
expression of active STAT3 amplified Th17 frequencies (Lankford and Frucht, 2003; Yang et 
al., 2007). However, it is now suggested, that IL-23 is not required for commitment to the 
Th17 lineage but rather functions in the survival and expansion of Th17 cells. This is 
consistent with the activation dependent expression of IL-23R by T cells (Mangan et al., 
2006). The significance of STAT3 upon Th17 differentiation was subsequently explained 
when it was shown that IL-6, which signals via STAT3 in consort with TGF drives Th17 
generation. Pro-inflammatory cytokines including IL-1 and Tumour Necrosis Factor (TNF), 
were also shown to synergise with IL-6 and TGF to increase Th17 frequencies (reviewed in 
(Dong, 2008)). The release of IL-6, TNF and IL-1 by IL-17 target cells, therefore provides 
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positive feedback for IL-17 production by Th17 cells. Likewise, IL-21, which is a major 
product of Th17 cells, can feed-forward on their development in a manner analogous to IFN 
and IL-4 in the positive regulation of Th1 and Th2 lineages respectively.  
 
The importance of TGF for the generation of a pro-inflammatory helper cell was 
counterintuitive, given its role in effector T cell suppression. Nevertheless, studies in mice 
faithfully showed a requirement for TGF in Th17 differentiation. Thus, Th17 and TReg 
lineages were said to be reciprocally related with IL-6 as the switch factor (Bettelli et al., 
2006). Human studies initially contradicted the observations in mouse suggesting that TGF 
and IL-6 inhibit Th17 differentiation (Acosta-Rodriguez et al., 2007a; Evans et al., 2007). 
However, later studies, conducted under serum free conditions refuted this claim, showing 
that low TGF in consort with pro-inflammatory cytokines such as IL-1, IL-6, IL-21,TNF 
and IL-23, is essential (Manel et al., 2008; Veldhoen et al., 2006; Volpe et al., 2008; Yang et 
al., 2008a). Each pro-inflammatory cytokine might uniquely impact the cytokine profile of the 
differentiated T cell (Volpe et al., 2008). The discrepant findings of earlier and later studies 
were suggested to involve the presence of human compatible TGF in serum media (Volpe et 
al., 2008). Indeed, whilst high levels of TGF might be inhibitory to Th17 differentiation, low 
levels appear to be inductive (Yang et al., 2008a). Another factor might have been kinetics, 
since TGF could increase in culture over time. Lastly, the proportion of naive and central 
memory T cells could have influenced the cytokine requirements. For example, Yang et al 
(2008) showed that highly purified central memory CD4+ cells could induce IL-17 expression 
in serum free medium following IL-1, IL-6 and IL-23 supplement, whilst naive cells from 
peripheral and cord blood required TGF and IL-21 (Yang et al., 2008a).  
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The role of TGF for naive T cell differentiation to the Th17 lineage can be explained by its 
ability to promote expression of the hallmark Th17 lineage transcription factor, RORt 
(RORC2 in humans) (Ivanov et al., 2006). TGF also induces TReg associated FoxP3, which 
in the absence of pro-inflammatory cytokines interacts with RORt inhibiting its 
transcriptional activity. Therefore, a post-translational mechanism might contribute to the 
reciprocal development of Th17 and TReg cells in the presence versus absence of pro-
inflammatory cytokines respectively (Zhou et al., 2008; Zhou and Littman, 2009). However, 
via STAT3, pro-inflammatory cytokines can also increase RORt expression. Interestingly, 
the IL-17 promoter itself contains a STAT3 binding site (Chen et al., 2006), thus in addition 
to increasing IL-17 expression via RORt, STAT3 could directly enhance IL-17 transcription. 
A recent study in mice further showed that whilst TGF does not alter RORt expression in 
differentiating and committed Th1 and Th2 wildtype cells, it inhibits STAT4 and GATA-4. 
Additionally, Stat-6-/-Tbet-/- mice, that are incapable of developing Th1 or Th2 responses, 
could generate vigorous Th17 responses in IL-6 supplemented cultures irrespective of TGF 
presence (Das et al., 2009). Together these data suggest that TGF might promote Th17 
differentiation by inhibiting Th1 and Th2 differentiation programs rather than being required 
for Th17 differentiation. This finding has recently been strengthened by others, who 
demonstrated that permissive epigenetic modifications of the il-17a-il-17f and rorc loci could 
occur in the absence of TGF, providing IL-23 was supplied in combination with IL-6 and 
IL-1 (Ghoreschi et al., 2010). Mechanistically, they demonstrated that IL-6 induces IL-23R 
expression in naive T cells to permit IL-23 signalling that in turn promotes RORt and IL-17 
expression. In addition, IL-23 itself could enhance IL-23R expression to increase Th17 
frequencies. Thus, the previous view that IL-23 is required for maintenance of Th17 cells 
rather than their induction (Evans et al., 2007), might need to be revised. Consistent with the 
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inhibitory effect of TGF upon T-bet and IFN expression, fewer Th17 cells were generated 
in the absence of TGF (Ghoreschi et al., 2010), therefore a role for TGF in establishing 
Th17 populations appears to be upheld. However, the greatest proportion of Th17 cells isolated 
from the CNS of EAE mice had an IL-23 driven phenotype, showing dual expression of 
RORt and T-bet. Furthermore, adoptive transfer of IL-23-induced Th17 cells instigated 
stronger disease than TGF induced Th17 cells in the EAE model (Ghoreschi et al., 2010). 
Cytokine profile analysis on T cells from human disease tissues including the gut of Crohn‟s 
patients (Annunziato et al., 2007) and joints of arthritis patients (Nistala et al., 2008) similarly 
revealed enrichment of IL-17+IFN+ T cells (Th17/1) at diseased sites. Thus, it seems likely 
that the Th17/1 population is particularly pathogenic, which might explain previously 
conflicting findings that both Th17 cells and T-bet are pathogenic in EAE (Bettelli et al., 
2004). However, it is possible that Th1 and Th17 cells are relevant at different stages of the 
disease and that inter-conversion between the two occurs. In support of this hypothesis, a 
number of groups have investigated the ability of Th17 and Th1 cells to interconvert or 
become Th17/1 hybrids that coincidently express IL-17 and IFN. Reasonably pure Th17 
starting populations were derived either from T cell clones (Annunziato et al., 2008), by  
reporter gene expression and FACS sorting (Lee et al., 2009) or through use of cytokine 
detection and capture assays (Nistala et al., 2010). All studies agreed that TGF maintains IL-
17 expression. By contrast, IL-12 alone promoted a switch to the Th1 phenotype and whilst 
the presence of TGF with IL-12 tended to favour the hybrid phenotype, in the absence of 
TGF, IL-23 favoured the Th17/1 profile. Thus, TGF in consort with pro-inflammatory 
cytokines might establish a cohort of IL-17+ cells, which can then be converted under 
conditions of IL-12 or IL-23 to Th17/1 or Th1 cells. The relevance of this conversion has been 
demonstrated in-vivo as following transfer of purified Th17 populations, IFN
+ T cells could 
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be detected in T cell deplete hosts (Bending et al., 2009; Kurschus et al., 2010; Lee et al., 
2009; Martin-Orozco et al., 2009). In addition, spectratyping of the TCR- variable chain 
(TRBV) determined that Th17/1 cells from the synovial fluid of arthritis patients might share 
ancestry with Th17 cells but not Th1 cells (Nistala et al., 2010). Furthermore, all of the Th1 
clones that shared a TCR spectratype with Th17 cells expressed CD161, which is a surface 
marker that identifies the Th17 precursor pool in cord blood (Cosmi et al., 2008). This 
suggests that some Th1 cells in the joint originated from Th17 cells. However, one study has 
recently shown that purified Th1 cells could convert to Th17 cells following adoptive transfer 
(Kurschus et al., 2010).  
 
1.2.11 Negative regulation of Th17 development 
Besides IFN and IL-4, IL-27, IL-25 (IL-17E) and the novel cytokine IL-35 appear to 
suppress the development of Th17 cells and in mouse models of autoimmune disease their 
absence has resulted in increased disease susceptibility (Dong, 2008; Niedbala et al., 2007). A 
function for the proliferative cytokine, IL-2 in Th17 suppression has also been suggested and 
is consistent with its pro-regulatory effect when supplied in consort with TGF (Acosta-
Rodriguez et al., 2007a; Laurence et al., 2007). However, exogenous IL-2 might expand 
differentiated Th17 populations (Volpe et al., 2008). 
 
1.2.12 Th17 lineage specific transcription factors 
As mentioned, RORt is the hallmark transcription factor of the Th17 lineage in both mice and 
man. It is a member of the retinoic-acid-receptor-related orphan nuclear hormone receptor 
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family and is encoded by the RORC locus. Evidence for its importance includes RORt 
induction under Th17 polarizing conditions, the loss of Th17 cells and attenuation of 
autoimmune disease in RORt deficient mice. Nonetheless, the mechanism by which RORt 
facilitates IL-17 expression remains unclear, although the presence of a ROR response 
element (RORE) within a non-coding region of the IL-17-IL-17F gene locus implies that 
direct binding might be involved (reviewed in (Dong, 2008)). In addition, it appears that 
RORt is not solely responsible for Th17 development, since residual numbers of Th17 cells 
are present in RORt deficient mice (Dong, 2008). Recently, a minor but synergistic role for 
the ROR family member, ROR, has been proposed (Yang et al., 2008d). Transcription 
factor, interferon regulatory factor four (IRF-4), might also be involved, lying upstream of 
RORs in the signalling network (Brustle et al., 2007). However, with the possible exception 
of Th1 cells, IRF4 appears to contribute to the development of all currently known T helper 
cells, thus it might function upstream of the lineage determination factors (reviewed by 
(Veldhoen, 2010)). Consistent with this, IRF4 deficiency reduced RORt and ROR. 
However, IRF4 might also influence the function of RORt or ROR, since ectopic 
expression of both factors only partially rescued Th17 differentiation in the absence of IRF4. 
Alternatively, this could be explained by the need for IRF4 in IL-21 responsiveness 
(Veldhoen, 2010). Similarly, promotion of IL-21 by cMaf, could explain the role of ICOS-
induced cMaf in Th17 differentiation (Bauquet et al., 2009). Runx1 (runt related transcription 
factor -1) is another transcription factor that may control Th17 development, since it too can 
complex with RORt and was shown to co-operate with RORt to promote Th17 
differentiation (Zhang et al., 2008). Similar to IRF4, however, Runx1 activity might not be 
unique to Th17 cells, since in TRegs, Runx1 interacts with FoxP3, up-regulates TReg associated 
molecules, suppresses IL-2 and IFN and permits their suppressive activity (Hu et al., 2007). 
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The aryl hydrocarbon receptor (AHR), which similar to ROR proteins is a member of the 
steroid nuclear receptor family, is also highly expressed in Th17 cells (Quintana et al., 2008; 
Stockinger et al., 2009; Veldhoen et al., 2008a). Through interaction with RORt, AHR might 
enhance IL-17 expression. Furthermore, AHR is required for induction of the Th17 associated 
cytokine, IL-22, which is also the hallmark cytokine of the novel Th22 lineage (Trifari et al., 
2009). Nuclear factor of activated T cell (NFAT) proteins, which are induced soon after T cell 
receptor activation in response to calcium signalling via calcineurin activation, also play a 
role in lineage development. Although they are induced in a relatively non-specific manner 
following TCR stimulation, NFAT proteins and their partners can access specific loci 
following chromatin remodelling. In Th17 development it is suggested that NFAT co-operates 
with the above mentioned transcription factors for RORt, IL-17, IL-21,IL-22 and IL-23R 
transcription (Hermann-Kleiter and Baier, 2010).  
 
1.2.13 Th17 cells in disease 
As discussed, the existence of the Th17 lineage grew from the discovery that the pathogenesis 
of autoimmune disease in certain mouse models involved IL-17 secreting CD4+ T cells rather 
than IFN expressing cells (Murphy et al., 2003). Since then, the involvement of Th17 cells in 
a number of mouse models of autoimmune and allergic disease has been studied and 
pathogenic effects concluded (reviewed in (Korn et al., 2009)). Th17 cells have also been 
associated with inflammatory human diseases including RA, asthma, SLE, MS, Crohn‟s 
disease and allograft rejection (Korn et al., 2009; Park et al., 2005; Steinman, 2007; van 
Beelen et al., 2007). However, these associations are largely circumstantial, based upon 
elevated IL-17 mRNA or IL-17 protein in the tissues or fluids of patients with the disease. 
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Additionally, increased levels of other Th17-associated cytokines, factors associated with 
Th17 differentiation and molecules expressed by target cells following IL-17 have been taken 
as evidence of Th17 activity in disease. However, a few reports have shown that T cells 
express IL-17 at sites of inflammation. For example, IL-17 was expressed by T cell clones 
generated from the skin of individuals with contact dermatitis (Pene et al., 2008) and 
increased Th17 frequencies, as measured by flow cytometry, were found ex-vivo in synovial 
fluid of RA patients (Colin et al., 2010; Leipe et al., 2010). and the gut of Crohn‟s disease 
patients (Annunziato et al., 2007) relative to controls. For psoriasis and some arthropathies 
neutralising antibodies to IL-17 or Th17 inducing cytokines have also been shown to reduce 
disease severity (Allantaz et al., 2007; Genovese et al., 2010; Miossec, 2009; Tak, 2009; 
Yokota et al., 2008). 
 
Besides their pathogenic effect in autoimmune and allergic conditions, Th17 cells, have a 
protective role in host defence against certain microbial infections including the gram positive 
bacterium, Propionibacterium acnes and gram negative Klebsiella pneumoniae (Ye et al., 
2001), Citrobacter rodentium (Mangan et al., 2006), Bacteriodes spp., Borrelia spp., acid-fast 
Mycobacterium tuberculosis (Khader et al., 2007) as well as fungal like pathogens: 
Pneumocystis carinii (Rudner et al., 2007) and Candida albicans (Huang et al., 2004). It 
might be that Th17 cells deal with the removal of different pathogens to Th1 cells. This is 
supported by the finding that human memory Th17 cells could react against antigens derived 
from Candida albicans whilst the memory T cells specific for Mycobacterium tuberculosis 
were of the Th1 phenotype (Acosta-Rodriguez et al., 2007b).  
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1.3 Reciprocal regulation of the Th17/iTReg balance   
Besides identifying the cytokines that are conducive to the development of one T effector 
lineage relative to another, the effective treatment and prevention of disease requires the 
identification of other physiological and environmental factors that favour the acquisition of 
one cell lineage over another.  
 
1.3.1 Regulation of the Th17/iTReg balance by steroid nuclear receptor ligands 
Recently a number of steroid nuclear receptor ligands have been studied for their effects upon 
CD4+ T cell differentiation, in particular their ability to regulate the Th17/iTReg balance. 
Amongst these are all-trans-retinoic acid (ATRA), the active form of vitamin A and a number 
of AHR ligands including the environmental toxins 2,3,7,8-tetracholorodibenzi-p-dioxin 
(TCDD) and -napthoflavone and the endogenous molecules formylindolo[3,2-b]carbazole 
(FICZ), and 2-(1‟H-indole-3‟carbonyl)-thiazole-4-carboxylic acid methyl ester (ITE). 
Specifically, ATRA enhances the TGF-dependent conversion of naïve T cells into TReg cells 
but suppresses Th17 differentiation under conditions of TGF and IL-6 (Schambach et al., 
2007). Such ATRA induced tolerance might be of particular relevance in the gut, contributing 
to oral tolerance, since firstly CD103+ DCs in gut associated lymphoid tissue (GALT) express 
high levels of retinal dehydrogenases for ATRA synthesis; secondly, ATRA signalling 
induces the expression of gut homing molecules 47 and CCR9 on the T cell surface 
(Coombes et al., 2007).  
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In contrast to ATRA, analysis of AHR deficient cells in the presence of dioxin or FICZ 
concluded a role for the AHR in Th17 induction (Veldhoen et al., 2008a; Volpe et al., 2008; 
Zhou and Littman, 2009). However, other studies suggest that AHR effects upon the 
Th17/iTReg balance are ligand specific (Quintana et al., 2008): TCDD promoted development 
of FoxP3+ cells that were functionally suppressive in-vitro and inhibited EAE pathogenesis, 
coincident with decreased CD4+IL-17+ and CD4+IFN+ cells. Similarly, ITE significantly 
reduced EAE severity. Conversely, FICZ did not induce FoxP3 expression but rather 
significantly worsened EAE and enhanced IL-17 and IFN secretion in-vitro. Since AHR can 
interact with both FoxP3 and RORt, such AHR ligand specific effects might relate to their 
differing abilities to modulate these interactions. However, different AHR ligand toxicities 
and their influence upon AHR degradation could equally explain the converse effects of 
TCDD and FICZ (Veldhoen et al., 2008a). Nonetheless, it is clear that steroid nuclear receptor 
ligands can profoundly influence the position of the Th17/ iTReg balance. Thus, they represent 
environmental factors that could influence susceptibility to immune disease.  
 
1.4 Vitamin D 
Vitamin D was identified in the early 1900s for its ability to cure childhood rickets and treat 
osteoporosis. In this capacity it functions as a hormone in the regulation of blood calcium and 
phosphorus, promoting increased calcium absorption at the intestine and proximal kidney 
tubule when calcium levels are low and in consort with parathyroid hormone vitamin D 
triggers calcium mobilisation from bone (reviewed in (Holick, 2007)). More recently, a range 
of non-classical activities for vitamin D have been suggested, including regulation of cell 
proliferation, differentiation, apoptosis and angiogenesis and of particular pertinence to this 
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study, immunomodulatory effects. Discovery of the vitamin D receptor (VDR) in tissues other 
than those involved in calcium and phosphate regulation persuaded the acceptance of such 
non-classical endocrinological functions for vitamin D (Mullin and Dobs, 2007). Amongst  
VDR-expressing cells are cells of the immune system, including: monocytes, macrophages, 
dendritic cells and activated T and B cells (Veldman et al., 2000). 
 
1.4.1 Vitamin D metabolism 
Few foods naturally contain or are supplemented with vitamin D (where D refers to D2 (plant 
derived ergocalciferol) or D3 (cholecalciferol)). Highest levels are found in oily fish and fish 
based products that provide  300–500 international units (IU) per serving (Mullin and Dobs, 
2007). Low levels are also present in butter, cream and egg yolk and some foods including 
milk, orange juice, cereals, breads, yogurts, and cheeses can be fortified with vitamin D 
(Baeke et al., 2008). The majority of vitamin D3 is attained through solar ultraviolet B 
mediated conversion of 7-dehydrocholesterol, present at high level in the cell membranes of  
keratinocytes of the stratum basal and stratum spinosum layers of the skin epidermis. 
Exposure to one minimal erythemal dose of UVB radiation whilst wearing a bathing suit is 
equivalent to ingesting 20,000IU vitamin D3 (Holick, 2007). 
 
Similar to other sterol hormones such as oestrogen, vitamin D requires further enzymatic 
conversion for activation: Two sequential hydroxylations at C1 and C25 are required (figure 
1.7). The first, to yield 25(OH)D3 (Calcidiol) is catalysed primarily in the liver by the 25-
hydroxylase activity of cytochrome–P450 enzyme, CYP27A1. The active metabolite,  
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Figure 1-7. Synthesis and metabolism of vitamin D 
 
Figure 1.7. Synthesis and metabolism of vitamin D. Ultraviolet B (UVB) radiation 
from sunlight converts 7 dehydrocholesterol in the skin to pre-vitamin D3 which is 
immediately converted to vitamin D3 in a heat-dependent process. Vitamin D3 can 
also be obtained from the diet. Excessive photo exposure degrades vitamin D3. 
Vitamin D3 is carried in blood by vitamin D binding protein (VDBP).  In the liver, 
vitamin D-25-hydroxylase converts vitamin D3 to 25-hydroxyvitamin D3, an inactive 
intermediate that is the major circulating form of vitamin D3 and used to determine 
vitamin D status. 25-hydroxy vitamin D3 is converted to the active form, 1,25–
dihydroxyvitamin D3, in a second hydroxylation reaction catalysed by 25-
hydroxyvitamin D3 1-hydroxylase (CYP27B1). That converted in the kidneys 
regulates calcium and phosphate homeostasis but VDR is also expressed at other 
body sites. Excess 1,25–dihydroxyvitamin D3 and 25-hydroxyvitamin D3 is 
hydroxylated and inactivated by 25-hydroxyvitamin D3  24-hydroxylase (CYP241).  
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1,25(OH)2D3 (Calcitriol), which has 1000 fold greater activity than 25(OH)D3, is finally 
synthesised via 25-hydroxyvitamin-D3-1-hydroxylase (CYP27B1). CYP27B1 expression 
was first discovered in the kidney but similar to the VDR, its much broader expression in 
prostate, breast, colon, immune, skin and  cells is now acknowledged. Despite being 
structurally identical, renal and extra-renal CYP27B1 demonstrate different mechanisms of 
regulation: Renal-CYP27B1 is suppressed by calcium, phosphate, PTH, phosphaturic factors, 
phosphatonins and 1-25(OH)2D3, consistent with the classical role of vitamin D in calcium 
homeostasis. By contrast, local agents, including cytokines and growth factors regulate extra 
renal-CYP27B1 (Leventis and Patel, 2008). As such, it is contended that extra-renal generated 
1,25(OH)2D3 regulates the functions of the tissues in which it is produced via autocrine and 
paracrine mechanisms. The comparatively short half life of 1,25(OH)2D3, which is in the 
order of hours rather than weeks, as measured for 25(OH)D3, further supports the need for 
local CYP27B1 activity (Mullin and Dobs, 2007). Serum 1,25(OH)2D3 levels are very low 
(~0.1nM) and remain relatively constant due to tight homeostatic regulation in which 25-
hydroxyvitamin D-24-hydroxylase (CYP24A1) hydroxylates both 25(OH)D3 and 
1,25(OH)2D3 to yield the inactive metabolites 24,25(OH)2D3 and 1,24,25(OH)2D3. 
Interestingly, vitamin D deficient persons usually show normal, even elevated 1,25(OH)2D3 
serum levels due to secondary hyperparathyroidism (Holick, 2007). By contrast, 25(OH)D3 
levels vary and are used to define vitamin D status. Most experts define vitamin D deficiency 
as a 25(OH)D3 serum level of less than 50nM (20ng/ml), although up to 80nM is considered 
relative insufficiency with respect to calcium regulation and bone health (Hollis, 2005). 
Vitamin D intoxication associated with hypocalcaemia and hyperphosphatemia is not 
observed until serum 25(OH)D3 peaks 374nM (150ng/ml). According to these parameters, 
one billion persons worldwide are estimated to be vitamin D deficient (Holick, 2007). The 
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Institute of Medicine recommends a daily dietary vitamin D intake of 200IU/day for children 
and adults up to 50 years, 400IU for adults between 51 and 70 years and 600 IU for persons of 
71 years and older.  
 
The majority (80-85%) of the lipid soluble 25(OH)D3 and 1,25(OH)2D3 metabolites are 
transported around the body in the blood bound with high affinity to vitamin D binding 
protein (VDBP) (White and Cooke, 2000), which was originally classified as group-specific 
component or Gc globulin (Hirschfeld, 1959). The remainder travels free or bound to 
albumin. Three common structural VDBP polymorphisms have been identified that are 
encoded by co-dominant alleles known as GC*1F, GC*1S and GC*2. In addition to these 
common variants, over 120 variant VDBP alleles are described worldwide (Cleve and 
Constans, 1988; White and Cooke, 2000). Interestingly, serum levels of vitamin D 
metabolites vary according to GC genotype suggesting differences in their abilities to bind 
vitamin D (Janssens et al., 2010). In addition to its role in vitamin D transport, the monomeric 
VDBP is a macrophage-activating factor, a scavenger of actin, and it augments the 
chemotactic effect of C5a for macrophages and neutrophils. In addition, VDBP has been 
detected on lymphocytes, neutrophils and monocytes and its expression might be regulated by 
cytokines (reviewed in (White and Cooke, 2000)). Thus, VDBP appears to have 
immunological functions besides those influenced by vitamin D metabolites themselves. 
Consistent with a range of immunological effects, VDBP polymorphisms have been 
associated with inflammatory conditions such as chronic obstructive pulmonary disorder 
(COPD), tuberculosis, RA and diabetes in some cohorts (Chishimba et al., 2010; Papiha and 
Pal, 1985). Free vitamin D metabolites can diffuse directly across lipid bilayers into cells 
whilst VDBP bound molecules are transported via a megalin/cubulin-mediated endocytic 
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process (Chishimba et al., 2010; Nykjaer et al., 1999; Nykjaer et al., 2001; Papiha and Pal, 
1985) (figure 1.8). Once inside the cell within clathrin-coated vesicles, VDBP is transported 
to endosomes where it is released from its receptors. These are recycled back to the plasma 
membrane and VDBP transported on to lysosomes where it is degraded and its cargo released 
into the cell (Chishimba et al., 2010; Papiha and Pal, 1985). Although this process was first 
detected in renal cells, it is reported in other tissues including macrophages (Chun et al., 
2008), implying that it has relevance for vitamin D modulated immune responses. 
 
1.4.2 Genomic actions of 1,25(OH)2D3  
1,25(OH)2D3 mediates most of its effects by directly regulating the transcription of its target 
genes (Deeb et al., 2007) (figure 1.8). In this mechanism, VDR, which is a member of the 
class II family of nuclear receptors becomes activated upon ligand binding and typically 
heterodimerises with the retinoid X receptor (RXR). In this way, ATRA and 1,25(OH)2D3 
signalling pathways are related as Retinoic Acid Receptors (RAR) , and  that recognise 
ATRA also control gene responses through binding to RXR (Hughes et al., 2006). The VDR-
RXR complex binds to vitamin D response elements (VDRE) in target genes, most of which 
are composed of two hexanucleotide repeats interspaced with varying numbers of nucleotides. 
In the main, for gene activation, VDR occupies the 3‟ half of the VDRE and RXR the 5‟ site. 
In the absence of ligand, co-repressor proteins complex with VDR to inhibit gene expression. 
They promote this inhibition by virtue of intrinsic chromatin remodelling functions, or by 
serving as a recruitment platform for chromatin remodelling proteins and basal transcription 
factors. Upon ligand binding, VDR is phosphorylated and undergoes conformational changes 
that lead to the release of repressor proteins. In addition, its activation function (AF2) sites 
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become exposed allowing the binding of stimulatory co-activators as well as the chromatin 
modifiers, CREB binding protein (CBP-p300) and PBAF (polybromo-and SWI-2-related gene 
associated factor). Subsequent histone acetylation opens the chromatin allowing the entrance 
of vitamin D receptor interacting proteins (DRIPs) that interact with the AF2 domains of 
VDR and with transcription machinery such as TF2B (transcription factor 2B) and RNA 
polymerase II, to promote transcription. For gene repression, the VDR-RXR heterodimer 
associates with the VDR-interacting repressor at E-box type negative VDREs (nVDREs) and 
histone acetyltransferase (HAT) coactivator is exchanged for the histone deacetylase (HDAC) 
co-repressor. 
 
1.4.3 Non-genomic actions of 1,25(OH)2D3 
In addition to direct genomic regulation, 1,25(OH)2D3 can have very rapid, non-genomic 
effects exemplified by the rapid induction of calcium absorption at the intestine. Although 
these signalling pathways are poorly understood, it is suggested that they can begin at the 
plasma membrane with reception of 1,25(OH)2D3 by a non-classical membrane receptor 
(memVDR) or a G protein coupled receptor. Activation of these receptors could lead to 
calcium influx via SOCS channels (in muscle cells), PI3Kinase, adenylate cyclase, 
phospholipase C and PKC activation. Phosphorylation of Ras or Raf could in turn activate 
the mitogen-activated protein kinase (MAPK)-extracellular signal regulated kinase (ERK) 1 
and 2 cascade. For some transcriptional responses, the Raf-MAPK-ERK pathway and the 
classical VDR pathway could co-ordinately regulate gene transcription and phosphorylation 
of VDR by PKC could enhance its stability. Thus, 1,25(OH)2D3 regulation appears to involve 
cooperation between genomic and non-genomic pathways (Deeb et al., 2007) (figure 1.8).  
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1.4.4 Immunomodulatory effects of 1,25(OH)2D3 
Immunomodulatory effects of 1,25(OH)2D3 are described for both the innate and adaptive 
arms of the immune system. In the innate system 1,25(OH)2D3 demonstrates antimicrobial 
properties inhibiting for example the growth of Mycobacterium tuberculosis in macrophage 
cultures (Rook et al., 1986). In-vivo studies on vitamin D deficient mice further indicate a 
reduced phagocytic response that is remedied by 1,25(OH)2D3 repletion (Bar-Shavit et al., 
1981). Recently the molecular basis for the antimicrobial effect of 1,25(OH)2D3 has been 
studied and is suggested to involve Toll Like Receptor 2 (TLR2) dependent up-regulation of 
macrophage VDR and CYP27B1 followed by induction of the defensin cathelicidin, whose 
promoter contains a VDRE (Liu et al., 2006a). In addition to cathelicidin, 1,25(OH)2D3 can 
induce other factors associated with bacterial killing, such as Nitric Oxide Synthase (Adams 
and Hewison, 2008). The induction of 1,25(OH)2D3 by human macrophages in response to 
signalling through other TLRs, such as the lipopolysaccharide (LPS) Pattern Recognition 
Receptor, TLR4, is also reported (Reichel et al., 1987a) but the broader involvement of TLRs 
in 1,25(OH)2D3 induction remains to be established. TLR2 mediated induction of CYP27B1 
and cathelicidin is also observed in keratinocytes wherein the initial induction of TLR2 might 
be driven by TGF released for example during wound repair (Sadeghi et al., 2006). Thus, in 
the skin, 1,25(OH)2D3 might link wound repair with enhanced innate immune surveillance. 
Despite such clear antimicrobial responses in these studies, 1,25(OH)2D3 is also reported to 
down-regulate monocyte TLR2 and TLR4 expression. Such negative feedback might be 
important to protect against inflammatory damage that would otherwise ensue (Adams and 
Hewison, 2008). 
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In the adaptive immune system, similar to vitamin A, 1,25(OH)2D3 demonstrates  modulatory 
properties. Specifically a number of in-vitro studies have shown that 1,25(OH)2D3 suppresses 
monocyte to DC differentiation resulting in CD1a-CD14+ cells. It also inhibits their 
maturation, down-regulating MHC II and co-stimulatory molecules, CD40 and CD80 (Berer 
et al., 2000; Canning et al., 2001; Penna and Adorini, 2000), although contrasting effects upon 
CD86 have been shown (Canning et al., 2001; Penna and Adorini, 2000). Nevertheless, 
1,25(OH)2D3 conditioned DCs demonstrate reduced ability to stimulate T cells and take up 
soluble antigen. In addition, 1,25(OH)2D3 suppresses DC production of IL-12 but enhances 
their production of IL-10 (Penna and Adorini, 2000). A switch of T cell phenotype from Th1 
to Th2 and TReg in response to 1,25(OH)2D3  has also been suggested, since attenuation of IL-2 
(Bhalla et al., 1984) and IFN (Lemire, 1992; Penna and Adorini, 2000) upon 1,25(OH)2D3 
supplementation has been observed, whilst IL-4 (Boonstra et al., 2001), TGF1 (Cantorna et 
al., 1998) and IL-10 (Barrat et al., 2002; Urry et al., 2009) were increased. However, the 
effect of 1,25(OH)2D3 upon the Th2 lineage remains controversial, since inhibition of IL-4 by 
1,25(OH)2D3 is also reported (Staeva-Vieira and Freedman, 2002). Most studies on 
lymphocyte responses to 1,25(OH)2D3 have been conducted in the presence of APC and could 
be consistent with the effect of 1,25(OH)2D3 upon APC cytokine profiles. However, in a few 
more recent studies effects of 1,25(OH)2D3 on T cells in the absence of APC were described 
(Barrat et al., 2002; Boonstra et al., 2001). Such findings are consistent with induction of the 
VDR in T cells upon stimulation (Bhalla et al., 1983). In addition, the presence of a VDRE in 
the IFN gene promoter (Cippitelli and Santoni, 1998) and VDR binding at the IL-2 gene 
promoter (Alroy et al., 1995) imply the involvement of direct effects of 1,25(OH)2D3 in T cell 
differentiation.  
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Consistent with the immunosuppressive properties of 1,25(OH)2D3 manifest in-vitro, 
population studies suggest that low dietary vitamin D intake, high latitude and VDR 
polymorphisms associate with increased risk of autoimmune diseases including: RA, Crohn‟s 
disease, MS and T1D (reviewed by (Arnson et al., 2007; Cantorna and Mahon, 2004)). Such 
associations highlight the importance of understanding mechanisms by which 1,25(OH)2D3 
influences the adaptive immune system, including the development of Th17 and TReg cells that 
appear critical players in the pathology of autoimmune diseases.  
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Figure 1-8. Vitamin D signalling  
Figure 1.8. Vitamin D signalling. A) The majority of vitamin D metabolites are 
transported in the blood bound to vitamin D binding protein (VDBP). The remainder 
travel free or bound to albumin. B) Uptake of VDBP-bound vitamin D by endocytosis 
is mediated by megalin and cubulin.  C) VDBP is released from megalin and cubulin 
in the lysosome and degraded. Vitamin D is metabolised by the cell. D) 1,25 
dihydroxyvitamin D3 (1,25(OH)2D3 ), the active form of vitamin D, binds to the vitamin 
D receptor (VDR) which becomes phosphorylated and heterodimerises with Retinoid 
X Receptor (RXR). Co-repressor proteins (CO-RP) are released, permitting VDR 
transcription factor activity. E) VDR-RXR heterodimer interacts with vitamin D 
response elements (VDRE) and recruits co-activator proteins (CO-ACT) and 
chromatin modifiers such as CBP-P300. Histone acetylation opens the chromatin. 
Vitamin D receptor interacting proteins (DRIPs) are recruited to the open chromatin 
and help to assemble the transcription factor machinery, including RNA-Polymerase 
II (RNA Pol II). Target genes, such as  cyp241, are transcribed. Although most 
responses to vitamin D involve direct gene regulation by VDR, vitamin D also has 
non-genomic effects (blue lines). These can be mediated by VDR but might also 
involve signalling from a membrane VDR or G protein-coupled receptor (GPCR) (F).
Adenylate cyclase (AC), PI-3-kinase (PI3K), phospholipase C  (PLC) and mitogen 
activated protein Kinase (MAPK) signalling pathways can be activated. In muscle 
cells, store-operated calcium channel opening  can also contribute. The expression of 
some genes might involve genomic and non-genomic VDR signalling due to 
activation of MAPK signalling. 
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Aims of the thesis 
In recent years, the model of CD4+ T cell differentiation has developed considerably from the 
binary Th1/Th2 model proposed by Mosmann and Coffman, with an increasing number of 
studies focussing on anti-inflammatory iTReg and pro-inflammatory Th17 subsets. Whilst these 
cells have clear roles in host protection, it is considered that dysregulation of their activities 
underlies many inflammatory diseases. Therefore, identifying factors that regulate their 
development holds therapeutic value.  
 
It is becoming apparent that as well as cytokines, environmental and dietary factors can 
regulate CD4+ T cell differentiation. Epidemiological studies suggest that low vitamin D 
status is a risk factor for autoimmunity and anti-inflammatory effects of 1,25(OH)2D3, have 
been demonstrated for APCs. Effects of 1,25(OH)2D3 upon Th1, Th2 and TReg cells in the 
presence of APCs are also described but the ability of 1,25(OH)2D3 to influence CD4
+ T cell 
differentiation directly has not been clearly shown, neither is the effect of 1,25(OH)2D3 upon 
Th17 cells reported. The first two aims of this thesis were therefore to:  
 
1) Establish APC containing and APC-free systems for generating Th17 and iTReg 
cells in-vitro from CD4
+
CD25
- 
T cells purified from healthy human blood. 
 
2) Investigate the effect of 1,25(OH)2D3 upon TReg and Th17 lineages in the presence 
and absence of APCs.  
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Strong homeostatic mechanisms maintain 1,25(OH)2D3 at a very low level in serum which 
does not vary markedly between individuals. Thus, local conversion of 25(OH)D3 by immune 
cells might be important for immune-modulation in-vivo. A third aim of this thesis was 
therefore to:  
 
3) Investigate whether immune cells can convert 25(OH)D3 sufficiently for immune-
modulatory effects of 1,25(OH)2D3 to be measured. 
 
Rheumatoid arthritis (RA) is one autoimmune condition in which IL-17 might be pathogenic. 
Defective TReg activity is also described in this condition. Interestingly, the concentration of 
IL-17 in synovial fluid stratified with disease outcome in a cohort of early synovitis patients, 
thus dysregulation of the Th17/TReg balance might predict disease outcome in these patients. 
VDR polymorphisms are also reported in RA, suggesting that lack of response to 
1,25(OH)2D3 could be involved in RA pathogenesis or influence the use of vitamin D in 
therapy. Therefore, this thesis also aimed to:  
 
4) Investigate the relationship between TReg and Th17 cells in early synovitis patients 
that develop RA versus those who develop non-RA forms of synovitis or show 
self-limiting disease.  
 
5) Study the ability of lymphocytes from synovitis patients to respond to 
1,25(OH)2D3 in-vitro. 
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2  METHODS 
2.1 Cell Culture 
All cells were cultured at 37C, 95% humidity and 5% CO2, in a MCO-17A1C Sanyo CO2 
incubator. 
 
2.1.1 Primary cells 
Primary human T cells, monocytes, DCs and macrophages were cultured in RPM1 1640 
medium (Invitrogen) supplemented with 2mM L-glutamine (Sigma), 10% foetal bovine serum 
(FBS) (Biosera or Invitrogen) and 1% penicillin and streptomycin (Invitrogen) (referred to as 
RPMI-FBS). For serum free conditions, CellGroSCGM media supplemented with 1% 
penicillin and streptomycin (Invitrogen) was used (referred to as serum free medium).  
 
2.1.2 CD86-GFP CHO transfectants  
Human CD86 with mutated stop codon was generated by PCR and cloned into the EGFP-N1 
expression vector (Clontech). Chinese Ovarian Hamster (CHO) cells were transfected with 
the plasmid vector by electroporation. Cells were cultured as below. Those stably expressing 
the plasmid were selected using G418 (500g/ml) and fluorescence activated cell sorting 
(FACS).  
Chinese Hamster Ovarian (CHO) cells were cultured in a T75 culture flask in DMEM 
medium supplemented with 2mM L-glutamine, 10% foetal FBS and 1% penicillin and 
streptomycin (DMEM-FBS). Cells were passaged every 2-3 days by trypsinisation. For this, 
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medium containing non-adherent cells was aspirated and adherent cells washed once with 5ml 
phosphate buffered saline (PBS). Following PBS removal, 2ml Trypsin-EDTA 
(ethylenediamine tetra-acetic acid) (Invitrogen) were added and cells incubated 2-3mins at 
37°C. Trypsin was quenched by addition of 8ml DMEM-FBS. To continue the culture, 1ml 
cell suspension was retained in the flask or transferred to a new flask and 19ml DMEM-FBS 
added.  
 
2.2 Cell Purification  
 
Unless otherwise stated, all washes involved centrifugation at 490g for 5 minutes. 
 
2.2.1 Isolation of PBMCs by Ficoll-Paque Plus centrifugation 
Primary cells were isolated from peripheral blood mononuclear cells (PBMC) obtained from 
buffy coats or leukocyte reduction system cones (LC) provided by the Birmingham National 
Blood Service. PBMC isolation was performed by the Ficoll-Paque PLUS method of density 
gradient centrifugation (GE Healthcare).  
 
Buffy coats or LCs were diluted 1:4 with phosphate buffered saline (PBS) and 25ml layered 
onto 15ml Ficoll-Paque PLUS in a 50ml Falcon tube. Following 25 minutes centrifugation at 
1060g, without brake, the upper plasma layer was removed by aspiration and PBMCs at the 
Ficoll-plasma interface transferred to a second 50ml Falcon tube using a Pasteur pipette. Cells 
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were re-suspended in 50ml PBS and centrifuged for 10 minutes at 1060g with brake. Cells 
were washed a second time with 50ml PBS and centrifuged for 5 minutes at 260g. A further 
50ml PBS wash was performed with centrifugation at 490g for 5 minutes followed by two 
washes with MACS® buffer (2mM EDTA, 0.5% Bovine Serum Albumin (BSA) in PBS). 
Cells were counted after each wash and the number of washes adjusted according to the extent 
of debris/platelet contamination.  
 
2.2.2 Isolation of monocytes from PBMCs using StemCell Technologies 
enrichment methods 
 
2.2.2.1 StemSep® CD14+ monocyte enrichment method (used to purify 
monocytes for studies reported in chapters three and four) 
CD14+ monocytes were isolated from PBMCs by magnetic colloid antibody based negative 
selection. The hapten antibody human monocyte enrichment cocktail included monoclonal 
antibodies against CD2, CD3, CD19, CD56, CD66b and glycophorin A. From PBMCs, a 
monocyte yield of 15% was typically obtained. The protocol was as follows. Note that all 
steps were performed in MACS® buffer.  
PBMCs were suspended at 100 x 106/ml and incubated with the monocyte enrichment 
cocktail (100l/ml) at 4C for 30 minutes in a 25ml universal. Following a single 25ml wash, 
they were re-suspended at 100 x 106/ml and incubated for a further 30 minutes at 4C with 
magnetic colloid (60l/ml). After washing, PBMCs were re-suspended at 150 x 106/ml and 
1ml applied to a primed LS column (Miltenyi Biotec) attached to a magnetic stand. The 
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column had been primed by rinsing with 3ml MACS® buffer immediately prior to the 
application of the PBMC suspension. Monocytes were collected from the column in 3 x 3ml 
washes. The purified monocytes were finally re-suspended in RPMI-FBS at 2 x 106/ml and 
incubated at 37C. Purity was checked by flow cytometry for CD4, CD14 and CD11c. 
Monocytes were CD4mid, CD14high CD11c+. 
 
2.2.2.2 EasySep® CD14+CD16- monocyte enrichment method (used to 
purify monocytes for studies reported in chapters five and six) 
The EasySep hapten antibody human monocyte enrichment cocktail used for the negative 
selection of CD14+CD16- monocytes included monoclonal antibodies against CD2, CD3, 
CD16, CD19, CD20, CD56, CD66b, CD123, glycophorin A and dextran. The protocol was as 
follows. Note that all steps were performed in MACS® buffer.  
 
PBMCs were suspended at 100 x 106/ml and incubated with the monocyte enrichment 
cocktail (100l/ml) at 4C for 10 minutes in a 15ml Falcon tube. EasySep magnetic particles 
were vortexed thoroughly and added to the cells at 100l/ml. Cells and particles were mixed 
well and incubated at 4°C for 5 minutes. MACS® buffer was added to a total volume of 9ml 
and the tube placed into the EasySep® magnet with cap removed. After 5 minutes, the magnet 
holding the tube was picked up and cells poured into a fresh 15ml Falcon tube. The tube was 
left inverted for 2-3 seconds. Magnetically labelled, unwanted cells remained in the tube. The 
magnetic removal step was repeated and negatively selected cells poured into a 25ml 
universal. Cells were then washed in 25ml MACS buffer at 260g for 5 minutes, re-
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suspended in culture medium at a density of 2 x 106/ml and incubated at 37C. Purity was 
checked by flow cytometry for CD4, CD14 and CD11c. Monocytes were CD4mid, CD14high 
CD11c+. 
 
2.2.3 Isolation of CD4+ cells from PBMCs using StemCell Technologies 
enrichment methods 
 
2.2.3.1 StemSep® CD4+ enrichment method (used to purify CD4+ T cells 
for studies reported in chapters three and four) 
A similar approach to that used to select CD14+ monocytes from PBMCs was used for the 
selection of CD4+ T cells. The hapten antibody human CD4+ T cell enrichment cocktail 
included monoclonal antibodies against CD8, CD14, CD16, CD19, CD56 and glycophorin A. 
Typically, a 20% CD4+ T cell yield was achieved from PBMC. The method used was as 
described in 2.2.2.1 with the exception that incubations with the enrichment cocktail and 
magnetic colloid were performed at room temperature for 15 minutes. Cells were finally re-
suspended in MACS® buffer at 100x106/ml for CD25 labelling (2.2.4).  
 
2.2.3.2 EasySep® CD4+ enrichment method (used to purify CD4+ T cells 
for studies reported in chapters five and six) 
The hapten antibody human CD4+ T cell enrichment cocktail used in this procedure included 
monoclonal antibodies against CD8, CD14, CD16, CD19, CD20, CD36, CD56, CD123, 
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TCR, glycophorin A and dextran. The protocol was as follows. Note that all steps were 
performed in MACS® buffer.  
 
PBMCs were suspended at a density of 100 x 106/ml and incubated with the CD4+ T cell 
enrichment cocktail (50l/ml) at room temperature for 10 minutes in a 15ml Falcon tube. 
EasySep magnetic particles were vortexed thoroughly and added to the cells at 100l/ml. 
Cells and particles were mixed well and incubated at room temperature for 5 minutes. 
MACS buffer was added to a total volume of 9ml and the tube placed into the EasySep® 
magnet with cap removed. After 5 minutes, the magnet containing the tube was picked up and 
the cells poured into a fresh 15ml Falcon tube by inverting the magnet and tube for 2-3 
seconds. Magnetically labelled, unwanted cells remained in the tube. The magnetic removal 
step was repeated and negatively selected cells poured into a 30ml universal. Cells were 
counted and pelletted by centrifugation at 490g for 5 minutes and re-suspended in MACS 
buffer at 100x106/ml for CD25 labelling.  
 
2.2.4 Selection of CD4+CD25- CD45RA+ or CD45RO+ T cells 
CD4+CD25- T cells were sorted from CD4+ T cells by negative selection using magnetic 
microbeads coated with monoclonal antibody to human CD25 (Miltenyi Biotec). Similarly, 
magnetic microbeads coated with monoclonal antibody to CD45RA or CD45RO (Miltenyi 
Biotec) were used to negatively sort CD4+CD25- T cells into memory and naive populations 
respectively. The general protocol involved incubation of the starter population in MACS 
buffer at a density of 100 x 106cells/ml with the microbeads (100l/ml) for 25 minutes at 4°C. 
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Following one wash in MACS buffer, the cells were re-suspended in 1ml MACS buffer and 
applied to a primed LS column attached to a magnetic stand (Miltenyi Biotec). Three x 3ml 
MACS buffer washes were used to flush the non-labelled cells from the column. The cells 
were pelletted by centrifugation and re-suspended at 2 x 106/ml in the appropriate culture 
medium.  
 
2.3 Cell Preparation Methods 
Unless otherwise stated, all washes involved centrifugation at 490g for 5 minutes. 
 
2.3.1 Generation of monocyte derived dendritic cells (DCs) 
CD14+ monocytes were cultured with granulocyte macrophage-colony stimulating factor 
(GM-CSF) (800U/ml, Peprotech) and IL-4 (400U/ml, Peprotech) for seven days in 12 well 
plates. At two days, cultures were supplemented with fresh medium containing GM-CSF and 
IL-4. When required, DCs were matured by overnight treatment with lipopolysaccharide 
(LPS) (1g/ml, Sigma).  
DCs used for stimulations in the presence of 25(OH)D3 (chapter 6) were cultured in RPMI 
supplemented with human plasma (20%). Human plasma was obtained from the top layer of 
the Ficoll-Paque Plus gradient separation. The plasma was filtered using a 2m gauge filter 
and heat inactivated by heating to 65°C for 20 minutes. Debris was pelletted by centrifuging 
at 1060g for 25 minutes and the supernatant used to supplement the culture medium.  
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When collecting DCs for use in stimulations, the culture plate was placed on ice for 20 
minutes to reduce DC adherence. Wells were washed with ice-cold PBS and cells suspended 
by gentle pipetting. The DCs were transferred to a 25ml universal, washed twice with PBS 
and re-suspended in culture medium at 0.5 x 106/ml. The DC phenotype was confirmed by 
flow cytometry for surface markers CD80, CD86, CD14, HLA-DR and CD11c. Immature 
DCs (iDCs) were CD80low, CD86low, CD14- and HLA-DR+. Mature DCs (mDCs) were 
CD80+, CD86+, CD14- and HLA-DR+. 
 
2.3.2 Carboxyfluorescein succinimidyl ester (CFSE) cell labelling  
Cells were washed twice with PBS and re-suspended in PBS at a density of 5-10 x 106/ml in a 
30ml universal. They were then incubated with 1M CFSE (Molecular Probes) at room 
temperature for 10 minutes in the dark. The universal was filled with RPMI-FBS to quench 
the labelling reaction. Cells were then washed a further two times with RPMI-FBS and re-
suspended in the appropriate culture medium.  
 
2.3.3 CellTrace Far Red DDAO-SE labelling  
Cells were washed twice with PBS and re-suspended in PBS at a density of 5-10 x 106/ml in a 
30ml universal. They were then incubated with 5M CellTrace Far Red DDAO-SE 
(Molecular Probes) at room temperature for 25 minutes. The universal was filled with RPMI-
FBS to quench the labelling reaction. Cells were then washed a further two times with RPMI-
FBS and re-suspended in RPMI-FBS.  
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2.4 CD4+CD25- T cell stimulation assays 
All T cell stimulation assays were carried out in flat bottom 96 well plates unless otherwise 
specified. 90,000 T cells were used per well in a total volume of 200l.  
 
Bead stimulations  
CD3/CD28 T Cell Expander Dynabeads® (Invitrogen) were used. Unless otherwise stated a 
1:4 bead: cell ratio was prepared by adding 0.5l beads to each well of 90,000 cells.  
Prior to re-stimulating bead cultures, old beads were removed by transferring cells to a 15ml 
Falcon tube and placing them in the EasySep® magnet for 5 minutes. Cells were then 
decanted into a universal and re-suspended in the appropriate culture medium.  
 
Monocyte stimulations  
Monocytes and T cells were cultured together at a ratio of 1:4 in the presence of anti-CD3 
(clone OKT) at 0.5g/ml. 
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2.4.1 Supplements  
Where indicated, the stimulations were supplemented with  
IL-1 (10ng/ml, Peprotech) 
IL-2 (200U/ml or as specified, Peprotech)  
IL-6 (20ng/ml, Immunotools)  
IL-23 (10ng/ml, R and D Systems)  
TGF (1ng/ml, R and D Systems)  
 
1,25(OH)2D3 (Sigma) was used at 100nM in studies carried out in RPMI-FBS but a change to 
10nM was implemented for later studies in serum free medium since this concentration gave 
similar outcomes and is more physiologically relevant than 100nM.  
 
25(OH)D3 (Sigma) was used at 50nM unless otherwise stated.  
 
For stimulations carried out in the presence of vitamin D, the plate was covered with tin foil 
to protect from light.  
 
Ketoconazole (Sigma) was used at the indicated concentrations.  
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2.4.1.1 Preparation of supplement stocks 
IL-1 (Peprotech). Lyophilized protein was dissolved in sterile H2O to 100g/ml then 
diluted to 10g/ml with 0.1% BSA-PBS. Working aliquots were stored at -20°C. 
IL-6 (Immunotools): Lyophilized protein was dissolved in sterile H2O to 100g/ml then 
diluted to 10g/ml with 0.1% BSA-PBS. Working aliquots were stored at -20°C. 
IL-23 (R&D): Lyophilized protein was dissolved in 0.1% BSA-PBS to 20g/ml. Working 
aliquots were stored at -20°C. 
IL-2 (Peprotech): Lyophilized protein was dissolved in 100mM acetic acid to 1x106Units/ml 
. Working aliquots were stored at -20°C. 
TGF (R&D): Lyophilized protein was dissolved in 4mM HCL containing carrier protein 
BSA at 1mg/ml to a concentration of 10g/ml.  
 
1,25(OH)2D3 (Sigma): 4mM stock was prepared in isopropanol and diluted to 0.1mM in 
absolute ethanol. Stock solutions were stored at -20°C protected from light. 
25(OH)D3 (Sigma): 4mM stock was prepared in isopropanol and diluted to 0.1mM in 
absolute ethanol. Stock solutions were stored at -20°C protected from light.  
Ketoconazole (Sigma): 50mM stock was prepared in methanol and stored at -20°C protected 
from light.  
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2.5 Flow Cytometry 
At least 80,000 cells were used for each stain, although for stimulations carried out in a 96 
well plate, all of the cells in a single well at the time point monitored were typically stained. 
Staining was done in 5ml round bottom polystyrene tubes for FACScaliburTM analysis or 5ml 
polypropylene tubes for DakoCyan analysis. 1ml PBS was used for each wash unless 
otherwise stated and centrifugation performed at 710g for 5 minutes. Wash solutions were 
removed by brief inversion of the tube and cells re-suspended in the remaining buffer by 
gentle vortex. The volume of each antibody used for staining is given in Table 2.1. All 
staining steps were carried out in the absence of light and after staining cells were stored at 
4C in the dark until analysis.  
 
Flow cytometry was performed on a FACScaliburTM (Becton Dickinson UK) or Dako Cyan 
fluorescence activated cell scanner. Data was analysed using FlowJoTM software (Tree Star, 
U.S.A). At least 10,000 events were collected for each sample. 
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Table 2-1. Antibodies used in flow cytometry 
Antibody Company Catalogue 
No. 
Isotype Clone Volume/ 
labelling 
(l) 
CD11c-APC BD 559877 Mouse IgG1, Bly6 3 
CD11c-PE BD 555392 Mouse IgG1, Bly6 3 
CD14-PE Serotec MCA596PE Mouse IgG2a UCHM1 2 
CTLA4-PE BD 555853 Mouse IgG2a, BN13 1 
CTLA4-APC BD 555855 Mouse IgG2a, BN13 2 
CD25-APC BD 555434 Mouse IgG1, M-A251 3 
CD25-Fitc BD 345796 Mouse IgG1,k 2A3 2 
CD25-PE BD 555482 Mouse IgG1, M-A251 3 
CD3-FITC BD 345763 Mouse IgG1, SK7 2 
CD3-PerCP BD 345766 Mouse IgG1, SK7 4 
CD3-PE BD 555340 Mouse IgG2a, HIT3a 3 
CD45RA-
FITC 
BD 31264X - - 4 
CD45RO-
FITC 
BD 555492 Mouse IgG2a, UCHL1 4 
CD4-APC BD 555349 Mouse IgG1, RPA-T4 3 
CD4-FITC BD 555346 Mouse IgG1, RPA-T4 3 
CD4-PE BD 555347 Mouse IgG1, RPA-T4 3 
CD69-FITC BD 555530 Mouse IgG1, FN50 3 
Foxp3-APC ebioscience 17-4776-73 Rat IgG2a, PCH101 2.5 
IFN-APC BD 554702 Mouse IgG1, B27 0.5 
IgG1-PE BD 345816 Mouse IgG1 X40 2 
IgG2a-PE BD 555574 Mouse IgG2a, G155-178 3 
IgG1,k-Fitc BD  555748 Mouse IgG1,k MOPC-21 - 
IgG1,k-APC ebioscience 51-4714-80 Mouse IgG1,k  - 
IgG2a,k-APC BD 555576 Mouse IgG2a,k G155/178 - 
IL-17-PE ebioscience 12 7178-71 Mouse IgG1  eBio64CAP17 2 
IL-2-PE BD 554566 Rat IgG2a, MQ1-17H12 0.5 
IL-10-PE BD 559337 Rat IgG1 JES3-9D7 5 
IL-21-647 ebioscience 51-7219 Mouse IgG1,k eBio3A3-N2 3 
IL-21-PE ebioscience 12-7219 Mouse IgG1,k eBio3A3-N2 3 
IFN-Pacific 
Blue 
ebioscience 57-7319 Mouse IgG1,k 4S.B3 3 
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2.5.1 Staining for surface antigens 
Surface antigens were stained on live cells. After transferring cells to FACS tubes they were 
washed once and buffer aspirated to leave a damp pellet. Cells were re-suspended in 75l 2% 
goat serum (Sigma-Aldrich) in PBS and incubated at room temperature for 30 minutes to 
block Fc binding sites. Directly conjugated antibodies were then added in a 25l total volume 
adjusted with PBS and cells incubated on ice for 30 minutes. Following staining, cells were 
washed twice with PBS and re-suspended in 200l PBS. Cells were either analysed 
immediately or fixed with 3% paraformaldehyde-PBS (PFA-PBS) as described in 2.5.2. 
 
2.5.2 Paraformaldehyde-PBS (PFA-PBS) fixation   
Cells were re-suspended in 1ml 3% PFA-PBS by gentle vortexing and incubated at room 
temperature for 12 minutes. Cells were then pelletted, washed once with 1ml PBS and re-
suspended in 200l PBS. Samples were covered with foil and stored at 4°C until FACS 
analysis.  
 
2.5.3 Cycling CTLA-4 staining 
Cells were transferred to FACS tubes, washed once and re-suspended in APC or PE 
conjugated anti-CTLA-4 (BD), prepared in 100l culture medium. Cells were incubated for 
30 minutes at 37°C before being washed twice with PBS. Cells were either FACSed 
immediately or fixed with PFA-PBS for later analysis.  
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2.5.4 Intracellular cytokine staining 
Cells were re-stimulated for 6-7 hours by the addition of phorbol myristate acetate (PMA) 
(50ng/ml, Sigma-Aldrich) and ionomycin (1M, Sigma-Aldrich) to the stimulation well. 
Brefeldin A (10g/ml, Sigma-Aldrich) was added during the last 4 – 5 hours to suspend 
protein trafficking. Cells were re-suspended and transferred to FACS tubes. They were fixed 
with 3% PFA-PBS. Cells were either stored overnight at 4°C or permeabilised and stained as 
described below.  
 
Cells were permeabilised by washing with 1ml 0.1% saponin in PBS. Supernatant was 
aspirated and cells blocked at room temperature for 30 minutes in 75l 2% goat serum 
prepared in 0.1% saponin-PBS. Antibodies were added in a 25l volume, adjusted with 0.1% 
saponin-PBS, and cells stained in the dark for 40 minutes at room temperature. Excess 
antibody was removed by one wash with 0.1% saponin-PBS followed by two PBS washes. 
Finally, cells were re-suspended in 200l PBS and collected by flow cytometry.  
 
2.5.5 Intracellular staining by the ebioscience FoxP3 staining protocol 
All buffers for this protocol were freshly prepared from the stock solutions provided in the 
ebioscience FoxP3 staining kit: 
Buffer 1 (fixation/permeabilisation buffer): Prepared by mixing 1 part 
fixation/permeabilisation concentrate with 3 parts fixation/permeabilisation diluent. 
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Buffer 2 (1 X permeabilisation buffer): Prepared by diluting 10X permeabilisation buffer 
with PBS.  
  
Cells were washed once with PBS and re-suspended by vortexing. Note that cells were not 
vortexed again during the staining process until final analysis. The re-suspended cells were 
fixed by incubation in 500l buffer 1 at 4°C for at least one hour or overnight. Following one 
PBS wash, cells were permeabilised with 1ml buffer 2. After pelletting, buffer 2 was removed 
by tipping, rather than aspiration, to avoid cell drying. Antibodies were diluted in buffer 2 and 
added as a 10l volume to the cells. Goat serum (Sigma Aldrich) was also added to a final 
concentration of 2% to reduce non-specific antibody binding and the extent of auto-
fluorescence. Cells were stained in the fridge for 45 minutes, after which they were washed 
once with buffer 2 then twice with PBS. Finally, the cells were re-suspended in 200l PBS for 
collection by flow cytometry.  
 
When cells were stained for surface proteins and FoxP3, the surface stain was performed first. 
After two PBS washes to remove excess antibody, cells were fixed and stained according to 
the ebioscience FoxP3 staining protocol. When FoxP3 and total CTLA-4 were stained 
together, antibodies for FoxP3 and CTLA-4 were added together.  
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2.6 RNA Extraction  
Cells were gently re-suspended in culture medium by pipetting and transferred to 1.5ml 
eppendorfs. They were pelletted by centrifugation for 5 minutes at 490g in a microcentrifuge. 
The supernatant was removed completely by aspiration and cells homogenised in TRIZOL® 
Reagent (Invitrogen) (<1x106 cells = 800l TRIZOL, 1x106 cells = 1000l TRIZOL).  Cells 
were homogenised by pipetting up and down more than 40 times with a P200 pipette. To 
further aid lysis, cells were frozen at -80°C for at least two hours prior to RNA isolation. 
Typical cell numbers used 
Un-stimulated T cells: 500,000 – 1x106 
Stimulated T cells: 250,000-1x106  
Antigen presenting cells 500,000-1x106 
 
Homogenised samples were thawed and held at room temperature (15-25°C) for 5 minutes. 
200l chloroform (Sigma-Aldrich) were added and tubes shaken vigorously for 15 seconds by 
hand. After leaving to stand for 2-3 minutes at room temperature, samples were centrifuged at 
12,000g for 15 minutes at 2-8°C. The upper aqueous phase was removed and transferred to an 
RNase free eppendorf. 1l glycoblue (Ambion) was added to allow later detection of the 
RNA. RNA was precipitated by mixing with 500l isopropyl alcohol (Sigma-Aldrich). Either 
samples were left to stand at room temperature for 10 minutes or when few cells were 
available, they were incubated overnight at -80°C to increase yield. Precipitated RNA was 
pelletted by centrifugation at 12,000g for 10 minutes at 2-8°C. Supernatants were removed 
and the gel like RNA pellets, washed with 1ml 75% ethanol (Sigma-Aldrich) prepared from 
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absolute ethanol and nuclease free water (Fisher). After vortexing, samples were centrifuged 
at 7,500g for 5 minutes at 2-8°C and the majority of supernatant removed. Remaining 
supernatant was collected by a further 1 minute spin at 7,500g supernatant. Samples were left 
to air-dry for a few minutes before re-suspending in nuclease free water. Finally, the RNA 
concentration was measured with a Nano-Drop 3300 (Thermo Scientific).  
 
2.7 cDNA synthesis  
 
2.7.1 SuperScript III Reverse Transcriptase system (Invitrogen)  
This system was used to prepare samples analysed in chapter four. 
 
RNase free water was added to 1g RNA to a total volume of 11l in a RNase free 0.2ml 
eppendorf. 1l random hexamers (Fermentas Life Sciences 0.2g/ml) and 1l 10mM dNTPS 
(Invitrogen) were added and the samples heated to 65°C for 5 minutes. The samples were 
immediately placed on ice for at least 1 minute and the following four components added to 
each tube: 
4l 5x First strand buffer  
1l 0.1M DTT,  
1l RNase OUT  
1l Superscript III Reverse Transcriptase  
 
When preparing multiple samples a master mix of the above reagents was prepared and 7l 
added to each reaction. Minus Reverse Transcriptase controls were also prepared to check for 
genomic DNA contamination. For these, Superscript III Reverse Transcriptase was replaced 
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with RNase free water. Samples were finally incubated at 25°C for 5 minutes followed by 60 
minutes at 50°C in a PTC-225 Peltier thermal cycler. Finally, to inactivate reverse 
transcriptase, samples were heated to 70°C for 15 minutes.  
 
cDNA was aliquotted and stored at -20°C. 
  
2.7.2 Multiscribe TaqMan Reverse Transcription system (Applied 
Biosystems)  
This system was used to prepare samples analysed in chapters five and six.  
 
For samples within a single experiment, equivalent amounts of RNA were reverse transcribed 
but between experiments, amounts converted ranged between 200ng and 700ng total RNA.  
 
Reactions were prepared in nuclease free 200l PCR strips. RNA and nuclease free water 
were mixed to a total volume of 6.95l. The following kit components were then prepared as 
a master mix and added to each tube. Volumes stated are for a single reaction:  
2l 10X RT buffer 
4.4l 25mM MgCl2 
 4l dNTPs 
1l random hexamers 
0.4l RNase inhibitor 
1.25l Multiscribe reverse transcriptase  
 
Minus reverse transcriptase reactions were also prepared by replacing Multiscribe Reverse 
Transcriptase with nuclease free water. The reactions were mixed thoroughly and collected by 
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brief centrifugation. They were then passed through the following incubation steps in a PTC-
225 Peltier thermal cycler. 
25°C for 10 minutes 
37°C for 60 minutes 
48°C for 30 minutes 
95°C for 5 minutes 
4°C hold 
cDNA was aliquoted and stored at -20°C 
2.8 Quantitative real-time PCR analysis  
Quantitative real-time PCR assays were performed using 20X assay on demand kits from 
Applied Biosystems including: IL-17A (Hs99999082_m1), IFN (Hs00174143_m1), CTLA-4
(Hs00175480_m1), FoxP3 (Hs00203958_m1), IL-10 (Hs00174086_m1), CYP27B1 
(Hs00168017_m1), VDR (Hs00172113_m1). VIC-labelled Ribosomal RNA control reagents 
(Applied Biosystems, 4308320) or a 20X VIC labelled 18S gene assay (Applied Biosystems 
4319413E) was used to measure 18S as an endogenous control. Reactions were performed in 
duplex or singleplex depending upon primer compatibility as determined below. Relative 
gene expressions were analysed by the Pfaffl method (Pfaffl, 2001) for which the equation is 
given below.  
E = efficiency, target = target gene, ref = endogenous control reference, Ct = number of 
cycles required to reach threshold fluorescence.  
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The independence of the target gene with 18S in a duplex reaction was assessed by comparing 
slopes of Ct value against concentration for singleplex and duplex reactions performed over a 
cDNA dilution series. Independence was concluded if the slopes differed by less than 0.1. 
Independence to 18S Ribosomal RNA control reagents was satisfied for IL-17A, IFN, 
CTLA-4, IL-10 and FoxP3. VDR and CYP27B1 did not satisfy independence with the 18S 
gene assay. Therefore, these reactions were run in singleplex. 10l reactions were prepared as 
below in a 96 well MicroAMPTM reaction plate with barcode (Applied Biosystems). The 
volume of cDNA to use was determined by titration for the particular gene assay. 
 
Singleplex qPCR reaction composition 
5l TaqMan 2 x PCR master Mix (Applied Biosystems)  
0.5l FAM labelled gene assay 
cDNA 
nuclease free water to a total volume of 10l  
 
Duplex qPCR reaction composition 
5l TaqMan 2 x PCR master Mix (Applied Biosystems)  
0.5l FAM labelled gene assay 
0.2l 18S Forward Primer (10M) 
0.2l 18S Reverse Primer (10M) 
0.0625l VIC-labelled 18S Probe (40M) 
cDNA 
nuclease free water to a total volume of 10l  
 
cDNA and master mix were collected by centrifugation for 1 minute at 1970g and reactions 
passed through the following incubation steps in an Applied Biosystems 7500 machine.  
50°C for  2minutes  (1 cycle) 
95°C for 10 minutes (1 cycle) 
95°C for 15 seconds, 60°C for 1 minute (40 cycles) 
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2.9 Chapter specific methods  
 
2.9.1 Responder T cell suppression assay (chapter four) 
1,25(OH)2D3 plus IL-2 suppressors and untreated control suppressors, were generated by 
stimulating CD4+CD25- T cells with monocytes and anti-CD3 (OKT3) (0.1g/ml) in the 
presence or absence of 1,25(OH)2D3 (100nM) and IL-2 (200U/ml). Stimulations were 
prepared in a 24 well plate. 1 million T cells and 250,000 monocytes (4:1 ratio) were added 
per well to a total volume of 2ml. For IL-2 treated cultures, IL-2 was supplemented at four 
days. At seven days, the stimulated cells were re-suspended and transferred to 30ml 
universals. Their CTLA-4/FoxP3 phenotypes were assessed by flow cytometry as described in 
2.5.5 and the remaining cells labelled with cell tracking dye DDAO-SE as described in 2.3.3.  
 
Monocyte derived DCs, autologous to the stimulated suppressor cells were cultured for six 
days. They were then matured overnight with 1g/ml LPS (Sigma-Aldrich). At day seven, the 
DCs were removed from the culture plate, washed and re-suspended in RPMI-FBS as 
described in 2.3.1.  
  
At seven days, allogenic responder CD4+CD25- T cells were freshly isolated from a buffy coat 
and labelled with CFSE as described in 2.3.2. Responder T cells, suppressor T cells and 
mature dendritic cells were then combined in 96 well flat bottom plates with anti-CD3 
(0.1g/ml). During assay development, a range of responder to suppressor ratios and DC to 
responder ratios were tested. 10 responders (70,000 cells/well) to 1 suppressor (7,000 
cells/well) to 2 DCs (14,000 cells/well) was determined optimum. After five days of culture, 
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cells were re-suspended, and FACSed live in PBS. CFSE+DDAO-SE- responder cells were 
selected by gating (figure 4.18B) and their median CFSE fluorescence intensity measured as 
an indication of division. 
 
2.9.2 Th17 selection and enrichment (Chapter five) 
2.9.2.1 Preparation of Th17 enriched cultures 
An IL-17+ enriched CD4+ T cell culture was prepared by stimulating >13million CD4+CD25- 
T cells with CD3/CD28 T Cell Expander Dynabeads® (Invitrogen) at a ratio of 1 bead to 32 T 
cells. Serum free medium supplemented with recombinant Th17 polarising cytokines (TGF 
1ng/ml, IL-1 10ng/ml, IL-6 20ng/ml, IL-23 10ng/ml) was used. Stimulations were prepared 
in 24 well plates with 900,000 T cells and 0.625l beads per well. At six days, cells were re-
suspended and beads removed using the EasySep magnet. Cells were counted, pelletted and 
re-suspended in the six day culture medium at 1 x 106/ml. 2ml of cells were plated per well of 
a 24 well plate. 4 million cells were left un-stimulated. The remainder were re-stimulated with 
phorbol 12, 13 dibutyrate (PdBU) (Sigma-Aldrich) and ionomycin for 2 hours. After this 
period, 100,000 cells from each culture were treated with brefeldin A for estimation of 
cytokine expression by intracellular staining. The protocol used included dead cell exclusion, 
as described in 2.9.2.3.  
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2.9.2.2 IL-17 secretion analysis and capture 
 
All centrifugation steps in this protocol were carried out for 7 minutes at 4°C, 490g in an 
accuSpinTM3R centrifuge (Fischer Scientific) unless otherwise stated.  
 
Re-stimulated and non-re-stimulated cells, prepared as above, were transferred to 15ml Falcon 
tubes for cytokine secretion staining. Cells were washed with cold MACS buffer and re-
suspended in ice cold medium (RPMI-FBS) at 1x107 cells/80L. 20l of IL-17 catch 
reagent/80l cells were then added and the cells incubated for 5 minutes on ice.  
 
For the secretion phase of the assay, cells were transferred to pre-warmed RPMI-FBS at 
1x105cells/ml. The cell suspension was distributed as 25ml aliquots into 50ml Falcon tubes. 
Cells were incubated for 40 minutes at 37°C, throughout which the tubes were turned several 
times every 5 minutes to maintain cell separation. The tubes were then topped up with ice-
cold MACS buffer and surrounded with ice for 10 minutes to slow cell secretion, thus 
reducing the risk of cross labelling during the following centrifugation steps. Cells were 
pelletted, the majority of supernatant removed and like treated cells combined in a 15ml 
Falcon. Following a second wash in MACS buffer cells were re-suspended in MACS 
buffer at 1x107cells/80l and 20l of IL-17-PE antibody added. Cells were incubated for 10 
minutes on ice before being washed with 10ml MACS buffer. Cells were re-suspended in 
1ml MACS buffer, counted and IL-17+ cells captured by MoFlo technology. FSC-W and 
SSC-W parameters were used to exclude non-singlet cells and the IL-17+ acceptance gate set 
upon cells that had not been re-stimulated with PdBU and ionomycin. 
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25,000 sorted cells were stimulated for three days in 96 well flat bottom plates under Th17 
polarising conditions (1:32 bead: cell ratio, serum free medium, TGF (1ng/ml), IL-1 
(10ng/ml), IL-6 (20ng/ml), IL-23 (10ng/ml), IL-2 (50U/ml)) in the presence or absence of 
1,25(OH)2D3 (10nM). 
 
2.9.2.3 Intracellular cytokine staining with live/dead discrimination 
At three days, cells were re-stimulated with PMA and ionomycin and blocked with brefeldin 
A as described in 2.5.4. Prior to fixation, dead cells were labelled with the LIVE/DEAD 
Fixable Near-IR dead cell staining kit (Invitrogen). For this, cells were washed once with 
PBS. Buffer was removed by aspiration and cells re-suspended in 250l LIVE/DEAD amine 
reactive fluorescent dye freshly prepared by diluting 1l of the reconstituted dye in 1ml PBS. 
Cells were protected from light and incubated 30 minutes on ice. They were then washed 
twice with PBS before being fixed with 3% PFA-PBS. Intracellular staining with IL-17-FITC, 
IFN-Pacific Blue and IL-21-APC was performed as described in 2.5.4 with the exception 
that cells were not blocked with goat serum prior to staining.  
 
2.9.3 CD86-GFP acquisition assay (Chapter five) 
 
Preparation of stimulated T cells for CD86-GFP acquisition assay 
CD4+CD25- T cells were stimulated with CD3/CD28 T Cell Expander Dynabeads® for four 
days in serum free medium. A ratio of one bead to four T cells was used. For this, 900,000 T 
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cells were plated per well of a 24 well plate and 5l beads added per well. To obtain cells 
with different levels of CTLA-4 they were stimulated under the following conditions:  
 Th17 polarising: 1ng/ml TGF (R&D), 10ng/ml IL-1 (Peprotech), 20ng/ml IL-6 
(Immunotools), 10ng/ml IL-23 (R&D) 
 Control: no supplement 
 1,25(OH)2D3 (10nM) 
At four days, cells were re-suspended and transferred to a 15ml falcon. Beads were removed 
using the EasySep magnet and cells tipped into 30ml universals. Cells were washed once 
with PBS and re-suspended in serum free medium at 1x106/ml.  
 
100,000 T cells from each population were stained for total CTLA-4 using the ebioscience 
FoxP3 staining protocol (2.5.5). 100,000 T cells were also stained for cycling CTLA-4 
following stimulation with CD3/CD28 T Cell Expander Dynabeads® (2.5.3). These 
stimulations were carried out for 3 hours in 96 well round bottom plates at a ratio of 1 bead:1 
T cell.  
 
500,000 CTLA-4-blocked T cells were prepared from each culture by incubating with 
blocking antibody to CTLA-4 (40g/ml) at 37°C for at least 40 minutes immediately prior to 
their use in the CD86-GFP acquisition assay.  
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Preparation of CHO-CD86-GFP cells 
CHO-CD86-GFP cells were prepared and cultured as described in 2.1.2. Following removal 
from the culture flask 5x106 cells were labelled with DDAO-SE as described in 2.3.3. 
Labelled cells were re-suspended in serum free medium at a density of 3x106/ml. 
 
150,000 DDAO-SE+ CHO-CD86-GFP cells were mixed with 50,000 T cells (+/- antiCTLA-4 
treatment) in a 96 well round bottom plate and anti-CD3 (0.5g/ml) added to promote CTLA-
4 cycling. Control wells were prepared in which CHO cells were absent. These were used to 
set the baseline GFP fluorescence for each population. Cells were cultured for 3 hours at 37°C 
after which the plate was placed on ice and cells FACSed live. Cells were analysed on the 
DakoCyan to permit selection of singlet populations based upon pulse width as shown in 
figure 2.1. 
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Figure 2-1. Gating strategy for analysis of CD86-GFP acquisition by T cells 
 
Figure 2.1. Gating strategy for analysis of CD86-GFP acquisition by T cells. 1) 
Live cells were gated by FSC vs SSC. 2) Single cells were selected by low pulse 
width. 3) DDAO-SE labelled CHO-CD86-GFP cells were excluded. 4) CD86 
acquisition was determined by % GFP+ve cells. The negative gate was set according 
to the autofluorescence of T cells that had not been co-cultured with CHO cells.    
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2.9.4 B7 depletion assay (Chapter five) 
 
Preparation of SEB reactive CD4
+
 T cells  
20x106 PBMCs were suspended in RPMI-FBS at 2x106/ml. 2x106cells were plated per well of 
a 24 well plate. Medium was supplemented with IL-2 (200U/ml) and cells stimulated with 
Staphylococcus aureus enterotoxin B (SEB) superantigen (100ng/ml). 10x106 cells were 
treated with 1,25(OH)2D3 (10nM). At 4 days, cultures were divided and 500l of fresh 
medium added to each well. For 1,25(OH)2D3-treated cultures, IL-2 and 1,25(OH)2D3 were 
also re-supplemented. At six days, 1,25(OH)2D3 cultures were supplemented a third time with 
1,25(OH)2D3 (10nM final). On day seven, PBMCs were re-suspended and dead cells depleted 
by gradient centrifugation. For this, 10ml Ficoll-Paque PLUS was aliquot into 30ml 
universals and cells layered on top. Cells were centrifuged for 25 minutes at 1060g without 
brake. The PBMC layer at the Ficoll-plasma interface was then transferred to a second 30ml 
universal. Cells were re-suspended in MACS buffer and centrifuged for 10 minutes at 
1060g, with brake. Cells were re-suspended in 10ml MACSbuffer, counted and re-suspended 
at a density of 100x106/ml. CD4+ T cells were isolated using the EasySep® CD4+ enrichment 
method as described in 2.2.3.2. Because cell numbers were low, after incubation with 
magnetic particles cells were re-suspended in 4ml MACS buffer and placed in the EasySep 
magnet. Purified cells were washed with PBS and labelled with CFSE as described in 2.3.2. 
After labelling, cells were re-suspended in RPMI-FBS at 750,000/ml. The phenotype of the 
cells was checked by surface staining for CD4, CD3 and CD8 and intracellular staining for 
total CTLA-4 and FoxP3 (figure 2.2).  
Methods 
85 
 
Half of the control and 1,25(OH)2D3-treated SEB reactive CD4
+ T cells were blocked with 
anti-CTLA-4 (40g/ml) for >40 minutes at 37°C immediately prior to co-culture with the 
SEB pulsed DCs as described below. 
 
Preparation of SEB-pulsed DCs 
Immature DCs were removed from the culture plate and transferred to a 25ml universal. DCs 
were washed with RPMI-FBS and re-suspended in 1ml RPMI-FBS. SEB was added at 1g/ml 
and incubated at 37°C for 2 hours. DCs were then washed once with medium and re-
suspended at 150,000/ml, 75,000/ml and 37,500/ml. 
 
SEB pulsed DCs and stimulated T cells were mixed at ratios of 1:5, 1:10 and 1:20 in a 96 well 
round bottom plate. To enable a sufficient number of DCs to be collected for FACS, one, two 
and four wells were prepared for each ratio respectively with 150,000 T cells being added per 
well. DCs and T cells were cultured for 24 hours. The plate was then placed on ice to reduce 
DC adherence. Wells were also rinsed twice with ice cold PBS and rinsings combined to 
maximise adherent cell collection. Cells were surface stained for CD80-PE and CD86-APC 
and FACSed live on the DakoCyan. Cells were gated on pulse width and CFSE negative cells 
excluded. CD80 and CD86 mean fluorescence intensities were recorded. 
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Figure 2-2. CTLA-4 and FoxP3 expression by SEB reactive CD4
+
 T cells 
 
Figure 2.2. CTLA-4 and FoxP3 expression by SEB reactive CD4+ T cells. PBMCs 
were stimulated with staphylococcus aureus enterotoxin B with IL-2 in the presence 
of 1,25(OH)2D3 or vehicle control. At seven days CD4+ T cells were isolated by the 
EasySep CD4+ T cell enrichment method. A) CD8 and CD4 expression by CD3+ T 
cells pre and post CD4+ T cell isolation. B) CTLA-4 and FoxP3 expression by purified 
CD4+ T cells.  
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2.10 Methods for analysis of samples from synovitis patients (chapter seven)  
The Solihull Local Research Ethics Committee (REC reference number 07/Q2706/2) granted 
ethical approval for the study. All of the patients enrolled gave written informed consent 
before samples were taken. Patients were seen by consultant rheumatologists, Dr Karim Raza 
or Dr Andrew Filer and were recruited as early synovitis patients if they had at least one 
swollen joint and had experienced symptoms for 3 months. A number was assigned to each 
sample so that it could be dealt with anonymously. After 18 months, the patient‟s condition 
was diagnosed as i) rheumatoid arthritis (RA), ii) non-RA persistent synovitis, iii) self-
limiting. For some patients, adequate follow-up data were not available and these patients 
were classified as “outcome unknown”. Patients were diagnosed with RA if their condition 
satisfied at least four of the American College of Rheumatology 1987 criteria (Arnett et al., 
1988) as listed in table 2.2. Non-RA-persistent synovitis was diagnosed if patients continued 
to show clinical evidence of joint inflammation but did not satisfy the 1987 ACR criteria for 
RA. Self-limiting disease was diagnosed if synovitis was no longer clinically apparent at the 
18-month assessment and the patient had not received glucocorticoid or disease modifying 
anti-rheumatic drug treatment within the previous 3 months. For comparison, patients 
presenting at first assessment with established RA were also included in the study and age-
matched colleagues without a history of illness or joint inflammation and who were not taking 
medication were recruited as healthy controls.  
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Table 2-2. American College of Rheumatology 1987 criteria for the classification of 
rheumatoid arthritis (RA). At least four criteria must be fulfilled for classification as 
RA. Abbreviations: Proximal Interphalangeal (PIP), Metacarpophalangeal (MCP), 
Metatarsophalangeal (MTP).  
Criteria Definition 
  
Morning stiffness Morning stiffness in and around the joints lasts for at least 1 
hour. 
  
Arthritis of 3 joints Soft-tissue swelling or fluid in at least three of the following 
areas: the left or right PIP, MCP, wrist, elbow, knee, ankle or 
MTP joints. 
  
Arthritis of the hand joints Swelling of the wrist, MCP or PIP joints. 
  
Symmetric arthritis Simultaneous involvement of the same joint areas (as above) 
on both sides of the body.  
  
Rheumatoid nodules Subcutaneous nodules present 
  
Rheumatoid factor Detected by a method that yields positive findings in <5% or 
normal cohorts. 
  
Radiographic changes Erosions or unequivocal bony decalcification localised to the 
joints of the hands and wrists. 
  
 
At initial assessment, the disease activity score 28 (DAS28), which has been validated for use 
in the assessment of disease activity in RA, was calculated (Prevoo et al., 1995). Serum C 
Reactive Protein (CRP) was measured and included in the DAS28 calculation (Paulus et al., 
1999). Blood samples were also analysed for Rheumatoid Factor (RF), anti-cyclic 
citrullinated peptide (CCP), erythrocyte sedimentation rate (ESR) and 25(OH)D3 level. EDTA 
anti-coagulated peripheral blood (PB) samples (10ml) and, where possible, synovial fluid (SF) 
samples, were taken for the isolation of mononuclear cells as described in 2.10.1. SF was 
extracted by ultrasound guidance as described in (Raza, 2004) or by palpation guidance. In 
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general, SF was obtained from the joint, which contained the largest amount of SF according 
to ultrasonographic assessment.  
 
2.10.1 Isolation of PBMCs and SFMCs from early synovitis patient blood and 
synovial fluid samples 
 
Prior to SFMC isolation, SF was treated with hyaluronidase (10U/ml) for 30 minutes at 37C. 
 
PBMCs and SFMCs were purified from PB and SF samples respectively, by the Ficoll-Paque 
Plus method (GE Healthcare) as described in 2.3.1, with the  exception that the top layer of 
the gradient (plasma or synovial fluid) was filtered with a 2m gauge filter and used to 
supplement the culture medium. A 1ml sample of the fluid was also stored at -20°C. All 
washes were carried out with PBS except the last, for which RPMI 1640 supplemented with 
10% self-plasma or SF, 1% penicillin and streptomycin (Invitrogen), 2mM L-glutamine 
(Sigma), was used. After washing, the cells were re-suspended to a density of 1x106/ml and 
allocated as follows (2.10.2-2.10.5) 
 
2.10.2 Surface staining for CD3, CD4 and CD45-RO  
80,000-100,000 cells were surface stained with CD45-RO-FITC, CD3-PE and CD4-APC 
directly ex-vivo and analysed live by flow cytometry.  
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2.10.3 Ex-vivo T17 analysis  
100,000-150,000 cells were plated per well of a 96 well plate for intracellular cytokine 
staining following PMA and ionomycin stimulation in the presence of brefeldin A as 
described in 2.5.4. During assay development, it was confirmed that the ex-vivo T17 
frequency was not influenced by resting the cells overnight prior to stimulation. Since 
samples were generally received late in the day, overnight resting was adopted for routine 
analysis. After stimulation, cells were intracellular stained with CD4-FITC, IL-17-PE, CD3-
PerCP and IFN-APC. Because PMA and ionomycin treatment often reduced CD4 expression 
to very low levels, it was decided to exclude CD4 distinction from the analysis and quote IL-
17 frequencies for CD3+ cells, defined as T17, rather than for CD3+CD4+ cells.   
 
2.10.4 Ex-vivo TReg analysis and CTLA-4 expression  
80,000-100,000 cells were surface stained with (i) CD4-FITC, CD25-PE and CD3-PerCP or 
(ii) CD4-FITC, and CD3-PerCP or (iii) appropriate isotype controls and fixed overnight in 
FoxP3 staining buffer A. The following day, samples were permeabilised with buffer B and 
processed as described in 2.5.5. Samples (i) and (ii) were stained with FoxP3-APC. Sample 
(ii) was also stained with CTLA-4-PE and the appropriate isotype control antibody was added 
to sample (iii). To enable CTLA-4 expression levels to be compared between individuals over 
time, the PE signal was normalised prior to collecting the samples, by passing PE fluorescent 
beads (Caltag Laboratories) through the cytometer and finely adjusting the laser voltage to set 
their MFI within 90 and 100 units. TReg frequencies were calculated as the frequency of CD3
+ 
cells that stained positive for CD4, CD25 and FoxP3.  
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2.10.5 Post-culture T17 analysis and 1,25(OH)2D3 sensitivity  
250,000 cells were plated per well of a 24 well plate and stimulated for seven days with anti-
CD3 (0.5g/ml, clone OKT) in the presence or absence of 1,25(OH)2D3 (100nM) in a total 
1ml volume. At seven days, cultures were assessed for stimulation by (i) presence of cell 
clusters by light microscopy, (ii) CD25 expression by CD3+ cells as measured by flow 
cytometry. For stimulated cultures, IL-17 and IFN expression by CD3+ cells was measured 
by intracellular staining and flow cytometry. 1,25(OH)2D3 sensitivity of IL-17+IFN- and IL-
17+IFN+ cells was calculated by the equation below. Thus, the larger the value, the greater 
the 1,25(OH)2D3 sensitivity of the subset. 
2.11 Statistical Analysis 
Graphpad Prism version 3.02 was used to assess normality of samples by the Kolmogorov-
Smirnov (KS) test and to check equivalence of variance between two samples by the F 
statistic. If both conditions were satisfied, two-tailed paired, or unpaired T tests, as 
appropriate, were conducted to check for the difference between the means of two 
populations. If these conditions were not satisfied, two-tailed, non-parametric Wilcoxon or 
Mann-Whitney U tests for paired and unpaired data sets respectively, were used to compare 
the medians of the two populations in question.  
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When comparing more than three data sets in chapter 7, one-way Analysis of Variance 
(ANOVA) was performed using SPSS 14.0 after checking for normality by the Kolmogorov-
Smirnov (KS) test. If equivalence of variance was not satisfied, as determined by the 
Levene‟s statistic, data was transformed by calculating Log10X and equivalence of variance 
re-tested. For all cases where equivalence of variance was met and a post-test was required, 
the Hochberg test was used to account for differences in sample size. If equivalence of 
variance was not satisfied, the Games Howell post-test was used. To specifically test for 
differences between early RA and established RA patients in the post-test analysis, the 
Bonferroni post-test in Graphpad Prism version 3.02 was used. 
 
For correlation analysis, Pearson‟s correlation coefficient (r) was calculated using Graphpad 
Prism version 3.02 after checking for normality by the Kolmogorov-Smirnov (KS) test.  
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2.12 Reagent and equipment suppliers 
Table 2-3. Addresses of reagent and equipment suppliers 
Company Address 
AbD Serotec Endeavour House, Langford Lane, Kidlington, OX5 
1GE. United Kingdom. 
BD The Danby Building, Edmund Halley Road, Oxford 
Science Park Oxford, OX4 4DQ. United Kingdom. 
eBioscience Ltd 2nd Floor, Titan Court, 3 Bishop Square, Hatfield, 
AL10 9NA. United Kingdom. 
Fisher Scientific UK Ltd Fisher Scientific UK Ltd, Bishop Meadow Road, 
Loughborough, Leicestershire, LE11 5RG. United 
Kingdom. 
Fermentas Life Sciences Fermentas UK, Sheriff House, Sheriff Hutton 
Industrial Park, York, Y060 6RZ. United Kingdom 
ImmunoTools Altenoyther Strasse 10, 26169 Friesoythe. 
Germany. 
Life Technologies Corporation 
(Includes Applied Biosystems and 
Invitrogen) 
5791 Van Allen Way, PO Box 6482, Carlsbad, 
92008. California. 
Miltenyi Biotec Miltenyi Biotec Ltd. Almac House, Church Lane 
Bisley, Suffey. GU24 9DR. United Kingdom 
Peprotech EC PeproTech EC Ltd, PeproTech House, 29 
Margravine Road, London W6 8LL. United 
Kingdom 
R & D Systems  R&D Systems Europe Ltd. 19 Barton Lane, 
Abingdon, Science Park, Abingdon, OX14 3NB. 
United Kingdom 
Sarstedt SelectScience Ltd, Church Farm Business Park, 
Corston, Bath, BA2 9AP. United Kingdom. 
Sigma-Aldrich Company Ltd Dorset, United Kingdom 
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3 ESTABLISHING SYSTEMS TO GENERATE TH17 AND TREG 
CELLS IN-VITRO 
 
3.1 Generating Th17 cells in-vitro 
Initial studies compared the abilities of monocytes and monocyte-derived dendritic cells 
(DCs) to promote IL-17 expression in CD4+ T cells. Intracellular cytokine staining with flow 
cytometry was chosen for cytokine expression analysis because it would allow the co-
expression of cytokines with other markers to be studied. Figure 3.1 shows that monocytes 
and DCs permitted the development of IL-17+ (Th17) cells, which included IFN
+ and IFN- 
subsets. However, monocytes repeatedly supported a greater Th17 population than did DCs. 
Therefore, monocytes were chosen to study the effect of 1,25(OH)2D3 upon APC-driven Th17 
differentiation in later studies. The efficiency of monocytes for promoting Th17 differentiation 
had been demonstrated by others (Acosta-Rodriguez et al., 2007a; Evans et al., 2007), which 
supports the relevance of the monocyte system for in-vitro Th17 studies. Others had also 
demonstrated that Th17 cells derive primarily from the memory population. To further 
compare my system with theirs, I negatively selected CD45-RA+and CD45-RO+ cells from 
CD4+CD25- cells and measured their IL-17 expression following monocyte stimulation. As 
shown in figure 3.2, greater Th17 frequencies arose from the CD45-RO
+ fraction than the 
CD45-RA+ fraction, whilst mixed cultures gave an intermediate Th17 frequency. 
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Figure 3-1. Monocytes induce greater Th17 frequencies than beads or dendritic cells 
 
Figure 3.1. Monocytes induce greater Th17 frequencies than beads or dendritic 
cells. CD4+CD25- T cells were stimulated with (i) dendritic cells (DC) + anti-CD3 (ii) 
monocytes + anti-CD3 or (iii) anti-CD3/CD28 beads. At five days cells were 
intracellular stained for CD3, IL-17 and IFN and analysed by flow cytometry. A) 
Representative FACS plots to illustrate IL-17 and IFN expression by CD3+ cells 
under each stimulation. B) Percentage of IL-17+ T cells generated by DC, monocyte 
or bead stimulation for multiple donors. Horizontal bars represent the median 
percentage of IL-17 producing cells.  Significance was tested by two-tailed Mann 
Whitney U tests.  
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Figure 3-2. IL-17
+
 cells derive mainly from the CD45-RO
+
 fraction 
 
Figure 3.2. IL-17+ cells derive mainly from the CD45-RO+ fraction. CD45-RA and 
CD45-RO enriched fractions were obtained from CD4+CD25- T cells. Population 
purities were assessed by flow cytometry.  Gates were positioned by the isotype  
control (A). At five days, cells were analysed for IL-17 and IFN expression by flow 
cytometry (B). FACS plots are from one experiment representative of two performed.  
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The effect of 1,25(OH)2D3 upon T cells stimulated in the absence of APCs was also to be 
investigated in this thesis. Therefore IL-17 and IFN expression by CD4+ T cells was 
measured following stimulation with dynabeads coated with agonistic antibodies to CD3 and 
CD28 (referred to as beads). Stimulation with beads induced a small Th17 population, which 
similar to Th17 populations generated by monocytes or DCs included both IFN
+ and IFN- 
cells (figure 3.1). These data are consistent with those by Evans et al. as they also observed 
low frequencies of IL-17+ cells when stimulating CD4+ T cells with anti-CD3/CD28 coated 
beads (Evans et al., 2007).  
 
3.2 Time course of IL-17 expression 
To determine the optimum time at which to measure Th17 frequencies, IL-17 expression was 
monitored by flow cytometry over a period of twelve days. Figure 3.3 shows that IL-17+ cells 
occurred at very low frequencies (0.5-1%) during the first two days of stimulation and 
generally lacked IFN expression. At three days, IL-17+ frequencies began to increase co-
incident with the onset of cell division, as monitored by CFSE dilution. Analysis further 
showed that IL-17+ cells accumulated in the dividing populations (figure 3.4). IL-17+ 
frequencies continued to rise reaching 10% by seven days. At four days, IL-17+IFN+ cells 
became evident and the proportion of IL-17
+ cells expressing IFN increased further over time 
(figure 3.3). Based upon this analysis and the finding that cell survival was greatest at earlier 
time points, it was decided to measure Th17 frequencies at five days.  
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Figure 3-3. Time course of IL-17 expression 
 
Figure 3.3.  Time course of IL-17 expression. CD4+CD25- T cells were stimulated 
with monocytes and anti-CD3. At the times stated, cells were stained for CD3, IL-17 
and IFN and analysed by flow cytometry. A) FACS plots from one experiment 
representative of two performed. B) A summary of the frequencies of IL-17+ cells 
from both experiments (n=1 for days 3 and 4). C) The contributions of IFN- and 
IFN+ subsets to the total IL-17+ cell frequency (data are from the FACS plots 
shown). 
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Figure 3.4. Dividing cells express IL-17. CD4+CD25- T cells were CFSE labelled 
and stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3. At four days, 
cells were intracellular stained for IL-17 and analysed by flow cytometry. A) FACS 
plot of IL-17 against CFSE. Vertical lines mark division stages where 1 is undivided
cells. B) The percentage of IL-17+ cells in each division. Data are from one 
experiment representative of n>3. 
Figure 3-4. Dividing cells express IL-17.
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To examine the possibility that soluble factors accounte for the different abilities of monocyte 
and bead stimulations to generate Th17 cells, supernatants were periodically collected from 
monocyte and bead stimulations during one round of stimulation and used to supplement 
primary stimulations of the opposite type. The transfer of bead supernatants onto monoycte 
stimulations reduced Th17 frequencies, whilst early stage monocyte supernatants permitted a 
small increase in bead driven Th17 frequencies. However, late stage monocyte supernatants 
were inhibitory to bead driven Th17 differentiation (figure 3.5). These data suggested that 
soluble factors inhibitory to Th17 differentiation were present at the early stage of bead 
stimulations and accumulated during the course of monocyte stimulations.  
 
3.3 IL-2 is inhibitory to Th17 differentiation 
One soluble factor that might be inhibitory to Th17 differentiation is IL-2 (Acosta-Rodriguez 
et al., 2007a; Laurence et al., 2007). Analysis of IL-2 production by T cells following bead or 
monocyte stimulation revealed a higher frequency of IL-2+ cells at an early stage of bead 
compared to monocyte stimulations. In addition, the level of IL-2 expressed by IL-2+ cells 
was greater for bead-stimulated cells (figure 3.6). Consistent with higher IL-2 levels, the IL-2 
receptor alpha chain, CD25, which is enhanced by IL-2 signalling, was expressed more 
strongly by bead versus monocyte-stimulated cells (figure 3.7). Thus, to investigate whether 
high IL-2 might contribute to low Th17 differentiation, monocyte stimulations were 
supplemented with increasing doses of IL-2 and the frequencies of IL-17+ and IFN+ T cells 
generated by five days measured. Figure 3.8 shows that IL-2 reduced IL-17+ and IFN+ 
frequencies by monocyte stimulated T cells. Interestingly, whilst IL-2 expression was low in 
monocyte stimulated T cells at early stages of stimulation, the frequency of IL-2+ cells 
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increased in these cultures over time (figure 3.6). Given the inhibitory effect of IL-2 upon 
Th17 differentiation, the accumulation of IL-2 in monocyte cultures supported the inhibitory 
effect of late stage monocyte supernatants upon Th17 differentiation (figure 3.5). Since 
increased IL-2 contributed to Th17 suppression in the bead system, it was hypothesised that 
reducing bead stimulation might increase Th17 frequencies. Figure 3.9 shows that by 
reducing bead to T cell frequencies over the range 1:1 to 1:32 the proportion of cells that 
committed to division was decreased but the Th17 frequency was increased. Taken together, 
these data suggest that strong stimulation in the bead system might yield high IL-2, which 
contributes to low Th17 frequencies.  
 
3.4 Generating TReg cells in-vitro 
FoxP3 and CTLA-4 are two molecules that are expressed at high levels on TReg cells, thus to 
monitor the development of TRegs from CD4
+CD25-  T cells were stimulated and total stained 
for CTLA-4 and FoxP3. Since FoxP3 is known to be transiently expressed in activated T cells 
(Horwitz et al., 2008b) its expression and that of CTLA-4 was monitored over time (figure 
3.10). For both bead and monocyte stimulations, CTLA-4 induction was observed within 36 
hours. Its expression gradually increased over four days but then decreased. Consistent with 
expectation, FoxP3 expression was transient. Although the level of FoxP3 was quite variable, 
those cells that acquired highest FoxP3 had greatest CTLA-4. In keeping with the finding that 
bead stimulated cells had higher CD25 than monocyte stimulated cells, the maximal CTLA-
4+FoxP3+ population was three fold greater in bead versus monocyte stimulated T cells. Since 
the CTLA-4+FoxP3+ population peaked at four days, this time was chosen for routine TReg 
analysis. 
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Figure 3-4. Bead supernatants inhibit monocyte induced Th17 differentiation 
 
Figure 3.5. Bead supernatants inhibit monocyte induced Th17 differentiation. A) 
FACS plots of IL-17 and IFN expression by CD4+ T cells stimulated with monocytes 
or anti-CD3/CD28 beads in the presence of supernatant collected from the alternative 
stimulation type after the time stated. Numbers in quadrants refer to percentage of 
CD3+ cells. B) Line graph summary of the IL-17+  frequencies determined from FACS 
plots in A. (n=1). 
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Figure 3-5. Bead stimulated T cells produce more IL-2 than monocyte stimulated cells at early time points 
 
Figure 3.6. Bead stimulated T cells produce more IL-2 than monocyte 
stimulated cells at early time points. CD4+CD25- T cells were stimulated with 
monocytes plus anti-CD3 (red) or anti-CD3/CD28 coated beads (blue) for two days. 
Cells were stained for CD3, IL-2 and IFN and analysed by flow cytometry. A) 
Histogram of IL-2 expression by CD3+ cells. Horizontal bar indicates IL-2+ cells 
whose median IL-2 fluorescence intensity is graphed in B. C) Time course of IL-2 
expression by bead and monocyte stimulated T cells. (n=1).  
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Figure 3-6. Bead stimulation induces greater CD25
 
expression than monocyte stimulation 
 
Figure 3.7 Bead stimulation induces greater CD25 expression than monocyte 
stimulation. CD4+CD25- T cells were stimulated with beads or monocytes plus anti-
CD3 for four days, stained for CD25 and analysed by flow cytometry. A) 
Representative histograms of CD25 expression. Shaded histogram indicates isotype 
control. B) CD25 median fluorescence intensity for multiple donors. Horizontal bars 
indicate median expression. Significance was tested by a two-tailed Wilcoxon 
matched pairs test.   
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 Figure 3-7. IL-2 suppresses IL-17 expression 
 
Figure 3.8. IL-2 suppresses IL-17 expression. CD4+CD25- T cells were stimulated 
with monocytes plus anti-CD3 in the presence of IL-2 over the range 0-200U/ml. At 
five days, cells were stained for CD3, IL-17 and IFN and analysed by flow cytometry. 
A) Representative FACS plots from one experiment. Numbers in quadrants refer to 
percentage of CD3+ cells. B) IL-2 concentration effect upon IL-17+ and IFN+ 
frequencies (n=3). Error bars show standard deviation.  
 
Generating Th17 and TReg cells in-vitro 
106 
 
Figure 3-8. Th17 frequencies are inversely related to bead: cell ratio. 
 
 
Figure 3.9. Th17 frequencies are inversely related to bead: cell ratio. A) 
CD4+CD25- T cells were stimulated with beads at the given ratio. At five days cells 
were stained for intracellular IL-17 and IFN and analysed by flow cytometry. B) 
CFSE labelled CD4+CD25- T cells were stimulated with beads at the given ratio. 
CFSE dilution was monitored by flow cytometry after 5 days. Data are from a single 
experiment representative of n>3.   
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Figure 3-9. Time course of FoxP3 and CTLA-4 expression by monocyte and bead stimulated T cells 
 
Figure 3.10. Time course of FoxP3 and CTLA-4 expression by monocyte and 
bead stimulated T cells. CD4+CD25- T cells were stimulated with monocytes plus 
anti-CD3 or anti-CD3/CD28 coated beads. At the indicated times, cells were stained 
for CD3, CTLA-4 and FoxP3 and analysed by flow cytometry. FACS plots from one 
experiment representative of two performed are shown.  Numbers in quadrants refer 
to percentage of CD3+ cells and boxes in the top right quadrants indicate CTLA-
4+FoxP3+ cells with highest FoxP3 expression. 
Generating Th17 and TReg cells in-vitro 
108 
 
Discussion 
The aim of the studies reported in this chapter was to develop systems for the in-vitro 
generation of Th17 and TReg cells from human CD4
+CD25- T cells. Systems were compared in 
which APCs were present or absent, since this would permit later analysis of the intermediary 
role of APCs in the response of T cells to different factors, including 1,25(OH)2D3. This 
revealed that monocytes support higher IL-17+ frequencies than DCs or beads. Such is 
consistent with data published by Evans et al (2007). Conversely, beads induced greater 
CTLA-4+FoxP3+ TReg populations than monocytes.  
 
The pro-Th17 effect of monocytes appears to relate largely to the cytokines that they release 
upon stimulation. Consistent with this hypothesis, using antibody blockade and caspase-1 
inhibition, Acosta-Rodriguez et al. demonstrated the importance of monocyte derived, STAT3 
signalling cytokines, IL-1 and IL-6, for Th17 generation (Acosta-Rodriguez et al., 2007a). 
They also showed that GM-CSF and IL-4 derived DCs produce comparatively little IL-1 and 
IL-6 in response to maturation stimuli but release IL-12 that promotes IFN expression. In 
addition, several groups have demonstrated an inhibitory effect of IFN upon IL-17 
expression (Harrington et al., 2005; Park et al., 2005), thus the lower frequencies of IL-17+ 
cells in DC stimulations compared to monocyte stimulations might relate to greater IFN 
expression as well as the comparative absence of STAT3 signalling cytokines. Potentially, 
competitive binding of STAT3 and STAT1 at the IL-17a promoter might underlie the process, 
as both have been shown to bind there (Laurence et al., 2007). However, it is likely that 
indirect mechanisms are also involved. For example, in the absence of STAT1 signalling, up 
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regulation of the IL-23R compared to the IL-12R2 was favoured and might promote a Th17 
outcome (Harrington et al., 2005).  
 
As mentioned, a clear distinction in the abilities of monocytes and beads to promote IL-17 
expression by T cells was observed in this study. When investigating possible reasons for this 
I found that the absence of monocyte derived cytokines in bead stimulations was not solely 
responsible for their low Th17 frequencies. Further investigation led to the identification that 
IL-2, which is expressed at high levels during the early stage of bead stimulations, was 
inhibitory to IL-17 expression. Consistent with this finding, an inhibitory effect of high IL-2 
concentration upon Th17 differentiation has been suggested by others (Acosta-Rodriguez et 
al., 2007a; Laurence et al., 2007). Laurence et al. also demonstrated that IL-17 inhibition by 
IL-2 depends upon STAT5a/b and they identified multiple STAT5 binding sites at the IL-17a 
locus. Interestingly, in support of the hypothesis that IL-2 produced endogenously by bead 
stimulated cells is sufficient to inhibit Th17, Laurence et al. showed that when cells were 
stimulated with antiCD3/CD28 beads, STAT5 bound appreciably to the IL-17a gene in the 
absence of exogenous IL-2 (Laurence et al., 2007).  
 
Analysis of IL-2 expression at later stages of stimulation revealed that IL-2 expression 
increases over time in monocyte-stimulated T cells. Whilst it is possible that accumulating IL-
2 feeds back to avoid persistent Th17 development, it might be that differentiation fate is 
governed primarily by the cytokine profile at the start of stimulation (Constant and Bottomly, 
1997; Nakamura et al., 1997) with inhibitory cytokines at later stages having little effect. To 
confirm this for IL-2 upon Th17 differentiation, it would be necessary to inhibit IL-2 at 
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increasingly delayed times post stimulation. If enhanced IL-17 frequencies were measured, a 
role for IL-2 in the avoidance of persistent Th17 inflammation might be implied. 
 
In this chapter, as well as investigating systems to generate Th17 cells a protocol to generate 
inducible TReg development from CD4
+CD25- T cells was also studied. Transient FoxP3 
induction was observed under both monocyte and bead stimulation. However, it was found 
that monocyte stimulated cells had lower FoxP3 expression compared to bead stimulated 
cells, only 5% acquiring a high CTLA-4 and FoxP3 phenotype by four days compared to 14% 
by beads. This distinction might again be reconciled by the greater level of IL-2 expression 
during the early stage of bead stimulations, since IL-2 is required for the development and 
expansion of FoxP3+ iTRegs in-vitro (Horwitz et al., 2008b). In addition, the release of STAT3 
dependent cytokines by monocytes might have contributed to FoxP3 inhibition in monocyte 
stimulated cells (Zhou and Littman, 2009; Zhou et al., 2008). Overall, it would seem that the 
pro-TReg anti-Th17 outcome of bead stimulations versus the anti-TReg pro-Th17 outcome of 
monocyte stimulations supports the view that TReg and Th17 lineages are reciprocal fates 
(Bettelli et al., 2006). 
 
In addition to soluble factors, varying surface molecule interactions may contribute to the 
differing abilities of beads and monocytes to induce IL-17 expression in-vitro. Indeed, for Th1 
and Th2 differentiation, there is evidence that whilst cytokines play a dominant role in lineage 
decision, factors including the strength and frequency of TCR engagement and the nature of 
co-stimulatory signals can contribute (reviewed by (Constant and Bottomly, 1997)). The 
general opinion is that for soluble antigens, low doses favour Th2 responses whilst high doses 
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promote a Th1 outcome. For co-stimulatory signals, CD28 signalling may favour Th2 but not 
Th1 responses and differential effects for CD86 and CD80 upon Th1 and Th2 subsets have 
been observed. However, neither B7 ligand clearly associates with either lineage (Constant 
and Bottomly, 1997). In this chapter, I observed that reducing bead to T cell ratios from 1:4 to 
1:32 increased Th17 frequencies. Very recently, others supported this finding as they 
demonstrated that decreased stimulation strength, administered by low antiCD3/anti-CD28 
bead or DC ratios dramatically increased human Th17 frequencies when pro-Th17 cytokines 
were present, although, they suggested a need for CD28 stimulation (Purvis et al., 2010). 
Conversely, in-vitro studies with mice imply that strong TCR signals are required for Th17 
differentiation (Bouguermouh et al., 2009; Gomez-Rodriguez et al., 2009). However, whilst 
Bouguermouh et al. demonstrated an inhibitory effect of CD28 signalling, showing increased 
IL-17+ frequencies when T cells were stimulated by DCs in the presence of CTLA-4-Ig, 
Gomez-Rodriguez et al. positively correlated CD28 signal strength with Th17 frequencies. 
Conflicting conclusions are likewise reached from in-vivo mouse studies as a range of 
outcomes for Th17 associated diseases have been observed following CD28 or B7 deletion 
(reviewed in (Bouguermouh et al., 2009)). Possibly, such discrepancies relate to differences in 
genetic background or reflect the importance of a fine balance between TCR and co-
stimulatory signal strength for Th17 differentiation as observed for Th2 (Tao et al., 1997). 
Nonetheless, the varying conclusions from these studies make it difficult to define the relative 
requirements of TCR and co-stimulatory signals for Th17 development.  
 
It is possible that factors besides stimulation strength could explain the effect of reduced bead 
to T cell ratios upon Th17 frequencies that I observed. Indeed, cells that committed to division 
in the low bead to T cell cultures might have received TCR and co-stimulatory signals of 
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equal strength to cells stimulated at higher bead to T cell ratio, since they passed through the 
same number of divisions. Because fewer cells committed to division as the bead to cell ratio 
decreased, it is likely that cytokines inhibitory to Th17, such as IL-2 and IFN, were at lower 
concentration in these cultures and governed the outcome. In support of this, Bouguermouh et 
al. demonstrated that anti-IFN or anti-IL-2 abrogated the suppressive effect of CD28 upon 
Th17 induction. However, the same was not seen by Purvis et al. rather they and Gomez-
Rodriguez et al. related signal strength to the activation of calcium dependent NFATc, that 
binds at the IL-17a promoter (Gomez-Rodriguez et al., 2009; Purvis et al., 2010). Thus, the 
strength of TCR and co-stimulatory signals as well as cytokines might contribute 
independently to Th17 differentiation.  
 
In support of a model in which strong TCR and CD28 signals are inhibitory to Th17 
differentiation, it is likely that both signals were stronger in the bead compared to monocyte 
system. Indeed, by clustering with the cells, beads probably provided a greater local anti-CD3 
concentration than achieved with soluble anti-CD3. Secondly, the affinity of anti-CD28 for 
CD28 is likely to be greater than that of CD86, via which monocytes would initially stimulate 
CD28. Thirdly, during the course of stimulation, bead stimulated cells could have continually 
experienced strong CD28 signals, whilst by CTLA-4 up-regulation and its engagement with 
B7, CD28 signals in monocyte-stimulated T cells could have subsided. An important role for 
weak CD86-CD28 interactions in Th17 development as proposed here, is supported by the 
presence of high frequencies of CD86+ cells relative to CD80+ cells in rheumatoid tissue and 
fluid in which IL-17 levels are also elevated (Balsa et al., 1996; Thomas and Quinn, 1996). 
Besides an importance for CD28/B7 signalling in the regulation of Th17 development, a study 
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in mice suggests that signalling through ICOS, which has been associated with Th2 
differentiation, might also enhance Th17 differentiation (Nurieva et al., 2003). The pro-Th17 
effect of ICOS may relate to reduced CD28 signal strength and IL-2 release as ICOS signals 
take over (Odobasic et al., 2008; Riley et al., 2001). This system could further favour Th17 
induction in the monocyte system but would be absent from beads. 
 
In summary, the studies in this chapter have shown that CTLA-4+FoxP3+ TReg and IL-17
+ 
Th17 populations can be induced by bead and monocyte plus anti-CD3 stimulations, although 
the former favours TReg induction whilst the latter promotes a Th17 outcome. It is likely that 
these distinctions reflect the release of pro-Th17, STAT3 signalling cytokines by monocytes 
compared to the early high expression of anti-Th17 cytokines such as IL-2 in bead 
stimulations. Differences between the strengths of TCR and co-stimulatory signals in the two 
systems might also contribute to their opposing Th17 and TReg outcomes.  
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4 DOES 1,25(OH)2D3 ACT DIRECTLY UPON CD4
+ T CELLS TO 
INFLUENCE THEIR PHENOTYPE? 
This chapter considers the effect of the biologically active form of vitamin D, 1,25-
dihydroxyvitamin D3 (1,25(OH)2D3 ) upon CD4
+ T cell responses in the presence and absence 
of antigen presenting cells (APCs). In particular, effects upon Th17 cells were monitored by 
studying expression of their associated cytokines: IL-17, IL-21 and IFN whilst effects upon 
regulatory T cells were observed by measuring CTLA-4, FoxP3 and IL-10.  
 
4.1 1,25(OH)2D3 directly attenuates CD4
+ T cell expression of pro-
inflammatory cytokines IL-17, IFN and IL-21 
The effect of 1,25(OH)2D3 upon pro-inflammatory CD4
+ T cell cytokines, including IL-17, 
IFN and IL-21 was investigated by adding 100nM 1,25(OH)2D3 at the start of monocyte and 
bead driven T cell stimulations. Across multiple donors and under both stimulation methods, 
all three cytokines were profoundly suppressed, as determined by flow cytometry (figure 4.1 
and figure 4.2). Notably, for cells expressing IL-17 or IL-21, those co-expressing IFN were 
the most sensitive to 1,25(OH)2D3-mediated suppression. To confirm these findings by a 
complementary method, quantitative real-time PCR for IL-17 and IFN transcripts was used 
(figure 4.3). These data supported the flow cytometry results, demonstrating strong 
suppression of IL-17 and IFN at the mRNA level. Because the anti-inflammatory effects of 
1,25(OH)2D3 could occur when T cells were stimulated in the absence of APC, the ability of 
1,25(OH)2D3 to modify T cells through direct signalling was concluded.  
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Figure 4-1. 1,25(OH)2D3 directly inhibits IL-17 and IFN expression 
 
Figure 4.1. 1,25(OH)2D3 directly inhibits IL-17 and IFN expression. CD4+CD25- T 
cells were stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3 in the 
presence of 1,25(OH)2D3 or vehicle control. At five days, cells were stained for CD3, 
IL-17 and IFN and analysed by flow cytometry. A) Representative FACS plots from 
one experiment. Numbers in quadrants refer to percentage of CD3+ cells expressing 
IL-17 or IFN. B) IL-17+ frequencies for multiple donors. Horizontal lines indicate 
median frequency. Significance was tested by a two-tailed Wilcoxon matched pairs 
test.  
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Figure 4-2. IL-21 and IFN are directly suppressed by 1,25(OH)2D3  
 
Figure 4.2. IL-21 and IFN are directly suppressed by 1,25(OH)2D3. CD4+CD25- T 
cells were stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3 in the 
presence of 1,25(OH)2D3 or vehicle control. At five days, cells were stained for CD3, 
IL-21 and IFN and analysed by flow cytometry. A) Representative FACS plots from 
one experiment. Numbers in quadrants refer to percentage of CD3+ cells expressing 
IL-21 or IFN. B) IL-21+ frequencies for multiple donors. Horizontal lines indicate 
median frequency. Significance was tested by a two-tailed Wilcoxon matched pairs 
test.  
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Figure 4-3. 1,25(OH)2D3 directly reduces IL-17 and IFN mRNA levels 
 
Figure 4.3. 1,25(OH)2D3 directly reduces IL-17 and IFN mRNA levels. 
CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads or monocytes plus 
anti-CD3 in the presence of 1,25(OH)2D3 (clear) or vehicle control (black). At four 
days IL-17 and IFN expression was analysed by quantitative real-time PCR. Mean 
expression is plotted relative to control. Error bars show standard deviation (n3).  
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4.2 Suppression of pro-inflammatory cytokine expression is not a 
consequence of reduced commitment to activate, divide and differentiate 
Since IL-17 expression increased at three days post stimulation and was expressed primarily 
by dividing cells (chapter 3, figures 3.3 and 3.4), it was reasoned that an inhibitory effect of 
1,25(OH)2D3 upon T cell proliferation (Lemire et al., 1985; Penna and Adorini, 2000) might 
explain the low frequencies of pro-inflammatory cytokines. To examine this, CD4+CD25- T 
cells were labelled with CFSE and cell division measured. Whilst for monocyte stimulations 
proliferation was inhibited by 1,25(OH)2D3, it was not reduced under bead stimulation (figure 
4.4). Furthermore, total cell counts confirmed equivalent cell numbers in bead stimulated 
cultures in the presence and absence of 1,25(OH)2D3. These results indicated that direct 
suppression of IL-17, IL-21 and IFN by 1,25(OH)2D3 was not due to reduced commitment to 
divide. They also suggest that the suppressive effects of 1,25(OH)2D3 upon T cell 
proliferation as reported by others (Lemire et al., 1985; Penna and Adorini, 2000) could be an 
indirect consequence of the reduced ability of the APC to stimulate. The ability of 
1,25(OH)2D3 to affect DC phenotype was therefore also assessed. Reduced expression of 
HLA-DR and CD80 was observed, whilst the monocyte marker, CD14, was maintained at a 
higher level (figure 4.5). These findings were consistent with those of others (Berer et al., 
2000; Canning et al., 2001; Penna and Adorini, 2000) and support the hypothesis that 
1,25(OH)2D3 reduces the ability of APCs to stimulate T cells. Thus, taken together my data 
indicate that 1,25(OH)2D3 can act through APCs to influence T cell proliferation and 
differentiation but it can also act directly upon T cells to affect their differentiation but not 
their proliferation.  
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Figure 4-4. 1,25(OH)2D3 indirectly attenuates T cell proliferation through effects upon the APC  
 
Figure 4.4. 1,25(OH)2D3 indirectly attenuates T cell proliferation through effects 
upon the APC. CFSE labelled CD4+CD25- T cells were stimulated with anti-
CD3/CD28 beads or monocytes plus anti-CD3 in the presence of 1,25(OH)2D3 or 
vehicle control for five days and analysed for cell division by flow cytometry. 
Representative CFSE histograms from one experiment are shown in (A) and division 
data from repeat experiments in (B). Division factor was calculated by CFSE  MFIun-
stimulated / CFSE MFIstimulated. Horizontal lines indicate median value.   
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Figure 4-5. 1,25(OH)2D3 affects APC phenotype  
 
Figure 4.5. 1,25(OH)2D3 affects APC phenotype. A) Representative histograms for 
the expression of surface markers on monocytes, DCs and DCs cultured in the 
presence of 1,25(OH)2D3, as assessed by flow cytometry (shaded). The clear 
histogram represents isotype control staining. B) Bar chart summary of APC surface 
marker expression (median fluorescence intensity). Error bars show standard 
deviation (n3).  
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4.3 1,25(OH)2D3 promotes a TReg phenotype, enhancing CTLA-4 expression, 
CTLA-4+FoxP3+ frequency and promoting IL-10 
To test the hypothesis that 1,25(OH)2D3 might also influence TReg development, the effect of 
1,25(OH)2D3 upon the expression of CTLA-4 and FoxP3, was monitored (figure 4.6 and 
4.7). This revealed that 1,25(OH)2D3 dramatically up-regulated CTLA-4 protein and mRNA 
transcripts under both bead and monocyte conditions and was highly significant when 
analysed for multiple donors. Induction was most dramatic under bead stimulation, fold 
increases in CTLA-4 MFI being 4.6 and 1.8 for bead and monocyte stimulations respectively 
(figure 4.6). However, only bead stimulations supported a 1,25(OH)2D3-driven increase in 
FoxP3 mRNA and the frequency of FoxP3+ cells. Furthermore, the CTLA-4+FoxP3+ 
population doubled for bead stimulated cells in the presence of 1,25(OH)2D3 but 1,25(OH)2D3 
did not affect the CTLA-4+FoxP3+ population under monocyte conditions. Analysis of 
CTLA-4 against CFSE further showed that 1,25(OH)2D3 could up-regulate CTLA-4 in 
undivided cells (figure 4.8), supporting the hypothesis that 1,25(OH)2D3 affects T cell 
differentiation rather than permitting the selective outgrowth of a population of CTLA-4high 
cells.  
 
I also investigated the anti-inflammatory activity of 1,25(OH)2D3 upon the regulatory 
associated cytokine, IL-10. This revealed that 1,25(OH)2D3 enhanced the frequency of IL-10
+ 
cells under bead but not monocyte stimulation (figure 4.9). However, IL-10 transcript was 
increased by 1,25(OH)2D3 in both systems (figure 4.10). Overall, these data, together with  
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Figure 4-6. CTLA-4 and  FoxP3 are directly enhanced by 1,25(OH)2D3 
 
Figure 4.6. CTLA-4 and FoxP3 are directly enhanced by 1,25(OH)2D3. CD4+CD25- 
T cells were stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3 in the 
presence of 1,25(OH)2D3 or vehicle control. At four days, cells were stained for CD3, 
total CTLA-4 and FoxP3 and analysed by flow cytometry. A) Representative FACS 
plots from one experiment. Numbers in quadrants refer to percentage of CD3+ cells 
expressing CTLA-4 or FoxP3. CTLA-4 median fluorescence intensity (MFI) is shown.  
B)  CTLA-4 MFI and CTLA4+FoxP3+ frequency data for multiple donors. Horizontal 
lines indicate median values. Significance was tested by a two-tailed Wilcoxon 
matched pairs test.  
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Figure 4-7. 1,25(OH)2D3 directly enhances CTLA-4 and FoxP3 mRNA levels  
 
 
Figure 4.7. 1,25(OH)2D3 directly enhances CTLA-4 and FoxP3 mRNA levels. 
CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads or monocytes plus 
anti-CD3 in the presence of 1,25(OH)2D3 (clear) or vehicle control (black). At four 
days, cells were re-stimulated and CTLA-4 and FoxP3 expression analysed by 
quantitative real-time PCR. Mean expression is plotted relative to control. Error bars 
show standard deviation (n3).  
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Figure 4-8. 1,25(OH)2D3 increases CTLA-4 expression in undivided cells 
 
 
 
 
 
 
 
 
 
Figure 4.8. 1,25(OH)2D3 increases CTLA-4 expression in undivided cells. 
CD4+CD25- T cells were labelled with CFSE and stimulated with anti-CD3/CD28 
beads in the presence of 1,25(OH)2D3 or vehicle control. Total CTLA-4 expression 
against division was analysed at three days by flow cytometry. Undivided cells are 
gated and their frequency shown. Their median fluorescence intensity (MFI) for 
CTLA-4 is also given. Data are representative of n>3.   
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Figure 4-9. 1,25(OH)2D3 increases IL-10 expression by CD4
+
 T cells  
 
Figure 4.9. 1,25(OH)2D3 increases IL-10 expression by CD4
+ T cells. CD4+CD25- 
T cells were stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3 in the 
presence of 1,25(OH)2D3 or vehicle control. At five days, cells were stained for CD3, 
IL-10 and IFN and analysed by flow cytometry. A) Representative FACS plots from 
one experiment. Numbers in quadrants refer to percentage of CD3+ cells expressing 
IL-10 or IFN. B) IL-10+ frequencies for multiple donors. Horizontal lines indicate 
median frequency. Significance was tested by a two-tailed Wilcoxon matched pairs 
test.  
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Figure 4-10. 1,25(OH)2D3 directly enhances IL-10 mRNA level  
 
 
 
 
 
 
 
 
Figure 4.10. 1,25(OH)2D3 directly enhances IL-10 mRNA level. CD4+CD25- T cells 
were stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3 in the 
presence of 1,25(OH)2D3 (clear) or vehicle control (black). At four days, cells were re-
stimulated, and IL-10 expression analysed by quantitative real-time PCR. Mean 
expression is plotted relative to control. Error bars show standard deviation (n3).  
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Figure 4-11. 1,25(OH)2D3 does not increase CTLA-4
+
FoxP3
+ 
phenotype stability during one round of 
stimulation 
 
Figure 4.11. 1,25(OH)2D3 does not increase CTLA-4
+FoxP3+ phenotype stability 
during one round of stimulation. CD4+CD25- T cells were stimulated with anti-
CD3/CD28 beads in the presence of 1,25(OH)2D3 or vehicle control. At the indicated 
times, cells were stained for CD3, total CTLA-4 and FoxP3 and analysed by flow 
cytometry. Numbers in quadrants refer to percentage of cells expressing CTLA-4 or 
FoxP3. FACS plots from one experiment representative of three performed are 
shown. CTLA-4+FoxP3+ cells are indicated by the box in the top right quadrant.  
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Figure 4-12. 5-aza-2-deoxycytidine reduces the rate of CTLA-4
+
FoxP3
+ 
 decline  
 
Figure 4.12. 5-aza-2-deoxycytidine reduces the rate of CTLA-4+FoxP3+  decline. 
CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads in the presence of 
1,25(OH)2D3. At four days cells were treated with IL-2 with or without 5-aza-2-
deoxycytidine (5-aza). At the indicated times, cells were stained for total CTLA-4 and 
FoxP3 and analysed by flow cytometry. FACS plots are from one experiment 
representative of three performed. FSC vs. SSC plots are shown for ten day cultures. 
Percentages of live cells based upon scatter are given.  
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those for CTLA-4+FoxP3+ frequencies, indicate that 1,25(OH)2D3 promotes a TReg phenotype 
under bead but not monocyte stimulation. 
 
4.4 1,25(OH)2D3 does not stabilise CTLA-4 or FoxP3 expression.  
Although FoxP3 is constitutively expressed at high level by natural TRegs (nTRegs), it appears to 
be transient in induced TRegs (iTRegs) (Horwitz et al., 2008a). Thus, it was of interest to 
ascertain whether 1,25(OH)2D3 influenced FoxP3 and CTLA-4 stability. Figure 4.11 
confirms that 1,25(OH)2D3 was not able to prevent the down-regulation of either marker but it 
did prolong ther expressions.  
 
In nTRegs, demethylation of a region within the FoxP3 locus, the TReg specific demethylated 
region (TSDR), is believed to account for the stability of their FoxP3 expression (Floess et al., 
2007). Thus, whether the DNA methyltransferase inhibitor, 5-aza-2-deoxycytidine (5-aza), 
could fix FoxP3 expression by 1,25(OH)2D3-treated cells was investigated. Whilst 5-aza 
reduced the rate of CTLA-4+FoxP3+ decline, stable CTLA-4+FoxP3+ expression was not 
achieved (figure 4.12). In addition, 5-aza reduced cell survival as evident from FSC versus 
SSC data.  
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4.5 1,25(OH)2D3 and IL-2 additively promote a TReg phenotype  
IL-2 is required for the induction and maintenance of FoxP3 expression in the periphery 
(Davidson et al., 2007). Thus, it was hypothesised that the lack of FoxP3 expression by 
monocyte-stimulated cells may be a consequence of lower IL-2 at the early stage of these 
stimulations compared to bead stimulations (chapter 3, figure 3.6). Therefore, the effect of 
IL-2 supplementation upon FoxP3 and CTLA-4 expression was investigated. At IL-2 
concentrations of 100U/ml and above, the frequency of CTLA-4+FoxP3+ T cells dramatically 
increased to 30-50% in 1,25(OH)2D3 treated monocyte cultures (figure 4.13 and 4.14). In 
addition, IL-2 and 1,25(OH)2D3 additively increased CTLA-4 expression. By contrast, even at 
200U/ml, IL-2 supplement had limited effect upon the features of bead stimulation (figure 
4.14). This finding further supported the hypothesis that bead stimulations generate greater 
IL-2 levels than monocyte stimulations. Corresponding with the TReg bias under 1,25(OH)2D3 
plus IL-2 treatment, IL-17+ and IFN+ frequencies were maintained at a low level under these 
conditions (figure 4.15). Analysis across multiple donors confirmed the significance and 
reproducibility of these observations. Hence, IL-2 and 1,25(OH)2D3 appear to be a potent 
cocktail for the induction of CD4+ T cells with regulatory features. It was further observed 
that periodic IL-2 supplementation throughout one round of stimulation could increase the 
duration of FoxP3 expression and raise FoxP3 expression frequencies in populations where 
the level had previously waned. However, combined supplement of 1,25(OH)2D3 and IL-2 
could not support a stable CTLA-4+FoxP3+ population. 
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4.6 Re-stimulation in the presence of 1,25(OH)2D3 and IL-2 can switch the 
phenotype of a previously Th17 polarised culture to one of regulatory nature 
Polarisation of T cell phenotype might be attained by subjecting cells to several rounds of 
stimulation under differentiation conditions (Grogan et al., 2001). Thus, CD4+CD25- T cells 
were passed through two rounds of stimulation with monocytes and anti-CD3 in the presence 
of 1,25(OH)2D3 and IL-2 to see if this would increase the TReg polarity of the culture. 
Although enhanced suppression of IL-17 and IFN (figure 4.16) and induction of CTLA-4 
and FoxP3 occurred (figure 4.17), CTLA-4 levels and CTLA-4+FoxP3+ frequencies were 
lower four days post second stimulation than at four days post primary stimulation. By 
contrast, repeat stimulation of cells under control conditions dramatically increased the 
frequency of IL-17+ cells to 30%, and rendered very low levels of CTLA-4 and FoxP3 
expression. Interestingly, re-stimulation of cells initially cultured under control conditions in 
the presence of 1,25(OH)2D3 and IL-2 markedly suppressed IL-17 and IFN but increased 
CTLA-4 and FoxP3. Conversely, primary stimulation in the presence of 1,25(OH)2D3 and IL-
2 followed by secondary stimulation under control conditions, permitted increased IL-17+ and 
IFN+ frequencies and suppression of CTLA-4 and FoxP3. These data support an anti-
inflammatory, pro-regulatory effect for 1,25(OH)2D3 and IL-2 and confirm that it can switch 
the phenotype of a previously Th17 polarised culture to one of regulatory nature.  
 
4.7 CD4+ T cells treated with 1,25(OH)2D3 and IL-2 are functionally 
suppressive 
Following observation that 1,25(OH)2D3 and IL-2 enhance T cell expression of regulatory 
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markers, it was important to determine if cultures enriched with cells of this phenotype were 
functionally suppressive. Since CTLA-4 was expressed at very high level on 1,25(OH)2D3 
treated cells, it was hypothesised that CTLA-4-mediated cell extrinsic mechanisms might 
contribute greatly to any suppression. Therefore, a suppression assay in which responder T 
cell division depended upon CD80 or CD86 co-stimulation was designed. Specifically, 
CD4+CD25- allogenic responder T cells were labelled with CFSE and stimulated with DCs 
and anti-CD3. Use of immature DCs (iDCs) versus DCs matured over night with 1g/ml 
lipopolysaccharide (LPS) (mDCs) was tested. Suppression effects were greatest when mDCs 
were used in place of iDCs for stimulation, thus the former were chosen for repeat analyses. 
DC to responder ratios of 1:5 and 1:10 were also compared because it was hypothesised that 
suppressor effects might be more apparent when the pool of co-stimulatory ligand was more 
limited. However, at a 1:10 ratio, responder proliferation was low, thus reducing the power of 
the assay. Therefore, repeat assays were conducted using mDCs at a 1:5 DC to responder 
ratio.  
 
During assay development, suppressor to responder ratios of 1:2, 1:4 and 1:10 were also 
tested (figure 4.18). A 1:10 ratio was chosen because although responder division increased 
as the suppressor: responder ratio decreased, at the highest ratios competitive proliferation by 
1,25(OH)2D3 plus IL-2 and untreated suppressor T cells seemed to contribute greatly to the 
suppression. Whilst this effect was of interest, suggesting that activated T cells can behave as 
suppressor cells, the lowest ratio of 1:10 enabled the involvement of 1,25(OH)2D3 plus IL-2 
induced regulatory features to be observed. Figure 4.19 confirms that in repeat experiments 
1,25(OH)2D3 plus IL-2 conditioned T cell cultures suppressed responder T cell proliferation to 
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a greater extent than untreated controls. However, untreated control T cells reduced responder 
division when compared to responders alone.  
 
4.8 1,25(OH)2D3 modifies T cell phenotypes at physiologically relevant 
concentrations  
The concentration of 1,25(OH)2D3 used in the studies described so far was 100nM. However, 
serum 1,25(OH)2D3 approximates 0.1nM (Mullin and Dobs, 2007) and it is estimated that 
mDCs synthesise 1,25(OH)2D3 from 25(OH)D3 in-vitro to a maximal concentration of 5nM 
(Fritsche et al., 2003). Thus, within secondary lymphoid tissues or at inflamed sites 
1,25(OH)2D3 concentrations might lie within the range 1-10nM. 1,25(OH)2D3 was therefore 
titrated over the range 1-100nM and its effects upon IL-17 and IFN monitored. Figure 4.20 
demonstrates that even at 1nM, 1,25(OH)2D3 suppressed IL-17
+ and IFN+ frequencies. Thus 
the effects of 1,25(OH)2D3 reported in this chapter are likely to be relevant in-vivo. 
Nonetheless, since T cell responses to 1,25(OH)2D3 were evident at concentrations lower than 
10nM, it was felt appropriate to reduce the 1,25(OH)2D3 concentration in future studies from 
100nM to 10nM.  
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Figure 4-13. The effect of IL-2 upon CTLA-4 and FoxP3 expression 
 
Figure 4.13. The effect of IL-2 upon CTLA-4 and FoxP3. CD4+CD25- T cells were 
stimulated with monocytes plus anti-CD3 in the presence of 1,25(OH)2D3 and IL-2 
concentrations over the range 0-200U/ml. At four days, cells were stained for CD3, 
CTLA-4 and FoxP3 and analysed by flow cytometry. A) Data are from one 
experiment representative of two performed. Numbers in quadrants refer to 
percentage of CD3+ cells expressing CTLA-4 or FoxP3. B) CTLA-4 median 
fluorescence intensity  (MFI) from data in A.  
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Figure 4-14. 1,25(OH)2D3 and IL-2 additively promote a regulatory phenotype 
 
Figure 4.14. 1,25(OH)2D3 and IL-2 additively promote a regulatory phenotype. 
CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads or monocytes plus 
anti-CD3 in the presence of 1,25(OH)2D3 or vehicle control with or without IL-2 
(200Units/ml). At four days cells were stained for CD3, total CTLA-4 and FoxP3 and 
analysed by flow cytometry. A) Representative FACS plots from one experiment. 
Numbers in quadrants refer to percentage of CD3+ cells expressing CTLA-4 or 
FoxP3. B) CTLA4+FoxP3+ frequency and CTLA-4 median fluorescence intensity data 
for multiple donors. Horizontal lines indicate median values. Significance was tested 
by a two-tailed Wilcoxon matched pairs test.  
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Figure 4-15. 1,25(OH)2D3 and IL-2 inhibit IL-17 and IFN expression 
 
Figure 4.15. 1,25(OH)2D3 and IL-2 inhibit IL-17 and IFN expression. CD4+CD25- 
T cells were stimulated with anti-CD3/CD28 beads or monocytes plus anti-CD3 in the 
presence of 1,25(OH)2D3 or vehicle control with or without IL-2 (200Units/ml). At five 
days, cells were stained for CD3, IFN and IL-17 and analysed by flow cytometry. A) 
Representative FACS plots from one experiment. Numbers in quadrants refer to 
percentage of CD3+ cells expressing IL-17 or IFN. B) IL-17+ and IFN+ frequencies 
for multiple donors. Horizontal lines indicate median frequencies. Significance was 
tested by a two-tailed Wilcoxon matched pairs test. 
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Figure 4-16. IL-17 and IFN are suppressed by 1,25(OH)2D3 and IL-2  during  a second round of 
stimulation 
 
Figure 4.16. IL-17 and IFN are suppressed by 1,25(OH)2D3 and IL-2  during  a 
second round of stimulation. CD4+CD25- T cells were stimulated with monocytes 
plus anti-CD3 in the presence or absence of 1,25(OH)2D3 plus IL-2 for seven days. 
IL-2 treated cells were supplemented with IL-2 at day four.  At seven days, cells were 
stimulated a second time with monocytes plus anti-CD3 under the conditions shown. 
Cells were stained for CD3, IL-17 and IFN at the end of the first stimulation period 
(A) and five days after second stimulation (B). Numbers in quadrants refer to 
percentage of CD3+ cells expressing IL-17 or IFN. Data are from a single 
experiment, representative of three performed.  
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Figure 4-17. 1,25(OH)2D3 and IL-2 promote CTLA-4 and FoxP3 though a second round of stimulation 
 
Figure 4.17. 1,25(OH)2D3 and IL-2 promote CTLA-4 and FoxP3 though a second 
round of stimulation. CD4+CD25- T cells were stimulated with monocytes plus anti-
CD3 in the presence or absence of 1,25(OH)2D3 plus IL-2 for seven days. IL-2 
treated cells were supplemented with IL-2 at day four.  At seven days, cells were 
stimulated a second time with monocytes plus anti-CD3 under the conditions shown. 
Cells were stained for CD3, total CTLA-4 and FoxP3 at the end of the first stimulation 
period (A) and four days after second stimulation (B). Numbers in quadrants refer to 
percentage of CD3+ cells expressing CTLA-4 or FoxP3 and CTLA-4 median 
fluorescence intensity (MFI) is shown. Data are from a single experiment, 
representative of three performed. 
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Figure 4-18. 1,25(OH)2D3 and IL-2 conditioned T cells are suppressive 
 
Figure 4.18. 1,25(OH)2D3 and IL-2 conditioned T cells are suppressive. 
Suppressor T cells (S) were generated by stimulation with monocytes in the presence 
or absence of 1,25(OH)2D3 and IL-2. Their CTLA-4/FoxP3 phenotype is shown in (A). 
Suppressors were labelled with DDAO-SE and added to dendritic cell + anti-CD3 
driven stimulations of CFSE labelled CD4+CD25-  responder T cells (R), prepared as 
1 DC : 5 responders. At five days post stimulation, responder division was analysed 
by CFSE dilution in flow cytometry. Suppressors were excluded from the analysis 
(B). Division by responders at different suppressor to responder ratios is shown in 
(C). Data are from a single experiment, representative of four performed. 
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Figure 4-19. T cells cultured in the presence of 1,25(OH)2D3 and IL-2 suppress responder T cell division 
 
 
 
 
 
Figure 4.19. T cells cultured in the presence of 1,25(OH)2D3 and IL-2 suppress 
responder T cell division. Suppressor T cells cultured in the presence or absence 
of 1,25(OH)2D3 and IL-2 were added to dendritic cell  + anti-CD3 driven stimulations 
of CFSE labelled CD4+CD25-  responder T cells at a 1:10 suppressor : responder 
ratio.  Five days post stimulation, responder division was analysed by CFSE dilution 
in flow cytometry. Data from several experiments reported as CFSE median 
fluorescence intensity (MFI) are shown. Horizontal lines show median values. 
Significance was tested by a two-tailed Mann Whitney U test.    
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Figure 4-20. 1,25(OH)2D3 concentration effects upon IL-17 and IFN 
 
Figure  4.20. 1,25(OH)2D3 concentration effects upon IL-17 and IFN. CD4+CD25- 
T cells were stimulated with monocytes plus anti-CD3 in the presence of 1,25(OH)2D3 
over the concentration range 0-100nM. At five days, cells were stained for CD3, IL-17 
and IFN and analysed by flow cytometry. A) Representative FACS plots from one 
experiment. Numbers in quadrants refer to percentage of CD3+ cells. (B) The effect 
of 1,25(OH)2D3 concentration upon IL-17 and IFN frequencies for multiple donors. 
Horizontal lines indicate median  frequencies.  
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4.9  Discussion 
Studies in this chapter examined the effect of 1,25(OH)2D3 upon CD4
+ T cell proliferation 
and differentiation towards inflammatory versus regulatory lineages. In addition by using 
monocyte and bead stimulation systems in parallel, direct effects of 1,25(OH)2D3 on T cell 
responses and indirect effects through the APC were investigated.  
 
Marked 1,25(OH)2D3-mediated suppression of CD4
+ T cell proliferation was observed in the 
presence of monocytes. However, under stimulation with beads no difference in proliferation 
between control and 1,25(OH)2D3 treatment was found. Recently, Ikeda et al. similarly 
suggested that 1,25(OH)2D3 does not directly affect T cell proliferation (Ikeda et al., 2010). 
Thus, 1,25(OH)2D3 does not appear to suppress T cell proliferation directly but indirectly 
through the APC. Potentially the ability of 1,25(OH)2D3 to down-regulate HLA and co-
stimulatory molecule expression by the APC as was shown here and by others (Berer et al., 
2000; Canning et al., 2001; Penna and Adorini, 2000), might be mechanistically relevant in 
this context. 
 
In contrast to proliferation, the impact of 1,25(OH)2D3 upon T cell differentiation was seen 
for both monocyte and bead stimulations, with strong suppression of the pro-inflammatory 
cytokines IL-17, IL-21 and IFN being seen. All three cytokines are associated with the Th17 
lineage, although IFN and IL-21 are also markers of Th1 and Tfh lineages respectively 
(Mosmann and Coffman, 1989; Vogelzang et al., 2008). Thus 1,25(OH)2D3 could affect 
differentiation to each of these lineages. Inhibition of Th17 development by 1,25(OH)2D3 is 
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supported by recent studies in which injection of 1,25(OH)2D3 reduced expression of IL-17, 
IL-23p19 and IL-6 in the colons of mice with colitis. This corresponded with reduced disease 
severity (Daniel et al., 2008). In another study, Tang et al. (2009) observed direct 
1,25(OH)2D3-mediated suppression of IL-17 by CD4
+ mouse T cells in-vitro and the ability of 
oral 1,25(OH)2D3 to reduce IL-17 secretion by CD4
+ T cells in the experimental autoimmune 
uveitis (EAU) model was shown. In addition, Th17 suppression in the EAU model was 
associated with prevention and partial reversion of disease (Tang et al., 2009). These data 
therefore support the relevance of 1,25(OH)2D3 mediated Th17 suppression in-vivo. 
Subsequent to the publication of data from this chapter (Jeffery et al., 2009), the direct 
inhibitory effect of 1,25(OH)2D3 upon human Th17 cells was demonstrated by others (Ikeda et 
al., 2010).  
 
Rather than simply globally inhibiting T cell differentiation, I observed that 1,25(OH)2D3 
dramatically up-regulates CTLA-4 expression and functions with IL-2 to yield a culture 
enriched for CTLA4+FoxP3+ cells. Such cultures were able to suppress the division of 
bystander CD4+CD25- T cells. In addition, 1,25(OH)2D3 increased regulatory associated IL-
10 by bead stimulated cells which is consistent with others‟ observations (Barrat et al., 2002; 
Urry et al., 2009). Therefore, 1,25(OH)2D3 appears to counter-regulate inflammatory and 
regulatory T cell states.  
 
The regulatory effect of 1,25(OH)2D3 that I observed is consistent with results from several 
in-vivo studies. For example Mathieu et al. demonstrated that co-transfer of splenocytes from 
1,25(OH)2D3-treated non-obese diabetic (NOD) mice prevented diabetes caused by the 
Effects of 1,25(OH)2D3 upon CD4
+
 T cells 
144 
 
transfer of splenocytes from diabetic NOD mice (Mathieu et al., 1994). More recently the 
1,25(OH)2D3 analogue, Ro-26-2198, was shown to arrest diabetes in NOD mice. This 
response corresponded with an increase in the frequency of CD4+CD25+ T cells in the 
pancreatic lymph node (Gregori et al., 2002). In addition, oral 1,25(OH)2D3 induced tolerance 
to islet allografts associated with down-regulation of co-stimulatory molecules on DCs and 
macrophages surrounding the graft. In addition an increase in the frequency of CD4+CD25+ 
cells that were able to prevent islet graft rejection was reported (Gregori et al., 2001). 
Although the FoxP3 status of these cells was not assessed, increased CTLA-4 expression was 
found. More recently it was reported that immunization through skin treated with the 
1,25(OH)2D3 analogue, calcipotriol, induced expansion of antigen specific 
CD4+CD25+FoxP3+ T cells, that had greater CTLA-4 expression than controls (Ghoreishi et 
al., 2009). Lastly, the relevance of enhanced CTLA-4 expression by 1,25(OH)2D3 is 
consistent with the finding that TReg cells from sarcoidosis patients in whom 1,25(OH)2D3 
production is excessive, have high CTLA-4 expression and enhanced activity (Miyara et al., 
2006).  
 
In the studies cited above, the induction of CD4+ T cells with regulatory phenotype was 
largely attributed to the well-established tolerogenic effect of 1,25(OH)2D3 upon DCs. The 
relevance of indirect regulation is supported by the finding that alloreactive T cells co-
cultured with 1,25(OH)2D3 conditioned DCs became hypo-responsive, marked by suppressed 
IFN production upon re-stimulation with untreated mature DCs. They also reported up- 
regulation of CTLA-4 by T cells stimulated by 1,25(OH)2D3-conditioned DCs (Penna and 
Adorini, 2000). However, the extent of this up-regulation was modest compared to the fold 
changes I observed. Furthermore, they did not address the ability of 1,25(OH)2D3 to induce 
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CTLA-4 by direct action upon the T cell. Overall, my data together with earlier findings, 
indicate that 1,25(OH)2D3 acts upon CD4
+ T cells via both direct and indirect mechanisms to 
create a suppressive immunological environment.  
 
One of the most striking observations in this chapter was the extent to which 1,25(OH)2D3 
could up-regulate CTLA-4. This ability might be important in the mechanism by which 
1,25(OH)2D3 promotes iTReg development because it is suggested that CTLA-4 up regulation 
early after T cell activation is required for iTReg formation (Zheng et al., 2006). However, 
nTReg development does not appear to require CTLA-4, as CTLA-4 knockout mice have 
nTRegs, albeit of impaired function (Kolar et al., 2009; Schmidt et al., 2009). My observation 
that 1,25(OH)2D3 enhanced CTLA-4 expression by monocyte stimulated T cells but did not 
increase FoxP3 expression in the absence of IL-2 could suggest that CTLA-4 alone is not 
central to FoxP3 induction. In addition, if CTLA-4 promotes FoxP3 expression it might be 
expected that 1,25(OH)2D3 would stabilise FoxP3 expression longer-term but I did not 
observe this. Rather, my data support the finding that CTLA-4 over-expression in human T 
cells could not enhance FoxP3 expression (Zheng et al., 2008b) implying that CTLA-4 is not 
required for FoxP3 expression. An alternative model for iTReg development suggests that 
FoxP3 is required for CTLA-4 expression (Yagi et al., 2004). Thus, if a way to fix FoxP3 
could be determined, CTLA-4 retention might be possible. Several studies have demonstrated 
the importance of CTLA-4 for TReg function (Friedline et al., 2009; Kolar et al., 2009; Onishi 
et al., 2008; Read et al., 2006; Schmidt et al., 2009; Tivol et al., 1995; Waterhouse et al., 
1995; Wing et al., 2008; Zheng et al., 2008b). Thus, by coupling the ability of 1,25(OH)2D3 to 
promote high CTLA-4 expression with a mechanism to fix FoxP3, an efficient and stable TReg 
population might be generated.  
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FoxP3 maintenance by nTRegs has been attributed to selective demethylation of a CpG rich 
intronic region within the FoxP3 locus (Floess et al., 2007) and a highly conserved non-
intronic upstream enhancer region (Lal et al., 2009). Other epigenetic modifications unique to 
nTRegs have also been found at this enhancer site (Lal et al., 2009). Treatment with the DNA 
methyltransferase inhibitor 5-axa-2-deoxycytidine (5-aza) resulted in demethylation of these 
regions in mice CD4+CD25- T cells and led to strong FoxP3 expression in the presence and 
absence of TGF. Enhanced FoxP3 expression in stimulated human CD4+CD25-  T cells was 
also reported at four days following 5-aza treatment and these cells were functionally more 
suppressive than TGF treated control T cells (Lal et al., 2009). I therefore investigated 
whether 5-aza could stabilise the 1,25(OH)2D3-induced CTLA4
+FoxP3+ phenotype. Although 
5-aza did decrease the rate of CTLA4+FoxP3+ decline, long-term stabilisation was not 
achieved. Possibly, the absence of TGF supplement in the culture might have limited the 
duration of FoxP3 expression, although TGF effects are to some extent provided by serum 
(Manel et al., 2008). Furthermore, others suggest that TGF is not required for FoxP3 
induction by 5-aza (Lal et al., 2009; Polansky et al., 2008). Further work is therefore required 
to confirm if 5-aza does induce stable demethylation at the FoxP3 locus in human T cells and 
to determine if there are conditions that can permit long-term maintenance of CTLA-
4+FoxP3+ cells.  
 
In this chapter re-stimulation in the presence of 1,25(OH)2D3 and IL-2 was also investigated 
as a means to „fix‟ the CTLA-4+FoxP3+ phenotype. Whilst by this method a second rise in 
CTLA-4 expression and the induction of FoxP3 occurred upon secondary stimulation, CTLA-
4+FoxP3+ frequencies and the magnitude of the CTLA-4 increase were lower than by primary 
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stimulation. 1,25(OH)2D3 could also suppress IL-17 and IFN in Th17 polarised cultures. 
These findings are encouraging in the context of disease treatment and are consistent with the 
ability of 1,25(OH)2D3 supplement to reduce disease symptoms in models of autoimmune 
disease (reviewed in (Adorini, 2002; Arnson et al., 2007; Mullin and Dobs, 2007; Smolders et 
al., 2008). However, my re-stimulation experiments do not definitively demonstrate the action 
of 1,25(OH)2D3 upon previously committed cells but might represent the selective outgrowth 
of CTLA-4+FoxP3+ cells balanced by a decline of inflammatory effector cells. Since I 
observed that 1,25(OH)2D3 could induce CTLA-4 in undivided cells, selective outgrowth 
alone cannot account for the increase in CTLA-4 in response to 1,25(OH)2D3.  
 
The rapid effect of 1,25(OH)2D3 upon gene expressions is consistent with a mechanism of 
direct gene regulation. This involves the heterodimeric binding of the vitamin D receptor 
(VDR) with the retinoid-X-receptor (RXR) to vitamin D response elements (VDREs) within 
the regulatory portions of target genes (Deeb et al., 2007; Haussler et al., 2010). Very 
recently, the results of a ChIP-seq-defined genome wide map of VDR binding sites in 
lymphoblastoid cell lines (LCLs) were published (Ramagopalan et al., 2010). This study 
identified 2776 VDR binding sites in 1,25(OH)2D3-treated LCLs compared to 623 in 
untreated LCLs. The binding sites were particularly enriched in intergenic or intronic regions. 
Consistent with the inhibitory effect of vitamin D upon autoimmune disease, VDR binding 
sites were enriched in a number of regions previously associated with disease. The ctla-4 
locus at chromosome 2q33 was one such region (Kristiansen et al., 2000; Ramagopalan et al., 
2010; Scalapino and Daikh, 2008), thus CTLA4 transcription might be directly regulated by 
VDR binding. Genes encoding other CD28 family members, CD28 and ICOS,   lie either side 
of the ctla-4 gene locus at this locus. Interestingly, I have also observed that 1,25(OH)2D3 can 
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up-regulate CD28 as well as CTLA-4, thus, VDR might co-regulate genes at this locus. 
However, I have not detected enhanced expression of ICOS by 1,25(OH)2D3. Therefore, 
regulation by VDR might not extend 3‟ of ctla-4 at the 2q33 locus. VDR binding sites have 
already been characterised in the promoters of genes encoding IFN (Cippitelli and Santoni, 
1998) and IL-10 (Matilainen et al., 2010). Thus, both pro-inflammatory and regulatory 
associated genes might be primary VDR targets. However, secondary responses could 
contribute to the T helper to TReg switch afforded by 1,25(OH)2D3. Consistent with this, 
1,25(OH)2D3 suppressed transcript expressions of receptors for IL-1, IL-6, IL-21 and IL-23 by 
CD4+ T cells (Ikeda et al., 2010). Thus, 1,25(OH)2D3 could inhibit Th17 induction and 
promote TReg development by suppressing the T cell‟s response to pro-Th17 cytokines .  
 
In this chapter, the function of 1,25(OH)2D3 plus IL-2 treated T cells was also assessed. 
Whilst 1,25(OH)2D3 plus IL-2 treated T cells reduced responder proliferation compared to 
control suppressor T cells, control T cells also reduced responder proliferation. The greater 
suppressive effect of 1,25(OH)2D3 plus IL-2 treated cells was most apparent at lower 
suppressor to responder ratios. As mentioned, CTLA-4 is thought to play an important role in 
suppression by TRegs (Friedline et al., 2009; Kolar et al., 2009; Onishi et al., 2008; Read et al., 
2006; Schmidt et al., 2009; Tivol et al., 1995; Waterhouse et al., 1995; Wing et al., 2008; 
Zheng et al., 2008b). Hence, its elevated expression by 1,25(OH)2D3 plus IL-2 treated cells 
could have contributed to their greater suppression efficiency. Another plausible explanation 
could be enhanced IL-10 and reduced IFN secretion by 1,25(OH)2D3 plus IL-2 treated cells, 
since both cytokine changes could lead to decreased B7 expression by DCs (Fujihara et al., 
1996; Moore et al., 2001). General suppression of responder T cells by stimulated T cells 
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might be explained in a number of ways. Firstly, due to their larger size, stimulated T cells 
might dominate APC space. Secondly, by their high CD25 expression stimulated cells could 
act as an IL-2 sink, depriving responder cells of the IL-2 they require for proliferation 
(Shevach, 2009). Furthermore, both of these mechanisms could be enhanced, as memory cells 
respond more rapidly than naive T cells to co-stimulation signals (reviewed by (Boesteanu 
and Katsikis, 2009). Nonetheless, the finding that untreated, stimulated cells could suppress 
responder cell division is also consistent with the transient expression of TReg associated 
markers by activated T cells (Pillai and Karandikar, 2007). Indeed it is now contended that 
activated T cells that express FoxP3 might have similar functions to TRegs (Pillai and 
Karandikar, 2007). Physiologically, acquisition of regulatory capacity upon activation could 
permit negative feedback of the immune response and avoidance of 
hyperlymphoproliferation.  
 
Taken together, the data presented here indicate that 1,25(OH)2D3 functions in the reciprocal 
regulation of Th17 versus TReg differentiation, acting directly upon CD4
+ T cells to inhibit the 
development of T helper cells expressing IL-17, IL-21 and IFN, whilst promoting in consort 
with IL-2 a population of CD4+CTLA-4+FoxP3+ cells with suppressive activity. Therefore, 
similar to other steroid nuclear receptors, including RAR (Schambach et al., 2007) and AHR 
(Quintana et al., 2008), signalling through VDR appears to influence the position of the 
Th17/TReg balance, deregulation of which is associated with immune disease. Data in this 
chapter therefore provide further insight into the molecular and cellular basis of the 
epidemiological link between low vitamin D status and autoimmune conditions (reviewed by 
(Arnson et al., 2007; Cantorna and Mahon, 2004; Mullin and Dobs, 2007)).  
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5 ARE PRO-REGULATORY EFFECTS OF 1,25(OH)2D3 
MAINTAINED IN THE ABSENCE OF SERUM?  
The data in chapter four of this thesis demonstrated the ability of 1,25(OH)2D3 to shift the 
Th17/TReg balance in favour of TReg development. Thus, 1,25(OH)2D3 appears to share 
immunological properties with the other steroidal vitamin, All Trans Retinoic Acid (ATRA). 
However, FoxP3 induction by ATRA required TGF (Benson et al., 2007; Elias et al., 2008; 
Mucida et al., 2007; Sun et al., 2007; Xiao et al., 2008). Since TGF responses have been 
observed in serum containing media in the absence of TGF supplement (Manel et al., 2008), 
I considered whether CD4+ T cell responses to 1,25(OH)2D3 likewise involved the interaction 
of 1,25(OH)2D3 with TGF. In this chapter, I therefore investigated the effect of 1,25(OH)2D3 
upon CD4+ T cell responses in chemically defined, serum free medium. 
 
5.1 1,25(OH)2D3 influences CD4
+ T cell phenotype alone and in consort with 
TGF  
To investigate whether CD4+ T cell responses to 1,25(OH)2D3 required TGF, bead 
stimulations were carried out in serum free medium with and without TGF in the presence of 
1,25(OH)2D3. Figures 5.1 and 5.2 show that, in the absence of serum, 1,25(OH)2D3 increased 
CTLA-4 and CD25 expression and suppressed IFN. However, IL-17 expression required 
TGF, thus in its absence 1,25(OH)2D3 did not affect IL-17 levels. By contrast, IL-21 was 
expressed at very high level in the absence of serum and was dramatically suppressed by 
1,25(OH)2D3 (figure 5.3). Similarly, 1,25(OH)2D3 mediated IL-22 suppression in the absence 
of serum components or TGF (figure 5.3). Thus, it was clear that 1,25(OH)2D3 did not 
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require serum or TGF to influence CD4+ T cell phenotype. However, in the absence of 
serum, FoxP3 expression was very low and 1,25(OH)2D3 had only a modest effect upon its 
level (figure 5.4). By supplying TGF, though, FoxP3 was strongly increased. Accordingly, 
1,25(OH)2D3 and TGF synergistically increased the CTLA-4
+FoxP3+ population. Equivalent 
FoxP3 induction was observed at TGF concentrations ≥1ng/ml (figure 5.5), hence 1ng/ml 
TGF was used throughout subsequent experiments. Induction of IL-10 by 1,25(OH)2D3 
similarly depended upon TGF (figure 5.6). Interestingly, when supplied individually, TGF 
and 1,25(OH)2D3 suppressed IL-10 relative to non-supplemented cultures but when provided 
together IL-10+ frequencies were increased. 
 
Although TGF was not required for 1,25(OH)2D3-mediated increase in CTLA-4, it tended to 
enhance it (figure 5.1). TGF is known to regulate the expression of a number of 
transcription factors including the hallmark TReg and Th17 transcription factors FoxP3 and 
RORC respectively (Ivanov et al., 2006; Zhou et al., 2008). Thus, whether the additive effects 
of TGF and 1,25(OH)2D3 upon CTLA-4 might involve TGF mediated VDR induction was 
considered. VDR mRNA level was measured for CD4+CD25-  T cells by quantitative real-
time PCR after 12 hours stimulation in the presence or absence of TGF, with or without 
1,25(OH)2D3. As shown in figure 5.7, stimulation marginally increased VDR but 
1,25(OH)2D3 did not influence this induction. However, TGF enhanced VDR in stimulated 
cells 4.3 fold and together 1,25(OH)2D3 and TGF supported highest VDR expression.  
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Figure 5-1. 1,25(OH)2D3 increases CTLA-4 and CD25 expression in the absence of TGF 
 
Figure 5.1. 1,25(OH)2D3 increases CTLA-4 and CD25 expression in the absence 
of TGF. CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads under 
serum free conditions in the presence of 1,25(OH)2D3 or vehicle control, with or 
without TGF. At four days, cells were stained for total CTLA-4 and CD25 and 
analysed by flow cytometry. A) Representative FACS plots from one experiment. 
Numbers in quadrants refer to percentage of cells. B)  CTLA-4 and CD25 median 
fluorescence intensities (MFI) for multiple donors. Horizontal lines indicate median 
values. Significance was tested by a two-tailed Wilcoxon matched pairs test.  
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Figure 5-2. 1,25(OH)2D3 suppresses IFN in the absence of TGF 
 
Figure 5.2. 1,25(OH)2D3 suppresses IFN in the absence of TGF. CD4+CD25- T 
cells were stimulated with anti-CD3/CD28 beads under serum free conditions in the 
presence of 1,25(OH)2D3 or vehicle control with or without TGF. At five days, cells 
were stained for intracellular IL-17 and IFN and analysed by flow cytometry. A) 
Representative FACS plots from one experiment. Numbers in quadrants refer to 
percentage of cells. B) IL-17+ and IFN+ frequencies for multiple donors. Horizontal 
lines indicate median frequencies. Significance was tested by a two-tailed Wilcoxon 
matched pairs test. 
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Figure 5-3. IL-21 and IL-22 are suppressed by 1,25(OH)2D3 in the absence of serum 
 
Figure 5.3. IL-21 and IL-22 are suppressed by 1,25(OH)2D3 in the absence of 
serum. CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads under serum 
free conditions in the presence of 1,25(OH)2D3 or vehicle control with or without 
TGF. At five days, cells were stained for IL-21 and IL-22 and analysed by flow 
cytometry. A) Representative FACS plots from one experiment. Numbers in 
quadrants refer to percentage of cells. B) IL-21+ and IL-22+ frequencies for multiple 
donors. Horizontal lines indicate median values. Significance was tested by a two-
tailed Wilcoxon matched pairs test.  
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Figure 5-4. TGF induces FoxP3 and with 1,25(OH)2D3 
 
enhances CTLA-4
+
FoxP3
+ 
frequencies 
 
Figure 5.4. TGF induces FoxP3 and with 1,25(OH)2D3 
 enhances CTLA-
4+FoxP3+ frequencies. CD4+CD25- T cells were stimulated with anti-CD3/CD28 
beads under serum free conditions in the presence of 1,25(OH)2D3 or vehicle control, 
with or without TGF. At four days, cells were stained for total CTLA-4 and FoxP3 
and analysed by flow cytometry. A) Representative FACS plots from one experiment. 
Numbers in quadrants refer to percentage of cells. B)  FoxP3+ and CTLA-4+FoxP3+ 
frequencies for multiple donors. Horizontal lines indicate median values. Significance 
was tested by a two-tailed Wilcoxon matched pairs test.  
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Figure 5-5. Effect of TGF upon CTLA-4 and FoxP3 expression 
 
Figure 5.5. Effect of TGF upon CTLA-4 and FoxP3 expression. CD4+CD25- T 
cells were stimulated with anti-CD3/CD28 beads under serum free conditions at 
increasing concentrations of TGF. At four days, cells were stained for total CTLA-4 
and FoxP3 and analysed by flow cytometry. Representative FACS plots from one 
experiment are shown. Numbers in quadrants refer to percentage of cells.  
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Figure 5-6. TGF is required for IL-10 induction by 1,25(OH)2D3 
 
Figure 5.6. TGF is required for IL-10 induction by 1,25(OH)2D3. CD4+CD25- T 
cells were stimulated with anti-CD3/CD28 beads under serum free conditions in the 
presence of 1,25(OH)2D3 or vehicle control, with or without TGF. At five days, cells 
were stained for intracellular IL-10 and IFN and analysed by flow cytometry. A) 
Representative FACS plots from one experiment. Numbers in quadrants refer to 
percentage of cells. B) IL-10+ frequencies for multiple donors. Horizontal lines 
indicate median frequencies. Significance was tested by a two-tailed Wilcoxon 
matched pairs test.  
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Figure 5-7. TGF enhances vitamin D receptor mRNA expression by stimulated T cells 
 
 
 
 
 
 
 
Figure 5.7. TGF enhances vitamin D receptor mRNA expression by stimulated 
T cells. CD4+CD25- T cells were stimulated for 12 hours with anti-CD3/CD28 beads 
under serum free conditions in the presence of 1,25(OH)2D3 or vehicle control, with 
or without TGF. Vitamin D receptor (VDR) expression was measured by quantitative 
real-time PCR. Expression was normalised to 18S rRNA and plotted relative to the 
level in autologous unstimulated CD4+CD25- T cells. Error bars indicate standard 
deviation, n=2.  
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5.2 1,25(OH)2D3 effects are maintained under pro-inflammatory conditions 
If 1,25(OH)2D3 is to be of benefit in the control of active disease it might be necessary that it 
can suppress effector T cell development and promote TReg populations under pre-established 
inflammatory conditions. To examine this, bead stimulations were repeated in the presence of 
Th17 polarizing cytokines. Figure 5.8 shows that TGF combined with IL-1, IL-6 and IL-
23, enhanced Th17 frequencies. Therefore, in this study a pro-Th17 environment was created 
by supplementing serum free medium with recombinant TGF, IL-1, IL-6 and IL-23. Figure 
5.9 confirms that even under pro-Th17 conditions, 1,25(OH)2D3 could suppress the expression 
of inflammatory cytokines IL-17, IFN, IL-21 and IL-22. At the same time, its ability to 
enhance CTLA-4, CD25 and IL-10 and increase CTLA-4+FoxP3+ frequencies was seen 
(figure 5.10). Thus the regulatory effect of 1,25(OH)2D3 could be maintained under pro-
inflammatory conditions.  
 
5.3 Pro-inflammatory cytokines suppress CTLA-4 but enhance its 
1,25(OH)2D3-dependent induction  
When studying the effects of 1,25(OH)2D3 under pro-Th17 conditions it was seen that pro-
inflammatory cytokines significantly suppressed CTLA-4 expression (figure 5.11 and 5.12). 
This observation did not merely reflect faster activation and proliferation kinetics in the pro-
Th17 cultures, since CFSE dilution experiments showed that CTLA-4 expression was reduced 
at all division stages (figure 5.11). Surprisingly, when 1,25(OH)2D3 was added, highest 
CTLA-4 levels were repeatedly found under the pro-Th17 conditions (figure 5.12). Thus, pro-
regulatory effects of 1,25(OH)2D3 might be strengthened under inflammatory conditions. 
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Figure 5-8. TGF plus pro-inflammatory cytokines, IL-1, IL-6 and IL-23, yields the highest 
IL-17+ frequencies 
 
Figure 5.8. TGF plus pro-inflammatory cytokines, IL-1, IL-6 and IL-23, yields 
the highest IL-17+ frequencies. CD4+CD25- T cells were stimulated for five days 
with anti-CD3/CD28 beads in serum free medium supplemented with combinations of 
the cytokines TGF, IL-1, IL-6 and IL-23 as indicated. Cells were stained for IL-17 
and IFN and analysed by flow cytometry. Data shown are for a single experiment 
representative of two performed. 
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Figure 5-9. Inflammatory cytokines are suppressed by 1,25(OH)2D3 under pro-Th17 conditions 
 
Figure 5.9. Inflammatory cytokines are suppressed by 1,25(OH)2D3 under pro-
Th17 conditions. CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads in 
serum free medium supplemented with TGF, IL-1, IL-6 and IL-23 in the presence 
of 1,25(OH)2D3 or vehicle control. At five days, cells were stained for IL-17, IFN, IL-
21 and IL-22 and analysed by flow cytometry. A summary of the cytokine frequencies 
for multiple donors is shown. Horizontal lines indicate median frequencies. 
Significance was tested by a two-tailed Wilcoxon matched pairs test.  
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Figure 5-10. 1,25(OH)2D3 enhances regulatory markers under pro-Th17 conditions 
 
Figure 5.10. 1,25(OH)2D3 enhances regulatory markers under pro-Th17 
conditions. CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads in serum 
free medium supplemented with TGF, IL-1, IL-6 and IL-23 in the presence of 
1,25(OH)2D3 or vehicle control. At four days, cells were stained for total CTLA-4, 
FoxP3 and CD25. At five days cells were stained for IL-10. All samples were 
analysed by flow cytometry. A summary of the data for multiple donors is shown. 
Horizontal bars indicate median values. Significance was tested by a two-tailed 
Wilcoxon matched pairs test.  
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Figure 5-11. Across division stages, pro-Th17 conditions suppress CTLA-4 expression whilst 1,25(OH)2D3  
enhances it. 
 
Figure 5.11. Across division stages, pro-Th17 conditions suppress CTLA-4 
expression whilst 1,25(OH)2D3  enhances it. CFSE labelled CD4+CD25-  T cells 
were stimulated with anti-CD3/CD28 beads in serum free medium without 
supplement (control) or in the presence of Pro-Th17 recombinant  cytokines (TGF, 
IL-1, IL-6 and IL-23) or Pro-TReg conditions (1,25(OH)2D3 + TGF). At four days, 
cells were stained for CTLA-4 expression and analysed by flow  cytometry. A) CTLA-
4 vs. FoxP3. B) CTLA-4 vs. CFSE. Numbers in gates indicate percentage of dividing 
cells and CTLA-4 median fluorescence intensities (MFI) are given in red. FACS plots 
are from a single experiment representative of n>3. 
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Figure 5-12. Pro-Th17 conditions suppress CTLA-4 expression but synergise with 1,25(OH)2D3 to enhance 
CTLA-4 up-regulation 
 
Figure 5.12. Pro-Th17 conditions suppress CTLA-4 expression but synergise 
with 1,25(OH)2D3 to enhance CTLA-4 up-regulation. CD4+CD25- T cells were 
stimulated with anti-CD3/CD28 beads in serum free medium in the absence of 
recombinant cytokines, with TGF alone or with the pro-Th17 cocktail (TGF, IL-1, 
IL-6 and IL-23). Stimulations were also treated with 1,25(OH)2D3 or vehicle control. At 
four days, cells were stained for total CTLA-4 and analysed by flow cytometry. 
Median CTLA-4 fluorescence intensities were calculated relative to the level in 
medium alone. A summary of the data for multiple donors is shown. Horizontal bars 
indicate median values. Significance was tested by a two-tailed Wilcoxon matched 
pairs test. For clarity not all significant comparisons are indicated.  
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5.4 CTLA-4 expression level affects ligand removal  
The involvement of CTLA-4 in suppression is established but its mechanism is controversial. 
My lab has recently identified that via CTLA-4, T cells can internalise B7 ligands and destroy 
them by lysosomal degradation (Qureshi et al. manuscript in preparation). This process of 
internalisation is termed transendocytosis. The varying levels of CTLA-4 displayed by T cells 
cultured under control, Th17 and 1,25(OH)2D3 conditions could thus affect their CTLA-4 
dependent regulatory capacity. To investigate this, CHO cells stably expressing CD86-GFP 
were co-cultured with T cells previously stimulated under Th17, control and 1,25(OH)2D3 
conditions. After three hours, T cell acquisition of CD86-GFP was measured by flow 
cytometry. Figure 5.13 shows that CD86-GFP acquisition was greatest by T cells expressing 
the highest levels of CTLA-4 level. To confirm that this trend related to CTLA-4 level, T cells 
were incubated with anti-CTLA-4 blocking antibody prior to culture with CD86-GFP CHO 
cells. Anti-CTLA-4 reduced acquisition by 60-70% across conditions, indicating the 
involvement of CTLA-4 engagement in CD86 acquisition.  
 
5.5 1,25(OH)2D3-conditioned T cells reduce CD80 and CD86 levels on co-
cultured DCs in a CTLA-4 dependent manner 
Through an artificial system, it was clear that 1,25(OH)2D3-treated T cells have greater ability 
than control T cells to acquire CD86 from a target cell (figure 5.13). However, if co-
stimulatory molecule depletion is a mechanism by which 1,25(OH)2D3-conditioned T cells 
suppress the division of responder T cells in DC stimulations, they should be able to deplete 
CD86 and CD80 from DCs during co-culture. It was considered that antigen targeting might 
be important for directing efficient DC and T cell engagement. Therefore, SEB reactive CD4+ 
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T cell populations were generated in the presence of IL-2 and 1,25(OH)2D3 or vehicle control 
and cultured overnight with SEB pulsed DCs. CD80 and CD86 expression by the DCs was 
then measured by flow cytometry. Data shown in Figures 5.14 and 5.15 support the 
hypothesis that 1,25(OH)2D3 conditioned T cells reduce CD80 and CD86 expression by DCs. 
Furthermore, pre-treating T cells with anti-CTLA-4, confirmed that depletion of CD80 and 
CD86 was largely CTLA-4 dependent. However, recovery for CD86 appeared to be less 
efficient than that for CD80 (figure 5.15). It was also of interest that anti-CTLA-4 enhanced 
CD80 and CD86 expression by DCs cultured with control T cells. This finding corresponds 
with the previous observation that stimulated control T cells with low CTLA-4 suppressed 
responder T cell proliferation compared to responders alone (figures 4.18 and 4.19).  
 
5.6 1,25(OH)2D3-induced CTLA-4 up-regulation contributes to 1,25(OH)2D3 
mediated suppression of dendritic cell driven CD4+ T cell stimulations 
1,25(OH)2D3 was previously shown to reduce the extent of T cell proliferation when T cells 
were stimulated by APCs (figure 4.4). Whilst direct signalling of 1,25(OH)2D3 at the APC 
could limit MHC and co-stimulatory molecule levels, increased CTLA-4 expression by T 
cells leading to elevated B7 removal from the APC might contribute to reduced responder T 
cell proliferation. To investigate the role of CTLA-4 in suppressing T cell proliferation under 
control and 1,25(OH)2D3 conditions, CFSE labelled T cells were stimulated with DCs for five 
days in the presence and absence of 1,25(OH)2D3 with and without CTLA-4 blocking 
antibody. Figure 5.16 shows that across a range of T cell: DC ratios, 1,25(OH)2D3 reduced 
proliferation relative to controls and anti-CTLA-4 partially overcame this suppression.  
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Figure 5-13. CD86 acquisition from a target cell is dependent upon CTLA-4 and relates to the level of 
CTLA-4 expressed 
 
Figure 5.13. CD86 acquisition from a target cell is dependent upon CTLA-4 and 
relates to the level of CTLA-4 expressed. CD4+CD25-  T cells stimulated in serum 
free medium under pro-Th17, control or 1,25(OH)2D3 conditions were re-stimulated 
with anti-CD3 and CHO cells expressing CD86-GFP in the presence or absence of 
anti-CTLA-4 blocking antibody. A) Cycling and total CTLA-4 expression for each T 
cell population as determined by flow cytometry. B) CD86 acquisition by the T cells 
was measured by flow cytometry and is shown as the percentage of GFP+ T cells . 
Data are from a single experiment representative of four performed.  
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Figure 5-14. 1,25(OH)2D3-treated T cells reduce CD86 and CD80 expression by DCs in a CTLA-4 
dependent manner 
 
Figure 5.14. 1,25(OH)2D3-treated T cells reduce CD86 and CD80 expression by 
DCs in a CTLA-4 dependent manner. A) FoxP3 and CTLA-4 expression by SEB 
reactive CD4+ T cells at the start of co-culture. B) CD86 and CD80 expression by 
SEB-pulsed dendritic cells was monitored by flow cytometry following their overnight 
culture with SEB reactive control (black) and 1,25(OH)2D3-treated (red) CD4+ T cells 
in the presence (dashed line) and absence (shaded histogram) of anti-CTLA-4 
blocking antibody. Clear histogram shows isotype control. Data are from a single 
experiment representative of two performed. 
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Figure 5-15. 1,25(OH)2D3-treated T cells reduce CD86 and CD80 expression by DCs in a CTLA-4 
dependent manner 
 
Figure 5.15. 1,25(OH)2D3-treated T cells reduce CD86 and CD80 expression by 
DCs in a CTLA-4 dependent manner. CD86 and CD80 expression on SEB-pulsed 
dendritic T cells was monitored by flow cytometry  following their overnight culture 
with increasing ratios of SEB reactive control (black) and 1,25(OH)2D3-treated (red) 
CD4+ T cells in the presence (clear bar) and absence (shaded bar) of anti-CTLA-4 
blocking antibody. CD80 and CD86 expression was calculated relative to the level 
following co-culture with control T cells at a 5:1 ratio. Mean values for two 
experiments are graphed. Error bars indicate standard deviation.  
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Figure 5-16. 1,25(OH)2D3-induced CTLA-4 up-regulation contributes to 1,25(OH)2D3-mediated 
suppression of dendritic cell driven CD4
+
 T cell stimulations 
 
Figure 5.16. 1,25(OH)2D3-induced CTLA-4 up-regulation contributes to 
1,25(OH)2D3-mediated suppression of dendritic cell driven CD4
+ T cell 
stimulations. CFSE labelled CD4+CD25-  T cells were stimulated with immature 
dendritic cells (iDC) and anti-CD3 in the presence  of 1,25(OH)2D3 or vehicle control. 
Parallel stimulations were conducted in the presence (red) versus the absence 
(black) of blocking antibody to CTLA-4. At five days, proliferation was monitored by 
CFSE dilution in flow cytometry. Division profiles are from a single experiment 
representative of three performed.  
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Therefore, 1,25(OH)2D3-mediated CTLA-4 up-regulation appears to contribute to 
1,25(OH)2D3-mediated suppression of T cell proliferation during primary stimulation.  
 
5.7 Can 1,25(OH)2D3 suppress IL-17 expression by committed Th17 cells? 
If 1,25(OH)2D3 is to be useful in the control of active inflammatory disease, it might be 
necessary that it can suppress IL-17 expression by committed Th17 cells. To study this, 
conditions were optimised for generating Th17 enriched cultures. In earlier studies, I had 
shown that reducing the bead to cell ratio increased Th17 frequencies (figure 3.10). Thus, a 
1:32 bead to cell ratio coupled with serum free, Th17 polarising conditions was tested for its 
ability to generate Th17 cells. Repeatedly ~15% IL-17
+ cells were obtained by six days. Since 
these conditions permitted strong IL-17 enrichment, they were used to generate IL-17+ cells. 
The ability of 1,25(OH)2D3 to regulate these cells was then studied.  
 
It was considered that if 1,25(OH)2D3 could rapidly modify the phenotype of previously 
committed cells, for example by direct gene regulation, then 1,25(OH)2D3 might be able to 
alter cell phenotype before selective outgrowth in a mixed population was possible. 
1,25(OH)2D3 responses by an IL-17
+ cell-enriched culture were therefore monitored over 
time. Effects upon CTLA-4 were clear within six hours of treatment and by 24 hours the 
maximal effect of 1,25(OH)2D3 was reached (figure 5.17 and 5.20). Suppression of IL-17, 
IFN and IL-21 by 1,25(OH)2D3 took longer: maximal responses being observed at 48 hours 
(figure 5.18, 5.19 and 5.20). In addition, IFN appeared less sensitive to 1,25(OH)2D3 than 
IL-17 or IL-21 throughout the time course studied (figures 5.18 and 5.20). Analysis of 
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1,25(OH)2D3 effects upon CTLA-4 and IL-17 transcripts likewise suggested that 1,25(OH)2D3 
modulates CTLA-4 expression more rapidly than IL-17 (figure 5.21). Although further 
studies are required to confirm this, these data could be indicative of direct versus indirect 
control of gene transcription for CTLA-4 and IL-17 respectively.   
 
The finding that CTLA-4 induction occurred rapidly suggested that 1,25(OH)2D3 can affect 
previously activated cells. However, the less rapid responses of cytokines to 1,25(OH)2D3 
meant that suppression by selective outgrowth or de-novo commitment could not be 
discounted. To address these possibilities, an attempt was made to purify live IL-17+ cells 
from the Th17 polarised population. For this, an IL-17 secretion assay enrichment and 
detection kit (Miltenyi Biotec) was used followed by MoFlo sorting. 99% IL-17+ purity was 
achieved (figure 5.22). Following culture of the IL-17+ cells for three days under pro-Th17 
conditions in the presence of 1,25(OH)2D3 or vehicle control their expression of IL-17 was 
measured by intracellular staining. In repeat experiments, IL-17 expression was reduced even 
in the absence of 1,25(OH)2D3 but 1,25(OH)2D3 reduced the frequency of IL-17
+ cells or their 
level of IL-17 expression further. However, IL-17  expression by IL-17+ cells appeared to be 
less sensitive to 1,25(OH)2D3 than the development of IL-17
+ cells in primary stimulations 
(figure 5.9). Therefore, these data suggest that 1,25(OH)2D3 can influence previously 
stimulated cells but its effect might be weaker than on primary stimulated cultures.  
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Figure 5-17. 1,25(OH)2D3 enhances CTLA-4 in re-stimulated cells 
 
 
 
Figure 5.17. 1,25(OH)2D3 enhances CTLA-4 in re-stimulated cells. Th17 polarised 
CD4+ T cells were re-stimulated with anti-CD3/CD28 beads in the presence of 
1,25(OH)2D3  or vehicle control. At the indicated times post second stimulation, cells 
were stained for total CTLA-4 and analysed by flow cytometry. Data are from a single 
experiment representative of three performed.  
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Figure 5-18. Time course of 1,25(OH)2D3 effect upon IL-17
+
 and IFN+ expression 
 
Figure 5.18. Time course of 1,25(OH)2D3 effect upon IL-17
+ and IFN+ 
expression. Th17 polarised cultures were re-stimulated with anti-CD3/CD28 beads in 
the presence of 1,25(OH)2D3 or vehicle control. At the indicated times, cells were 
stained for IL-17 and IFN and analysed by flow cytometry. IL-17+ and IFN+ 
frequencies from the FACS plots in A are graphed in B. Data are from a single 
experiment representative of three performed.   
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Figure 5-19. Time course of IL-21 depletion by 1,25(OH)2D3 
 
Figure 5.19. Time course of  IL-21 depletion by 1,25(OH)2D3. TH17 polarised 
cultures were re-stimulated with anti-CD3CD28 beads in the presence of 
1,25(OH)2D3  or vehicle control. At the indicated times, cells were stained for IL-21 
and IFN and analysed by flow cytometry. IL-21+ frequencies from the FACS plots in 
A are graphed in B. Data are from a single experiment representative of three 
performed.  
 
1,25(OH)2D3  effects in the absence of serum 
176 
 
Figure 5-20. Vitamin D sensitivities of CTLA-4 and inflammatory cytokines in Th17 polarised cultures 
 
 
 
 
 
Figure 5.20. Vitamin D sensitivities of CTLA-4 and inflammatory cytokines in 
Th17 polarised cultures. Th17 polarised cultures were re-stimulated with beads in 
the presence of 1,25(OH)2D3 or vehicle control. Fold differences in level of 
expression (CTLA-4) or percentage of positive cells (IL-17, IFN and IL-21) between 
control and 1,25(OH)2D3-treated re-stimulation cultures were determined by flow 
cytometry and are plotted over a period of 96 hours post re-stimulation. Dotted lines 
indicate the positions of no change. Data are from results shown in figures 5.17 – 
5.19.   
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Figure 5-21. Time course of 1,25(OH)2D3 effect upon CTLA-4 and IL-17 mRNA transcripts 
 
Figure 5.21. Time course of 1,25(OH)2D3 effect upon CTLA-4 and IL-17 mRNA 
transcripts. TH17 polarised cultures were re-stimulated with anti-CD3/CD28 beads in 
the presence of 1,25(OH)2D3  or vehicle control. At the indicated times, CTLA-4 and 
IL-17 mRNA expressions were determined by quantitative realtime PCR. Expression 
was normalised to 18S rRNA and plotted relative to the level at the start of re-
stimulation (n=1).  
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Figure 5-22. 1,25(OH)2D3 reduces IL-17 expression by sorted IL-17
+
 cells 
 
Figure 5.22. 1,25(OH)2D3 reduces IL-17 expression by sorted IL-17
+ cells. 
CD4+CD25-  T cells were stimulated for six days with antiCD3/CD28 beads at a ratio 
of 1 bead to 32 cells in serum free medium supplemented with Th17 polarising 
cytokines. A) IL-17, IFN and IL-21 expression by the culture as measured by 
intracellular staining and flow cytometry. B) Live IL-17+ cells (P5) were sorted from 
the Th17 culture to 99% purity using an IL-17 secretion, detection and capture kit 
(Miltenyi Biotec) and MoFlo sorting. Following culture for three days under Th17 
polarising conditions in the presence of 1,25(OH)2D3 or vehicle control, cells were 
stained for intracellular IL-17, IFN and IL-21 and analysed by flow cytometry (C). 
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5.8 Discussion 
In this chapter the effect of 1,25(OH)2D3 upon T cell differentiation in the absence of serum 
was addressed and the role of TGF investigated. I observed that when T cells were 
stimulated with beads under serum free conditions, the effect of 1,25(OH)2D3 upon CTLA-4, 
CD25, IFN, IL-21 and IL-22 was similar to when serum containing medium was used 
(chapter four). This implies that 1,25(OH)2D3 can promote a regulatory T cell phenotype in 
the presence or absence of factors in serum. However, TGF was required for IL-17 
expression, as shown by others (Manel et al., 2008; Volpe et al., 2008; Yang et al., 2008a) and 
TGF was needed to stimulate FoxP3 induction. Therefore, TGF promoted the 
1,25(OH)2D3-dependent formation of a CTLA-4
+FoxP3+ population. Interestingly, IL-10 up-
regulation by 1,25(OH)2D3 also required TGF.  
 
The requirement of TGF for FoxP3 expression by iTRegs is now established (Horwitz et al., 
2008a; Shevach et al., 2008; Tran et al., 2007) as is the role of TGF in maintaining FoxP3 
expression by nTRegs in the periphery (Marie et al., 2005). TGF signalling involves 
phosphorylation of receptor associated Smads (2 or 3) that in turn heterodimerise with Smad4. 
This complex binds to regulatory elements in target genes and interacts with other DNA 
binding factors to control gene expression (O'Shea et al., 2009). Whilst Smad deficiencies do 
not impair nTReg suppression and only mildly affect nTReg numbers, Smads 2, 3 and 4 are non-
redundant in iTReg differentiation (Malhotra et al., 2010; Martinez et al., 2009; Takimoto et 
al., 2010; Yang et al., 2008c). The dependency of FoxP3 expression upon TGF is supported 
by the presence of a Smad3 binding site in the FoxP3 promoter and an enhancer element 
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upstream of the FoxP3 ATG start site (Ruan et al., 2009; Tone et al., 2008). Interestingly, the 
affinity of the enhancer site for Smad3 is increased by AP-1 or all trans retinoic acid (ATRA) 
signalling (Xu et al., 2010). The latter is consistent with the synergistic effect of TGF and 
ATRA in FoxP3 induction. In contrast to ATRA, I did not observe synergy between 
1,25(OH)2D3 and TGF for FoxP3 expression even though both RAR and VDR partner RXR 
in their signalling. It might be that although two potential RAR-RXR binding sites are present 
at the FoxP3 locus (Xu et al., 2010), VDR binding cannot substitute RAR. Indeed it has been 
shown that RAR is important for ATRA enhanced FoxP3 (Schambach et al., 2007). 
Recently, whether ATRA regulates FoxP3 expression mainly through direct or indirect 
mechanisms has been a matter of debate (Hill et al., 2008; Mucida et al., 2009). My 
observations, together with those of others might support the former, since unlike ATRA, 
1,25(OH)2D3, did not enhance FoxP3 even though it could influence the same indirect 
mechanisms by which ATRA might increase FoxP3. For example, like ATRA, 1,25(OH)2D3  
could increase Smad3 (Cao et al., 2003b; Xiao et al., 2008) and suppress inflammatory 
cytokines and receptors for pro-Th17 signals (Cao et al., 2003b; Hill et al., 2008; Ikeda et al., 
2010; Xiao et al., 2008). Thus, whilst 1,25(OH)2D3 and ATRA both appear to regulate the 
Th17/TReg balance, there are clear differences in their actions. 
 
In this chapter inter-dependency of TGF and 1,25(OH)2D3  for IL-10 expression was also 
observed. One explanation could be that TGF-induced Smads and VDR both regulate the IL-
10 gene. Consistent with this, a Smad4 binding site (Kitani et al., 2003) and VDRE 
(Matilainen et al., 2010) are present at the IL-10 locus. The importance of TGF for IL-10 
induction is supported by the observation that induced TGF promoted IL-10+ cells in the 
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spleen and lamina propia of mice (Kitani et al., 2003) and TGF was necessary for the 
development of IL-10+ TRegs from FoxP3
+ and FoxP3- precursor cells (Maynard et al., 2007). 
Furthermore, the combined importance of TGF and IL-10 in regulation was seen as TGF 
induction could not protect against colitis in il-10 deficient mice (Kitani et al., 2003). 
Although none of these in-vivo studies investigated the combined requirement of 
1,25(OH)2D3 with TGF for IL-10 expression, as I observed, they do not oppose it, since it is 
likely that 1,25(OH)2D3 or a replacement factor would be present in-vivo. 
 
A number of studies have confirmed the ability of 1,25(OH)2D3 to promote IL-10 expression. 
For example, 1,25(OH)2D3 supplement in glucocorticoid-resistant asthmatic patients 
increased IL-10 production and enhanced their responsiveness to dexamethasone (Xystrakis et 
al., 2006) Similarly, 1,25(OH)2D3 potentiated the beneficial effects of allergen specific 
immunotherapy in an IL-10 and TGF dependent manner (Taher et al., 2008). Given the 
importance of IL-10 and TGF in the regulation of immune responses, my finding that 
1,25(OH)2D3 permitted TGF induced IL-10, suggests a central role for 1,25(OH)2D3 in 
regulatory responses. It will be of interest to investigate whether other factors can substitute 
for 1,25(OH)2D3 in this effect. 
 
An additive effect of TGF and 1,25(OH)2D3 in CTLA-4 up-regulation was also observed in 
this study, although, in contrast to its role in IL-10 expression, TGF was not essential for 
CTLA-4 up-regulation by 1,25(OH)2D3. Interestingly, TGF enhanced VDR mRNA 
expression, consistent with the report that phosphorylated Smad3 increased VDR transcription 
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(Daniel et al., 2007). Thus, TGF might enhance CTLA-4 expression in response to 
1,25(OH)2D3 by increasing VDR availability. Alternatively, TGF could enhance VDR 
transactivation via Smad3 (Yanagisawa et al., 1999). The latter might have relevance in the 
regulation of CTLA-4 expression, since a VDR binding site is present within the CTLA-4 
locus (Ramagopalan et al., 2010).  Interestingly, in addition to TGF, I observed that pro-
Th17 cytokines (IL-1, IL-6 and IL-23) could actually enhance the 1,25(OH)2D3-mediated 
increase in CTLA-4 expression, whilst in the absence of 1,25(OH)2D3 they suppressed CTLA-
4. Reduction of CTLA-4 by pro-Th17 cytokines might have relevance in-vivo, as it could 
permit a more sustained T cell response by reducing CTLA-4 facilitated suppression during 
inflammation. It is possible that elevated levels of Th17 cytokines in autoimmune diseases 
would also result in reduced CTLA-4 expression by effector T cells or TRegs. Indeed, TRegs 
isolated from the peripheral blood of children with newly diagnosed diabetes had low CTLA-
4 transcript expression (Luczynski et al., 2009). If low CTLA-4 leads to reduced TReg 
effectiveness this could contribute to disease. The fact that CTLA-4 levels reached their 
highest following 1,25(OH)2D3 supplementation under Th17-polarising conditions might 
suggest that rather than inhibiting the regulatory properties of 1,25(OH)2D3, inflammatory 
conditions might actually support them. However, for this observation to have functional 
relevance it requires that the level of CTLA-4 expression can influence the regulatory 
capacity of the cell.  
 
Although many studies point to a major role for CTLA-4 in the function of TRegs (Friedline et 
al., 2009; Kolar et al., 2009; Onishi et al., 2008; Read et al., 2006; Schmidt et al., 2009; Tivol 
et al., 1995; Waterhouse et al., 1995; Wing et al., 2008; Zheng et al., 2008b), the mechanism 
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by which CTLA-4 suppresses effector T cells and how regulation relates to the level of its 
expression is not clear. Data from my lab suggest that CTLA-4 contributes to regulation by 
internalising its B7 ligands, in a process termed transendocytosis (Qureshi et al. manuscript in 
preparation). Thus, to investigate whether the level of CTLA-4 on stimulated cells could 
affect their regulatory potential, I performed transendocytosis assays. These revealed that the 
extent of internalisation corresponded with the level of cycling CTLA-4 and was CTLA-4 
dependent. Thus, 1,25(OH)2D3-treated cells showed enhanced CD86 acquisition relative to 
control cells. In further support of this finding and its relevance immunologically, I observed 
that 1,25(OH)2D3-treated T cells could deplete CD80 and CD86 on co-cultured DCs more 
extensively than could control T cells. Furthermore, blocking CTLA-4 confirmed that the 
majority of B7 depletion was CTLA-4 dependent. I also demonstrated that CTLA-4 blockade 
could reduce 1,25(OH)2D3-mediated suppression of T cell division in DC driven stimulations. 
Together, these data suggest that CTLA-4 dependent depletion of B7 contributes greatly to 
the mechanism of suppression by 1,25(OH)2D3-treated T cells. Consistent with this 
conclusion, others have shown that TRegs down-regulate DC B7 in a CTLA-4 dependent 
manner leading to reduced stimulatory capacity of the DC (Oderup et al., 2006; Wing et al., 
2008).  
 
A number of regulatory mechanisms might converge on B7 depletion. The cytokine profile of 
1,25(OH)2D3-treated cells might contribute, since IL-10, which is enhanced in 1,25(OH)2D3 
treated cells, can suppress B7 ligands (Moore et al., 2001). Furthermore, in the absence of 
CTLA-4, IL-10 blockade abrogated TReg function (Read et al., 2006). By contrast, IFN, 
which is decreased in 1,25(OH)2D3-treated T cells, enhances B7 (Fujihara et al., 1996; Moore 
et al., 2001). Although not measured in this study, 1,25(OH)2D3 can increase TGF (Cao et 
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al., 2003b) and TGF can suppress B7 (Misra et al., 2004). Others have shown that CTLA-4 
engagement leads to enhanced TGF and suppressed IFN expression by CD4+ T cells 
(Gomes et al., 2000). It is therefore possible that TGF, IL-10, IFN and CTLA-4 exist in a 
suppressive feedback loop, which can be favoured by the action of 1,25(OH)2D3. In the 
future, it will be of interest and potentially of therapeutic use, to investigate the nature and 
relative contribution of CTLA-4 dependent and independent suppression mechanisms 
employed by 1,25(OH)2D3-conditioned T cells. 
 
If 1,25(OH)2D3 is to be useful therapeutically, it would be important that it not only influences 
the differentiation of T cells undergoing primary stimulation but that it can also affect 
previously stimulated T cells. To test this, Th17 polarised cultures were re-stimulated in the 
presence of 1,25(OH)2D3 and their phenotype monitored over time. CTLA-4 was up-regulated 
within six hours. The fast kinetics of this response might suggest that 1,25(OH)2D3 can switch 
the phenotype of previously stimulated T cells. However, the kinetics of IL-17 and IL-21 
suppression in response to 1,25(OH)2D3 were slower and suppression of IFN was minimal 
over the time studied. These distinctions between CTLA-4 and cytokine expressions might be 
indicative of direct versus indirect signalling mechanisms respectively, or the use of slower, 
non-VDR mediated signalling for cytokine regulation. However, the presence of a VDRE in 
both the CTLA-4 (Ramagopalan et al., 2010) and IFN (Cippitelli and Santoni, 1998) gene 
promoters implies that both loci are potential VDR binding sites.  
 
The lack of response by IFN compared to CTLA-4 might alternatively reflect differences in 
the chromatin state around their loci. Indeed, previous studies suggest that Th1 and Th2 cells 
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lose their ability to acquire the opposite cytokine program after only three to four divisions 
(Grogan et al., 2001). Epigenetic analysis further revealed the enrichment of permissive 
histone H3 lysine 4 trimethylation (H3K4me3) at the IFN locus compared to suppressive 
histone H3 lysine 27 trimethylation (H3K27me3) at IL-4 and IL-17 loci in Th1 cells. By 
contrast, in Th2 cells, the IL-4 locus contained permissive H3K4me3 whilst IFN and IL-17 
loci were marked by suppressive H3K27me3 (reviewed by (Zhou et al., 2009a).  
 
The greater 1,25(OH)2D3 sensitivity of IL-17 compared to IFN is consistent with reports that 
Th17 cells retain plasticity (Zhou et al., 2009a), failing to maintain IL-17 expression in the 
absence of TGF and IL-6, and becoming converted to Th1 or Th2 cells in the presence of IL-
12 or IL-4 respectively (Lexberg et al., 2008). Thus, it would seem that the histone 
modifications that form at the IL-17A/IL-17F locus (Akimzhanov et al., 2007) are not stable. 
Adoptive transfer of Th17 cells has further demonstrated the ability of Th17 cells to convert 
into Th1 and Th17/1 populations (Bending et al., 2009; Kurschus et al., 2010; Lee et al., 2009; 
Martin-Orozco et al., 2009). In addition, plasticity of the Th17 lineage has been demonstrated 
as repeat stimulation of Th17 cells in the presence of TGF and IL-6 led to their expression of 
IL-10 and a switch to regulatory phenotype capable of suppressing EAE (McGeachy et al., 
2007). Interestingly, although regarded less plastic than Th17 cells, Th1 cells co-expressed 
IFN and IL-10 when re-stimulated in the presence of TGF and showed reduced 
encephalitogenicity in the EAE model (Huss et al., 2010). In addition, whilst most studies 
suggest that Th1 cells do not acquire IL-17 expression, Kurschus et al. recently suggested this 
might be possible (Kurschus et al., 2010). Thus, it would seem that Th1 and Th17 cells could 
both demonstrate plasticity under the right conditions.  
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To rule out the possibility that 1,25(OH)2D3-mediated IL-17 suppression in previously 
stimulated cultures arose through selective outgrowth of IL-17- cells or de-novo commitment 
of previously un-stimulated cells, an attempt was made to purify live IL-17+ cells from a Th17 
polarised culture using a cytokine secretion and capture assay. Although 99% IL-17+ purity 
was obtained, it is possible that by this method false positives were labelled, as IL-17- cells 
captured IL-17 from neighbouring IL-17-secreting cells. The data indicate that 1,25(OH)2D3 
could suppress IL-17 expression and similar to its effects upon primary cultures, the Th17/1 
population was the most sensitive. However, sensitivity was less than seen when primary 
stimulations were supplemented with 1,25(OH)2D3. These data might therefore support the 
initial dogma that T cell phenotypes become increasingly fixed upon stimulation. Whilst 
resistance to 1,25(OH)2D3 could question the benefit of 1,25(OH)2D3 supplementation in the 
control of inflammation at sites of established disease, its ability to promote tolerance at the 
cell population level is arguably of great importance. In support of this, several studies in 
mouse models of autoimmune disease now report the ability of 1,25(OH)2D3 to suppress Th17 
populations and correlate this suppression with reduced disease severity (Arnson et al., 2007; 
Cantorna and Mahon, 2004; Mullin and Dobs, 2007). Thus, 1,25(OH)2D3 remains an 
attractive molecule for use in the control of chronic inflammatory disease.  
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6 IS LOCAL CONVERSION OF 25(OH)D3 BY DENDRITIC CELLS 
SUFFICIENT TO SUPPORT A REGULATORY CD4+ T CELL 
PHENOTYPE? 
 
The finding in chapter 5 of this thesis that the regulatory effects of 1,25(OH)2D3 could be 
maintained and even enhanced under inflammatory conditions, suggests that 1,25(OH)2D3 
might be useful in the treatment of autoimmune disease. However, the hypercalcaemic effect 
of 1,25(OH)2D3 questions the safety of such an approach. Furthermore, 1,25(OH)2D3 has 
limited stability, and strong homeostatic mechanisms operate to retain 1,25(OH)2D3 serum 
levels at approximately 0.1nM (Mullin and Dobs, 2007). Thus, although 1,25(OH)2D3 
supplementation might be immunologically effective, it is likely that any effects would be 
short lived. Supplementation with 25(OH)D3 might be a safer and longer lasting option, but to 
be of benefit 25(OH)D3 must be sufficiently converted at a site of immune activation. 
Conversion is carried out by the cytochrome P450 enzyme 25-hydroxyvitamin-D3-1-
hydroxylase (CYP27B1). Monocyte derived macrophages and dendritic cells (DCs) have been 
shown to express CYP27B1 and facilitate conversion in-vitro (Fritsche et al., 2003; Hewison 
et al., 2007; Liu et al., 2006a) but whether the 1,25(OH)2D3 generated can in turn modulate 
the T cell phenotype has not been studied. This chapter therefore looks at whether 
1,25(OH)2D3-mediated CD4
+ T cell responses can be observed when CD4+ T cells are 
stimulated in the presence of inactive 25(OH)D3 in place of active 1,25(OH)2D3.  
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6.1 25(OH)D3 promotes a regulatory CD4
+ T cell phenotype in the presence 
of APCs 
It was considered that T cells stimulated by APCs in the presence of 25(OH)D3 might show 
1,25(OH)2D3-mediated responses, since others have demonstrated that APCs can convert 
25(OH)D3 to 1,25(OH)2D3 in-vitro (Fritsche et al., 2003; Hewison et al., 2007; Liu et al., 
2006a). Furthermore, because T cells and APCs co-habit immune sites, such stimulations are 
potentially relevant in-vivo. To determine the type of APC to use for T cell stimulation, 
CYP27B1 and VDR transcripts were compared for monocytes, immature DCs (iDCs) and 
LPS matured DCs (mDCs) by quantitative real-time PCR (figure 6.1). Low CYP27B1 
expression was found in monocytes and iDCs but maturation with LPS dramatically up-
regulated its expression in DCs. Similarly, mDCs showed the highest VDR expression. Based 
upon these data, it was hypothesised that of the APCs studied, mDCS would support the 
greatest conversion of 25(OH)D3 to 1,25(OH)2D3 and would be the most sensitive to 
1,25(OH)2D3. Hence, mDCs were used initially to investigate the ability of T cells to respond 
to locally converted 25(OH)D3. To determine the sensitivity of the response, 25(OH)D3 and 
1,25(OH)2D3 were titrated over the range 0-50nM and T cell expression of CTLA-4, FoxP3, 
IL-17 and IFN was monitored by flow cytometry. As seen for 1,25(OH)2D3, concentration 
dependent induction of CTLA-4 and the CTLA-4+FoxP3+ phenotype (figure 6.2) as well as 
suppression of IL-17 and IFN (figure 6.3) was observed across the 25(OH)D3 titration. 
However, in contrast to 1,25(OH)2D3, for which effects were evident at 0.1nM, responses to 
25(OH)D3 were not seen below 1nM. For the four T cell markers, responses at 50nM 
25(OH)D3 mirrored those at 10nM 1,25(OH)2D3. Therefore, 50nM 25(OH)D3 was chosen for 
future experiments. Using this concentration, it was confirmed for multiple donors that 
25(OH)D3 enhanced CTLA-4 expression by mDC stimulated T cells to a level equivalent to 
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that attained with 1,25(OH)2D3 (figure 6.4). At the same time, 25(OH)D3 suppressed T cell 
expression of IL-17, IFN and IL-21 (figure 6.5).  
 
6.2 Ketoconazole inhibits CTLA-4 induction by 25(OH)D3 supplementation 
The broad spectrum cytochrome p450 inhibitor, ketoconazole (KC), has been used by others 
to demonstrate enzymatic conversion of 25(OH)D3 in-vitro (Fritsche et al., 2003; Hewison et 
al., 2007). Therefore, to test if the effects of 25(OH)D3 upon CD4
+ T cell phenotype were a 
consequence of its local enzymatic conversion, KC was used. Hewison et al, showed that at 
5M, KC could suppress 1,25(OH)2D3 generation in DC and macrophage cultures treated 
with 25(OH)D3 concentrations up to 150nM (Hewison et al., 2007). Thus, 5M KC was used 
for initial CYP27B1 blocking studies and CTLA-4 was chosen as the response marker for 
1,25(OH)2D3 signalling, due to its strong 1,25(OH)2D3 sensitivity. 5M KC was found to 
slightly reduce the proliferation of mDC stimulated T cells. Since CTLA-4 expression might 
have been suppressed by compromised stimulation, the effect of KC upon CTLA-4 expression 
was only compared for activated T cells expressing CD25. This showed that KC reduced the 
25(OH)D3 mediated increase in CTLA-4 expression by mDC stimulated T cells three fold 
(figure 6.6).  
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Figure 6-1. VDR and CYP27B1 expression in antigen presenting cells 
 
Figure 6.1. VDR and CYP27B1 expression in antigen presenting cells. CYP27B1 
(A) and VDR (B) mRNA expression levels in monocytes, immature DCs (iDCs) and 
LPS-matured DCs (mDC) were measured by quantitative real-time PCR. Levels were 
normalised to 18S rRNA and are plotted relative to one other. Horizontal lines 
indicate median expression.  
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Figure 6-2. 1,25(OH)2D3 and 25(OH)D3 affect CTLA-4 and FoxP3 expression 
 
Figure 6.2. 1,25(OH)2D3 and 25(OH)D3 affect CTLA-4 and FoxP3 expression. 
CD4+CD25- T cells were stimulated with mature dendritic cells plus anti-CD3 in the 
presence of varying concentrations of 1,25(OH)2D3, 25(OH)D3 or vehicle control. At 
four days, cells were stained for CD3, CTLA-4 and FoxP3 and analysed by flow 
cytometry. A) FACS plots are from one experiment representative of two performed. 
Numbers in quadrants refer to percentage of CD3+ cells. B) CTLA-4 frequencies for 
two donors. Mean frequencies  are plotted and error bars indicate standard deviation.  
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Figure 6-3. 1,25(OH)2D3 and 25(OH)2D3 inhibit IL-17 and IFN 
 
Figure 6.3. 1,25(OH)2D3 and 25(OH)2D3 inhibit IL-17 and IFN. CD4+CD25- T cells 
were stimulated with mature dendritic cells plus anti-CD3 in the presence of varying 
concentrations of 1,25(OH)2D3, 25(OH)D3 or vehicle control. At five days, cells were 
stained for CD3, IL-17 and IFN and analysed by flow cytometry. A) FACS plots are 
from one experiment representative of two performed. Numbers in quadrants refer to 
percentage of CD3+ cells. B) IL-17+ and IFN+ frequencies for two donors. Mean 
frequencies are plotted and error bars indicate standard deviation.  
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Figure 6-4. Conversion of 25(OH)D3 during mature dendritic cell-driven stimulations increases 
CTLA-4 expression and CTLA-4+FoxP3+ frequencies 
 
Figure 6.4. Conversion of 25(OH)D3 during mature dendritic cell-driven 
stimulations increases CTLA-4 expression and CTLA-4+FoxP3+ frequencies. 
CD4+CD25- T cells were stimulated with mature dendritic cells plus anti-CD3 in 
serum free medium supplemented with IL-2 in the presence of 10nM 1,25(OH)2D3, 
50nM 25(OH)D3 or vehicle control. At four days, cells were stained for CTLA-4 and 
FoxP3 and analysed by flow cytometry. A) Representative FACS plots are from one 
experiment. Numbers in quadrants refer to percentage of cells. B) Relative CTLA-4 
median fluorescence intensities and CTLA-4+FoxP3+ frequencies for multiple donors. 
Horizontal lines indicate median values. Significance was tested by a two-tailed 
Wilcoxon matched pairs test.  
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Figure 6-5. 25(OH)D3 conversion during mature dendritic cell-driven stimulations suppresses IL-17, IFN
and IL-21 expression 
Figure 6.5. 25(OH)D3 conversion during mature dendritic cell-driven 
stimulations suppresses IL-17, IFN and IL-21 expression. CD4+CD25- T cells 
were stimulated with mature dendritic cells plus anti-CD3 in serum free medium in the 
presence of 10nM 1,25(OH)2D3, 50nM 25(OH)D3 or vehicle control. At five days, cells 
were intracellular stained for CD3, IL-17, IL-21 and IFN and analysed by flow 
cytometry. A) Representative FACS plots are from one experiment. Numbers in 
quadrants refer to percentage of cells. B) IL-17 and IFN frequencies for multiple 
donors. Horizontal lines show median frequencies. Significance was tested by a two-
tailed Wilcoxon matched pairs test.
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Figure 6-6. Ketoconazole inhibits 25(OH)D3-mediated CTLA-4 up-regulation during mature dendritic 
cell-driven stimulations 
 
Figure 6.6. Ketoconazole inhibits 25(OH)D3-mediated CTLA-4 up-regulation 
during mature dendritic cell-driven stimulations. CD4+CD25- T cells were 
stimulated with mature dendritic cells plus anti-CD3 in serum free medium 
supplemented with IL-2 in the presence of 50nM 25(OH)D3 (blue) or vehicle control 
(black) with or without ketoconazole (5M). At four days, cells were stained for CD25 
and CTLA-4 and analysed by flow cytometry. CTLA-4 expression by CD25+ cells 
gated is shown. Shaded histogram illustrates isotype control staining. Data are from a 
single experiment.  
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In light of the finding that freshly isolated monocytes have very low CYP27B1 expression 
relative to mDCs (figure 6.1), whether 25(OH)D3 could affect T cell responses in monocyte 
driven stimulations was also assessed. As illustrated in figure 6.7, under these conditions 
strong induction of CTLA-4 and suppression of inflammatory cytokines, IL-17, IFN and IL-
21 still occurred, suggesting that CYP27B1 is induced in monocytes upon stimulation or that 
low CYP27B1 expression is sufficient for conversion.  
 
6.3 25(OH)D3 is poorly converted by T cells in the absence of APCs  
The striking effect of 25(OH)D3 upon APC stimulated T cells prompted consideration of 
whether 25(OH)D3 could also work autonomously upon the T cell. Therefore, CYP27B1 
expression was measured in un-stimulated and stimulated T cells by quantitative real-time 
PCR. Whilst CYP27B1 expression was very low in un-stimulated T cells, it was increased 
upon stimulation. The maximum level of CYP27B1 transcript was detected at 6-24hr post 
stimulation. However, relative to 18SrRNA, CYP27B1 was much lower in stimulated T cells 
compared to mDCs (figure 6.8). To test the ability of T cells to convert 25(OH)D3, its effect 
upon their expression of CTLA-4 and pro-inflammatory cytokines was measured after 
stimulation with beads. Consistent with the low expression of CYP27B1 in T cells, induction 
of CTLA-4 upon 25(OH)D3 treatment was modest and suppression of cytokines, IL-17, IL-21 
and IFN was small compared to the effect of 1,25(OH)2D3 (figures 6.9-6.10).  
 
To investigate further whether this limited response of T cells to 25(OH)D3 in the absence of 
APCs was a consequence of CYP27B1 mediated 25(OH)D3 conversion, bead stimulations 
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were repeated in the presence of KC. Interestingly, KC concentrations above 0.05M strongly 
impaired the proliferation of bead stimulated T cells. This was in contrast to its effects upon 
mDC stimulations. Since both CYP27B1 and VDR are expressed at very low levels in un-
stimulated T cells but are increased upon stimulation, whether bead stimulation for three days 
prior to 25(OH)D3 and KC treatment would improve T cell tolerance to KC treatment was 
tested. Th17 polarising conditions were also used, since these enhance VDR expression and 
would maximise 1,25(OH)2D3-mediated CTLA-4 induction. CFSE dilution confirmed 
division at all KC concentrations across the range 0-2.5M. Furthermore, KC concentration 
dependent inhibition of 25(OH)D3-mediated CTLA-4 induction was observed for dividing 
cells, with total inhibition occurring at 2.5M KC (figures 6.11). Therefore, CYP27B1 
catalysed conversion of 25(OH)D3 by the T cell appeared to facilitate its up-regulation of 
CTLA-4 following 25(OH)D3 treatment.  
 
Overall, data reported in this chapter suggest that APCs express high levels of CYP27B1 and 
can efficiently convert 25(OH)D3 to support 1,25(OH)2D3-modulated responses in 
surrounding T cells. By contrast, T cells express low levels of the converting enzyme, thus, in 
the absence of APCs, 25(OH)D3 supplementation has modest anti-inflammatory effects upon 
T cell phenotype.  
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Figure 6-7. In-vitro conversion of 25(OH)D3 during monocyte driven T cell stimulations suppresses IL-17, 
IFN and IL-21 expression 
 
Figure 6.7. In-vitro conversion of 25(OH)D3 during monocyte-driven T cell 
stimulations suppresses IL-17, IFN and IL-21 expression. CD4+CD25- T cells 
were stimulated with monocytes plus anti-CD3 in serum free medium in the presence 
of 10nM 1,25(OH)2D3, 50nM 25(OH)D3 or vehicle control. A) At four days, cells were 
stained for CD3, CTLA-4 and FoxP3. B) At five days, cells were intracellular stained 
for CD3, IL-17, IFN and IL-21 and analysed by flow cytometry.  Data are shown for 
several donors. Horizontal lines indicate median values. Significance was tested by a 
two-tailed Wilcoxon matched pairs test.  
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Figure 6-8. Stimulated T cells express CYP27B1 
 
 
 
 
Figure 6.8. Stimulated T cells express CYP27B1. CYP27B1 mRNA expression by 
un-stimulated and antiCD3/CD28 stimulated T cells was measured by quantitative 
real-time PCR and compared against expression by mature DCs. Levels were 
normalised to 18S rRNA and expression relative to that in unstimulated T cells 
calculated. Data is for 3 donors and error bars indicate standard deviation. 
Significance was tested by a two-tailed Mann-Whitney U test.  
 
 
 Can 25(OH)D3 conversion  support a TReg phenotype? 
200 
 
Figure 6-9. In-vitro activation of 25(OH)D3 during bead-driven stimulations modestly increases CTLA-4 
expression and the frequency of CTLA-4
+
FoxP3
+ 
T cells 
 
Figure 6.9. In-vitro activation of 25(OH)D3 during bead-driven stimulations 
modestly increases CTLA-4 expression and the frequency of CTLA-4+FoxP3+ T 
cells. CD4+CD25- T cells were stimulated with anti-CD3/CD28 beads in serum free 
medium supplemented with TGF in the presence of 10nM 1,25(OH)2D3, 50nM 
25(OH)D3 or vehicle control. At four days, cells were stained for CTLA-4 and FoxP3 
and analysed by flow cytometry. A) Representative FACS plots from one experiment. 
Numbers in quadrants refer to percentage of cells. B) Relative CTLA-4 median 
fluorescence intensities and CTLA-4+FoxP3+ frequencies for multiple donors. 
Horizontal lines show median values. Significance was tested by a two-tailed 
Wilcoxon matched pairs test.  
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Figure 6-10. Inflammatory cytokines are modestly reduced following conversion of 25(OH)D3 during 
bead-driven T cell stimulations 
 
Figure 6.10. Inflammatory cytokines are modestly reduced following 
conversion of 25(OH)D3 during bead-driven T cell stimulations. CD4+CD25- T 
cells were stimulated with anti-CD3/CD28 beads in serum free medium 
supplemented with TGF, IL-1, IL-6 and IL-23 in the presence of 10nM 
1,25(OH)2D3, 50nM 25(OH)D3 or vehicle control. At five days, cells were intracellular 
stained for IL-17, IL-21 and IFN and analysed by flow cytometry. A) Representative 
FACS plots from one experiment. Numbers in quadrants refer to percentage of cells. 
B) IL-17, IFN and IL-21 frequencies for multiple donors. Horizontal lines indicate 
median frequencies. Significance was tested by a two-tailed Wilcoxon matched pairs 
test.  
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Figure 6-11. Ketoconazole inhibits 25(OH)D3-mediated CTLA-4 up-regulation during bead driven T cell 
stimulations 
 
Figure 6.11. Ketoconazole inhibits 25(OH)D3-mediated CTLA-4 up-regulation 
during bead-driven T cell stimulations. CFSE labelled CD4+CD25- T cells were 
stimulated for three days with beads in serum free medium supplemented with TGF 
and IL-2. Cells were then treated with 50nM 25(OH)D3 (blue) or vehicle control 
(black) and ketoconazole (2.5M) or corresponding control. At five days, cells were 
stained for CTLA-4 and analysed by flow cytometry. CTLA-4 expression was 
compared for divided cells (pink quadrant). Data are from a single experiment.  
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6.4 Discussion 
Physiologically, it is important that serum 1,25(OH)2D3 is tightly maintained at a low level of 
approximately 0.1nM (Mullin and Dobs, 2007). Although I observed that CTLA-4 could be 
enhanced at this concentration, effects upon inflammatory cytokines were minimal. Others 
have shown that APCs express the converting enzyme 25-hydroxyvitamin-D3-1-hydroxylase 
(CYP27B1) and can generate 1,25(OH)2D3 in-vitro (Fritsche et al., 2003; Hewison et al., 
2007; Liu et al., 2006a) but whether this production permits regulation of the T cell phenotype 
has not been addressed. It was therefore important to determine whether immune cells can 
sufficiently convert 25(OH)D3 to 1,25(OH)2D3 for 1,25(OH)2D3-mediated effects upon T cell 
phenotype to be observed.  
 
It was demonstrated in this chapter that 25(OH)D3 treatment induced CTLA-4 up-regulation 
and suppressed IL-17, IFN and IL-21 production by CD4+ T cells when they were stimulated 
with mDCs or monocytes. The efficiency of 25(OH)D3 conversion in these stimulations was 
clear, as the magnitude of the T cell response was comparable to that obtained upon 
1,25(OH)2D3 supplementation. Consistent with these observations, APCs were found to 
express CYP27B1 and in keeping with others‟ reports, strong induction of CYP27B1 
occurred upon DC maturation with LPS (Fritsche et al., 2003). The finding that KC, a 
cytochrome P450 enzyme inhibitor, greatly reduced CTLA-4 up-regulation in mDC driven 
stimulations also supported conversion of 25(OH)D3 by CYP27B1 in these assays. The fact 
that incomplete blockade was observed might be explained by the greater affinity of KC for 
24-hydroxylase (CYP24) than for CYP27B1 (Yee et al., 2006). CYP24 converts 25(OH)D3 
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and 1,25(OH)2D3 into biologically inactive products, thus such differing affinities could result 
in the accumulation of 1,25(OH)2D3 at low level and therefore weak induction of CTLA-4.  
 
The observation that freshly isolated monocytes had very low levels of CYP27B1 relative to 
mDCs but permitted equivalent 1,25(OH)2D3-mediated T cell responses following 25(OH)D3 
supplementation, could suggest that cross-talk between the monocyte and the T cell leads to 
maturation of the monocyte and its induction of CYP27B1. By this model, it would seem that 
the activated immune system is armed for efficient use of 25(OH)D3, which could be 
particularly important for restoring immune homeostasis.  
 
It was further shown in this chapter that T cells can respond to 25(OH)D3 in the absence of 
APCs. However, CTLA-4 up-regulation upon 25(OH)D3 supplementation was weak 
compared to the effect of 1,25(OH)2D3, as was suppression of IL-17, IFN and IL-21. This 
low level of response correlated with the comparatively low level of CYP27B1 detected in 
stimulated T cells. Nonetheless, the finding that KC could block 25(OH)D3 mediated CTLA-4 
up-regulation supports a functional role for CYP27B1 in T cells. Presently, literature 
describing the expression of CYP27B1 in T cells is limited: Adams and Hewison mentioned 
their observation of it (Adams and Hewison, 2008) and Von Essen et al. alluded to CYP27B1 
activity in their T cell assays (von Essen et al., 2010). Correale et al. also reported CYP27B1 
expression and activity by stimulated T cells, however their assays imply the presence of 
contaminating CD4+ APCs (Correale et al., 2009). My observations therefore strengthen 
suggestions that CYP27B1 is expressed by stimulated T cells and demonstrate its potential 
functional importance there. Identifying factors that regulate CYP27B1 activity in T cells 
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might shed light on the types of immune response that are strongly regulated by vitamin D. In 
addition, such factors could contribute to individual variability in vitamin D responses. 
 
Studies of 25(OH)D3 effects in the innate immune system have highlighted the importance of 
Toll Like Receptor (TLR) 2 and 4 signalling for CYP27B1 induction in macrophages (Liu et 
al., 2006a; Reichel et al., 1987a) and DCs (Fritsche et al., 2003) as well as in keratinocytes 
(Schauber et al., 2007). However, TLR mRNAs have also been detected in purified T cells 
(Hornung et al., 2002; Urry et al., 2009; Zarember and Godowski, 2002) and their ability to 
respond to TLR2, 5, 7, 8 and 9 ligands shown (Caron et al., 2005; Komai-Koma et al., 2004; 
Urry et al., 2009). It is therefore tempting to speculate that signalling through TLRs might 
influence CYP27B1 expression in T cells. Indeed, the observation that 1,25(OH)2D3 could 
regulate T cell expression of TLRs 2,3, 5, 7 and 9 (Urry et al., 2009) might support their role 
in the control of vitamin D metabolism.  
 
Overall, the data presented in this chapter strongly suggest that local 25(OH)D3 conversion by 
APCs and T cells could be sufficient to support the anti-inflammatory effects of 1,25(OH)2D3  
described in earlier chapters of this thesis. It should also be considered that local 1,25(OH)2D3 
levels could be topped up by CYP27B1 activity in non-immune cells, as its expression in a 
diverse range of tissues and cell types is described {Zehnder, 2001 #506}. The question that 
then remains is, what serum 25(OH)D3 concentration is sufficient to support 1,25(OH)2D3 
mediated immune modulation?  
50nM 25(OH)D3 was used for most experiments in this chapter but in mDC stimulations, 
concentrations as low as 1nM gave mild anti-inflammatory effects. Thus, if serum level 
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directly related to the level within the tissues, even vitamin D deficient individuals who have 
a 25(OH)D3 level of below 25nM might be expected to have sufficient vitamin D for immune 
homeostasis. However, the finding that T cell responses to 25(OH)D3 were concentration 
dependent across typical, even insufficient concentrations (Holick, 2007; Hollis, 2005), is 
consistent with epidemiological data inversely correlating vitamin D status with disease 
severity for a number of inflammatory diseases (reviewed by (Arnson et al., 2007; Cantorna 
and Mahon, 2004; Mullin and Dobs, 2007)). The fact that immunomodulatory effects of 
25(OH)D3 were evident in my assays at arguably insufficient concentrations might be 
explained by the existence of CYP27B1 regulation in-vivo, which is mediated by cytokines 
and growth factors (Leventis and Patel, 2008). Although serum 25(OH)D3 levels necessary 
for efficient immune function need further investigation, the data presented in this chapter 
support the concept that 25(OH)D3 supplementation could reduce the risk or severity of 
inflammatory diseases. 
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7 CAN THE TREG/T17 RATIO PREDICT DISEASE OUTCOME IN 
EARLY SYNOVITIS PATIENTS? 
7.1 Introduction 
A number of inflammatory diseases are now associated with IL-17 overproduction. However, 
in most instances, the direct contribution of IL-17 to the disease pathogenesis is not known 
(reviewed by (Miossec, 2009). Neither is it always clear that T cells are the responsible 
producer, since studies have often reported IL-17 protein levels in body fluids or mRNA 
levels in tissues (reviewed in (Korn et al., 2009; Park et al., 2005; Steinman, 2007; van Beelen 
et al., 2007)).  Rheumatoid arthritis (RA) is one of the most studied inflammatory diseases 
with regard to a role for IL-17. It is a painful and disabling condition characterised by the 
destruction of articular cartilage and bone, although multiple organs are often affected, 
including the skin, blood vessels, heart, lungs and muscles. It affects approximately 1% of the 
population with strong female bias and has a peak age of incidence of 40 to 60 years 
(Firestein, 2003).  
 
Studies into the pathogenic mechanisms underlying RA began in the mid 20th century. 
Initially it was characterised as an immune complex-mediated disease, since rheumatoid 
factor (RF) was identified in the blood of affected patients, complement and RF were present 
in RA synovium and immune complexes were found in their cartilage (Firestein, 2003). 
However, the presence of a large number of T cells in the RA synovium suggested that they 
too could participate in the pathology of RA (Firestein, 2003).  
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Consistent with T cell involvement, the strongest genetic association in RA maps to the third 
hypervariable region of the HLA-DR chain, which is a component of the MHC class II 
complex that presents antigen to CD4+ T cells (Firestein, 2003; Nepom et al., 1989). Other 
genetic polymorphisms associated with RA also involve T cell related genes including those 
encoding the co-stimulation molecules CD28, ICOS, CTLA-4 and CD40 and the lymphoid 
specific phosphatase, PTPN22 (Kim et al., 2010; Plant et al., 2010). T cells might also support 
TNF production which has been measured at high concentration in synovial tissue cultures 
(Elliott et al., 1994). Furthermore, CTLA4-Ig and anti-TNF therapies that target T cell 
activities are both effective in RA (Firestein, 2003; Kremer et al., 2003). Lastly, inhibition of 
lymphocyte apoptosis and lymphocyte retention in the joint is reported. This occurs in 
response to factors released from stromal cells, including the hyperplastic fibroblasts that are 
a hallmark of chronic inflammation in RA (reviewed in (Raza, 2010)). Despite these 
associations, the role of the T cell in RA pathology met with opposition as cytokines, such as 
IL-2 and IFN, believed to be markers of T cell activation, were present at low concentrations 
in the RA synovium and synovial fluid. Conversely, macrophage and fibroblast products, 
including IL-1, IL-6, IL-15, IL-18, TNF, GM-CSF and various chemokines were abundant 
(Firestein, 2003; Firestein et al., 1990; Smeets et al., 1998).  
 
An  indication of the potential involvement of IL-17 in RA came from the discovery that RA 
synovial tissue contained IL-17 mRNA whilst that from osteoarthritis (OA) patients did not 
(Chabaud et al., 1999). In addition, RA but not OA synovial tissue generated IL-17 when 
cultured in-vitro and immuno-staining of synovial tissue demonstrated the presence of IL-17+ 
cells (Chabaud et al., 1999). A mechanism of IL-17-mediated pathogenesis has been 
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described for RA following the discovery that IL-17 can act upon most parenchymal cells, 
including macrophages and fibroblasts, that are present at high frequency in the synovium, to 
induce a pro-inflammatory pattern similar to that found in an inflamed joint (Firestein, 2003; 
Firestein and Zvaifler, 1987; Miossec et al., 2009). IL-17 could also contribute to bone 
erosion as it induces RANKL expression by osteoblasts. The engagement of RANKL with 
RANK expressed by osteoclasts leads to their  activation and consequentially bone erosion 
(Miossec et al., 2009; Udagawa et al., 2002).  
 
Given the potential involvement of T cells in RA and the detection of IL-17 in RA tissues and 
synovial fluid (SF) (Chabaud et al., 1999; Hirota et al., 2007; Kotake et al., 1999; Ziolkowska 
et al., 2000), it seems reasonable to speculate that IL-17+ T cells could contribute to the 
pathogenesis of RA. Consistent with this, in the collagen induced arthritis model of 
autoimmune arthritis, IL-23 deficient mice did not have IL-17+ CD4+ T cells and completely 
lacked disease even though Th1 cells were present (Murphy et al., 2003). Before the start of 
this study, reports on the frequencies of IL-17+ T cells in peripheral blood (PB) or SF of RA 
patients had not been made, although immuno-staining had implied the presence of IL-17+ 
cells amongst T cell populations (Chabaud et al., 1999). A few studies have now been 
published describing the frequencies of Th17 cells in the PB and SF of RA patients but data 
are conflicting (Church et al., 2010; Colin et al., 2010; Leipe et al., 2010; Yamada et al., 
2008), thus the role of IL-17+ T cells in RA remains to be established. There is also evidence 
to suggest that the molecular and cellular mechanisms operating in early versus established 
stages of RA might differ and that the features of early synovitis could relate to disease 
outcome. In support of this, within three months of symptom onset a number of cytokines 
were found to be elevated in the SF of individuals that went on to develop RA relative to 
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those who did not. Furthermore, the pattern was not present in established disease. 
Interestingly IL-17 was amongst this group of elevated early cytokines (Raza et al., 2005). For 
many years, it has been recognised that treatment, during the early, so-called „therapeutic 
window of opportunity,‟ can reduce the cumulative inflammatory burden of the disease and 
thereby improve outcome. For RA, this therapeutic window might be only three to four 
months (Raza, 2010). To distinguish within this period individuals that are destined for RA 
from those that are not, an understanding of the molecular mechanisms that operate at early 
stages of disease, is required.  
 
If Th17 cells contribute to RA, dysregulation of the TReg/Th17 balance might be predicted, 
given that a reciprocal relationship between Th17 and TReg cells has been observed (Bettelli et 
al., 2006; Quintana et al., 2008; Schambach et al., 2007; Veldhoen et al., 2008a). The studies 
in this chapter therefore set out to address whether dysregulation of the TReg /T17 balance is 
evident in early synovitis patients and whether it might be used to predict their disease 
outcome.  
 
In previous chapters in this thesis, pro-regulatory effects of vitamin D even under 
inflammatory conditions have been clearly shown. The second aim of work in this chapter 
was therefore to see if cells from synovitis patients could respond to 1,25(OH)2D3 in-vitro and 
if the response related to disease outcome.  
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Results  
Raw data from studies in this chapter are tabulated in appendix tables 10.1 to 10.5. 
 
7.2 Early synovitis disease outcome is not related to TReg or T17 frequencies 
To test the hypothesis that dysregulated frequencies of TRegs or T17 cells might be involved in 
the development of RA, mononuclear cells were isolated from the peripheral blood (PB) and 
synovial fluid (SF) of early synovitis patients who were recruited according to stated criteria 
(chapter 2.10). Frequencies of CD4+CD25+FoxP3+ (TReg) and IL-17
+ (T17) T cells were 
measured ex-vivo. As shown by figures 7.1 and 7.2, low frequencies of T17 cells were 
present in the PB of all patients and one-way ANOVA against outcome indicated no 
difference between the frequencies of T17 cells in the PB of patients diagnosed at eighteen 
months to have RA, versus those whose disease resolved (figure 7.3A). In addition, no 
difference in T17 frequency was observed between those who developed RA and those who 
showed non-RA forms of persistent synovitis (figure 7.3A). Furthermore, the peripheral 
blood T17 frequencies of early synovitis patients were not different to those of healthy 
controls or established RA patients. Thus, an alteration of the T17 frequency in PB does not 
appear to occur during the progression of RA or contribute to the disease outcome.  
 
IL-17 production by T cells within the joint might be of greater influence in the development 
of RA. Interestingly, very few T17 cells were likewise identified in SF for most patients, 
although the frequency in SF was significantly greater than the frequency in PB when 
analysing all data (figure 7.2) and paired samples only (figure 7.5B). Interestingly, the 
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highest T17 frequencies in SF were measured in samples from self-limiting and non-RA 
persistent patients (figure 7.3B). However, more SF samples are required before a breakdown 
analysis against outcome can be performed for T17 frequencies in SF.  
 
TReg frequencies were generally low (median = 4.6) in the PB of early synovitis patients 
(figure 7.1 and figure 7.2), although one-way ANOVA suggests that they might be elevated 
in non-RA persistent cases relative to RA or self-limiting disease (figure 7.4A). More non-
RA persistent samples are required, however, to test this finding more strongly. TReg 
frequencies in early synovitis patients did not differ from those of healthy controls or 
established RA patients according to one-way ANOVA, however, post-hoc analysis carried 
out specifically for established RA patients compared to early synovitis patients who 
progressed to RA, showed a significantly higher percentage of TRegs in established disease. A 
clear enrichment of TReg cells in SF compared to PB was also seen when considering all data 
(figure 7.2) and paired samples only (figure 7.5B). However, the ratio of TReg vs. T17 cells 
was not altered between PB and SF (figure 7.5B), possibly suggesting that the balance 
between pro and anti-inflammatory activities is maintained in the two compartments. 
Furthermore, the TReg/T17 ratio in PB did not appear to stratify with disease classification 
(figure 7.5A) implying that TReg/T17 dysregulation in PB might not influence disease 
outcome. In addition, contrary to the concept of a reciprocal relationship between Th17 and 
TReg cells (Bettelli et al., 2006), no correlation was observed between T17 and TReg 
frequencies in PB or SF (figure 7.6). Notably, all SF T cells displayed a memory CD45-RO 
phenotype, whilst only 51.414.36% of CD4+ T cells from PB were CD45-RO+ (figure 7.2). 
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Interestingly, established RA has been associated with a low level of IFN in SF (Firestein 
and Zvaifler, 1987). Low IFN concentrations were also measured in the SF of early synovitis 
patients who developed RA, whilst higher levels were detected in those who progressed to 
non-RA persistent synovitis (Raza et al., 2005). Therefore, the frequency of IFN+ T cells was 
also compared across outcome groups. As for T17 frequencies, no differences in IFN+ 
frequencies were detected for early synovitis patient outcome groups or for the combined one-
way ANOVA of early synovitis patients, established RA and healthy controls (figure 7.7A). 
However, post-hoc analysis performed specifically for established RA patients compared to 
early synovitis patients that progressed to RA, showed a significantly higher expression of 
IFN by patients with established disease. Strikingly, T cells isolated from SF showed very 
high IFN expression compared to those from PB (figure 7.2). In addition, T17 cells in PB 
were primarily IFN- whilst T17 cells from SF included both IFN- and IFN+ subsets (figure 
7.8).  
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Figure 7-1. Ex-vivo analysis of T17 and TReg frequencies in the blood and synovial fluid of synovitis 
patients  
 
 
Figure 7.1. Ex-vivo analysis of T17 and TReg frequencies in the blood and 
synovial fluid of synovitis patients. PBMCs and SFMCs were isolated from 
synovitis patients and  T cells were analysed for IL-17, IFN, FoxP3 and CD25 
expression by flow cytometry. Representative  FACS plots from one patient are 
shown. Numbers in quadrants indicate percentages of CD3+ T cells (A) and 
CD3+CD4+ T cells (B).  
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Figure 7-2. Comparison of ex-vivo IL-17
+
, IFN+, FoxP3+CD25+ and CD45-RO+ T cell frequencies in the 
blood versus the synovial fluid of early synovitis  patients 
 
Figure 7.2. Comparison of ex-vivo IL-17+, IFN+, FoxP3+CD25+ and CD45-RO+ T 
cell frequencies in the blood versus the synovial fluid of early synovitis  
patients. PBMCs and SFMCs were isolated from synovitis patients and  T cells 
analysed for IL-17, IFN, FoxP3, CD25 and CD45-RO expression by flow cytometry. 
Horizontal lines indicate median frequencies. Significance was tested by a two-tailed 
Mann Whitney U test.   
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Figure 7-3. IL-17
 
expression by T cells from the blood and synovial fluid of synovitis patients 
 
Figure 7.3. IL-17 expression by T cells from the blood and synovial fluid of 
synovitis patients. PBMCs (A) and SFMCs (B) were isolated from early synovitis 
patients (classified at follow up as RA, non-RA-persistent, self-limiting or not known), 
established RA patients and healthy controls. Frequencies of IL-17+ T cells were 
analysed directly ex-vivo by flow cytometry. Horizontal lines indicate mean 
frequencies. Two-tailed, one-way ANOVA was performed for T cells from PB. P>0.05 
for early synovitis outcomes alone and all known outcomes combined. 
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Figure 7-4. FoxP3+CD25+ (TReg) frequencies in the blood and synovial fluid of synovitis patients 
Figure 7.4 FoxP3+CD25+ (TReg) frequencies in the blood and synovial fluid of 
synovitis patients. PBMCs (A) and SFMCs (B) were isolated from early synovitis 
patients (classified at follow up as RA, non-RA-persistent, self-limiting or not known), 
established RA patients and healthy controls. Frequencies of FoxP3+CD25+ T cells 
were analysed directly ex-vivo by flow cytometry. Horizontal lines indicate mean 
frequencies. Two-tailed one-way ANOVA was performed for T cells from PB. 
Significant differences for early synovitis patients alone (black) and all known 
outcomes combined (red) are shown. 
TReg/T17 ratio in early synovitis  
218 
 
Figure 7-5. The TReg/T17 ratio is maintained in blood and synovial fluid 
 
Figure 7.5. The TReg/T17 ratio is maintained in blood and synovial fluid. PBMCs 
and SFMCs were isolated from synovitis patients and the ex-vivo frequencies of IL-
17+ and CD4+FoxP3+CD25+ T cells determined by flow cytometry. A) TReg/T17 ratio 
for PB T cells from early synovitis patients (classified at follow up as RA, non-RA-
persistent, self-limiting or not known), established RA patients and healthy controls. 
Horizontal lines indicate mean ratios. Two-tailed one-way ANOVA was performed. 
P>0.05 for early synovitis patient outcomes alone and for all known outcomes 
combined. B) T17, TReg and TReg/T17 ratio for PB T cells versus SF T cells from early 
synovitis patients. Significance was tested by a two-tailed Wilcoxon matched pairs 
test.  
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Figure 7-6. TReg and T17 relationships in blood and synovial fluid 
 
Figure 7.6. TReg and T17 relationships in blood and synovial fluid. PBMCs (A) 
and SFMCs (B) were isolated from early synovitis patients and ex-vivo frequencies of 
IL-17+ and CD4+FoxP3+CD25+ T cells determined by flow cytometry. Correlation of 
IL-17+ (T17) versus CD4+FoxP3+CD25+ (TReg)  frequencies for PBMCs and SFMCs is 
shown.  Pearson’s correlation coefficient (r) was calculated and used to determine 
the level of significance (P).  
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Figure 7-7. IFN expression by T cells in the blood and synovial fluid of synovitis patients 
 
Figure 7.7. IFN expression by T cells in the blood and synovial fluid of 
synovitis patients. PBMCs (A) and SFMCs (B) were isolated from early synovitis 
patients (classified at follow up as RA, non-RA-persistent, self-limiting or not known), 
established RA patients and healthy controls. Frequencies of IFN+ T cells were 
analysed directly ex-vivo by flow cytometry. Horizontal lines indicate mean 
frequencies. Two-tailed one-way ANOVA was performed for T cells from PB. P>0.05 
for early synovitis patient outcomes alone but P<0.05 for early versus established RA 
patients when all known outcomes were combined.   
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Figure 7-8. T cells isolated from the blood and synovial fluid of early synovitis patients show different IL-
17 and IFN expression profiles 
 
Figure 7.8. T cells isolated from the blood and synovial fluid of early synovitis 
patients show different IL-17 and IFN expression profiles.  PBMCs and SFMCs 
were isolated from early synovitis patients and IL-17 and IFN expression by T cells 
measured by flow cytometry. Frequencies of T17 cells classified as IFN- (square) or 
IFN+ (triangle) are shown. Horizontal lines indicate median frequencies. Significance 
was tested by a two-tailed Mann Whitney U test.  
 
TReg/T17 ratio in early synovitis  
222 
 
7.3 25(OH)D3 status does not reflect disease outcome or the frequency of T 
cells expressing IL-17, IFN or FoxP3 and CD25  
Since epidemiological studies associate low vitamin D status with increased risk of 
autoimmune diseases, including RA (Arnson et al., 2007; Cantorna and Mahon, 2004; 
Merlino et al., 2004), whether serum 25(OH)D3 level varied across early synovitis disease 
outcome was examined but no differences were observed (figure 7.9A). Since ex-vivo IL-17+, 
IFN+ and TReg frequencies were variable, whether they correlated with 25(OH)D3 status was 
also tested. No correlation was observed for IL-17+ or IFN+ frequencies but surprisingly 
negative correlation was detected for PBMC TReg frequencies (figure 7.9B). In agreement 
with this trend, CTLA-4 expression by CD4+FoxP3+ T cells from blood appeared to correlate 
inversely with 25(OH)D3 level, although more samples are needed to qualify this statistically 
(figure 7.9B).   
 
Arguably, vitamin D might have its greatest effect at the inflammatory site where matured 
APCs convert 25(OH)D3 to 1,25(OH)2D3. Whether serum 25(OH)D3 correlated with IL-17
+, 
IFN+ or TReg frequencies in SF was therefore examined but no correlation was seen for any 
marker (figure 7.10).  
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Figure 7-9. 25(OH)D3 level does not influence disease outcome or the expression of inflammatory and 
regulatory markers by peripheral blood T cells 
 
Figure 7.9. 25(OH)D3 level does not influence disease outcome or the 
expression of inflammatory and regulatory markers by peripheral blood T cells. 
A) Serum 25(OH)D3 level of early synovitis patients grouped according to disease 
outcome. Horizontal lines indicate mean frequencies. Significance was tested by two-
tailed one-way ANOVA. B) Relationships between serum 25(OH)D3 and ex-vivo IL-
17+, IFN+ and FoxP3+CD25+ frequencies and CTLA-4 expression level. Pearson’s 
correlation coefficient (r) was calculated and used to determine the level of 
significance (P).   
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Figure 7-10. Expression of inflammatory and regulatory markers by synovial fluid T cells is not affected 
by serum 25(OH)D3 status 
 
Figure 7.10. Expression of inflammatory and regulatory markers by synovial 
fluid T cells is not affected by serum 25(OH)D3 status.  Relationships between 
serum 25(OH)D3 status, and ex-vivo T cell IL-17, IFN and FoxP3+CD25+ frequencies 
are shown. Pearson’s correlation coefficient (r) was calculated and used to determine 
the level of significance (P).   
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To investigate whether 25(OH)D3 status might relate to the level of disease activity, 
correlation between 25(OH)D3 status and disease activity score 28 (DAS28) was tested. 
Figure 7.11 shows an inverse correlation. Because the DAS28 has not yet been validated as a 
marker of disease activity in synovitis conditions other than RA, serum 25(OH)D3 was also 
analysed against the erythrocyte sedimentation rate (ESR), which is used as a measure of 
inflammation. ESR was chosen over C Reactive Protein (CRP), because CRP was included in 
the DAS28 assessment. Inverse correlation of ESR with 25(OH)D3 was again observed, thus 
implying that 25(OH)D3 could influence disease activity.  
 
7.4 Induced IL-17 and IFN expression and 1,25(OH)2D3 response do not 
predict disease outcome 
Although no association was found between ex-vivo T17 frequencies and disease outcome, it 
is possible that individuals may differ in their propensity to express IL-17 or IFN upon 
stimulation and that this might relate to disease outcome. Similarly, an individual‟s sensitivity 
to 1,25(OH)2D3 during stimulation could influence disease outcome. These questions were 
addressed by stimulating PBMCs and SFMCs in the presence or absence of 1,25(OH)2D3 
before measuring IL-17 and IFN frequencies (figure 7.12, 7.13 and 7.14). As shown by 
figure 7.13, IL-17 and IFN expression by stimulated T cells from PB did not differ across 
early synovitis outcome groups. Neither were IL-17+ and IFN+ frequencies different when 
also considering established RA and healthy individuals. 1,25(OH)2D3 suppressed IL-17
+ and 
IFN+ frequencies in all groups and ANOVA analysis implied no difference between any 
groups in the sensitivity of IL-17 and IFN expression to 1,25(OH)2D3 treatment (P>0.05). 
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Thus, T cells from synovitis patients, including established RA patients, were sensitive to 
1,25(OH)2D3.  
 
For patients combined, a wide range of IL-17+ and IFN+ frequencies at seven days were 
measured in the absence of 1,25(OH)2D3. Since the stimulations had been conducted in 
medium supplemented with self-serum, whether serum 25(OH)D3 might have influenced IL-
17+ and IFN+ frequencies was also examined but no correlation was found (figure 7.15). 
Although 1,25(OH)2D3 strongly suppressed IL-17 and IFN production by PB T cells, it had 
limited effect upon T cells from SF: IL-17 expression was only slightly decreased and IFN 
was not significantly suppressed (figure 7.14). However, for both PBMCs and SFMCs, IFN+ 
T17 cells were the most sensitive to suppression by 1,25(OH)2D3 as determined from the ratio 
of expressing cells under control versus treatment conditions (figure 7.16). This might imply 
that T cells in synovial fluid are more permanently polarised than CD4+ T cells in PB.  
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Figure 7-11. 25(OH)D3 inversely correlates with disease activity in early synovitis patients 
 
Figure 7.11. 25(OH)D3 inversely correlates with disease activity in early 
synovitis patients. Serum 25(OH)D3 concentration was plotted against A) disease 
activity score 28 (DAS28) including C reactive Protein level (CRP) and B) erythrocyte 
sedimentation rate (ESR). Pearson’s correlation coefficient (r) was calculated  and 
used to determine the level of significance (P). The linear regression line is shown in 
red (solid line) and 95% confidence interval residuals shown (dotted lines).  
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Figure 7-12. Effect of 1,25(OH)2D3 upon IL-17 and IFN expression by T cells from the blood and synovial 
fluid of synovitis patients 
 
 
 
Figure  7.12. Effect of 1,25(OH)2D3 upon IL-17 and IFN expression by T cells 
from the blood and synovial fluid of synovitis patients.  PBMCs and SFMCs from 
synovitis patients were stimulated for seven days with anti-CD3 in the presence or 
absence of 1,25(OH)2D3 (100nM) and T cells analysed for IL-17 and IFN expression 
by flow cytometry. Representative FACS plots for one patient are shown.  
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Figure 7-13. IL-17
+
 and IFN+ post-culture frequencies do not differ across outcome groups 
 
Figure 7.13. IL-17+ and IFN+ post-culture frequencies do not differ across 
outcome groups. PBMCs from early synovitis patients (classified at follow up as 
non-RA-Persistent, RA, self-limiting or not known), established RA patients and 
healthy controls were stimulated with anti-CD3 in the presence of 100nM 1,25(OH)2D 
3 (red) or vehicle control (black). At seven days, IL-17 and IFN expression by T cells 
was determined by intracellular staining and flow cytometry. Horizontal lines indicate 
mean frequencies. Two-tailed, one-way ANOVA was performed for IL-17 and IFN 
expression by control cultures. P>0.05 for early synovitis outcomes alone and for all 
known outcomes combined. 
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Figure 7-14. Synovial fluid T cells are less sensitive to 1,25(OH)2D3 than T cells from blood 
 
Figure 7.14. Synovial fluid T cells are less sensitive to 1,25(OH)2D3 than T cells 
from blood. PBMCs and SFMCs from synovitis patients were stimulated with anti-
CD3 in the presence of 100nM 1,25(OH)2D3 (red) or vehicle control (black). At seven 
days, frequencies of T cells expressing IL-17 or IFN were determined by intracellular 
staining and flow cytometry. Horizontal lines indicate median frequencies. 
Significance was tested by a two-tailed Mann Whitney U test.   
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Figure 7-15. Serum 25(OH)D3 does not influence IL-17 or IFN expression by peripheral blood T cells in 
response to stimulation 
 
Figure 7.15. Serum 25(OH)D3 does not influence IL-17 or IFN expression by 
peripheral blood T cells in response to stimulation. Relationship between serum 
25(OH)D3 and the frequencies of IL-17+ and IFN+ T cells following seven day anti-
CD3 stimulation of PBMCs from early synovitis patients. Pearson’s correlation 
coefficient was calculated (r) and used to determine the level of significance (P).   
 
TReg/T17 ratio in early synovitis  
232 
 
Figure 7-16. The IFN+ subset of T17 cells is more sensitive to 1,25(OH)2D3 than the IFN
-
 subset 
 
 
 
Figure 7.16. The IFN+ subset of T17 cells is more sensitive to 1,25(OH)2D3 than 
the IFN- subset. PBMCs and SFMCs from synovitis patients were stimulated with 
anti-CD3 in the presence of 100nM 1,25(OH)2D3 or vehicle control. At seven days, 
frequencies of T cells expressing IL-17 or IFN were determined by intracellular 
staining and flow cytometry. 1,25(OH)2D3 sensitivity was calculated for each subset 
by frequencycontrol/frequency1,25(OH)2D3. The higher the value, the greater the 
suppression by 1,25(OH)2D3. Significance was tested by a two-tailed Mann Whitney 
U test. Horizontal lines indicate median values.  
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7.5 Discussion  
In this chapter, I have presented data from an ongoing study designed to investigate whether 
dysregulation of the TReg/T17 balance in the synovial fluid (SF) or peripheral blood (PB) of 
early synovitis patients relates to their disease outcome. Ex-vivo frequencies of IL-17+ (T17) 
and CD4+FoxP3+CD25+ (TReg) T cells from the PB and SF of early synovitis patients have 
been measured and analysed against outcome as determined at 18-months. Presently, for T 
cells from PB, no difference is evident between T17 or TReg frequencies across early synovitis 
outcome groups, although for TRegs, increased numbers in established RA relative to early RA 
are seen. Interestingly, for T17, TReg and IFN
+ frequencies in PB, no difference was observed 
between synovitis patients and healthy controls, although, more controls are needed to 
strengthen this analysis. Others have likewise observed no difference between Th17 
frequencies in the blood of healthy controls and established RA patients (Church et al., 2010; 
Yamada et al., 2008). However, two groups recently reported higher Th17 frequencies in 
PBMCs from RA patients relative to healthy or OA controls (Colin et al., 2010; Leipe et al., 
2010). Furthermore, Leipe et al. found that Th17 frequencies positively correlated with disease 
activity scores (DAS28 and CRP) but Yamada et al. did not observe this. However, in the 
study by Leipe et al., Th17 frequencies were at the limit of detection for controls and were 
very low even for RA patients (~0.5%). By comparison, in my study and those by Church et 
al., Colin et al., and Yamada et al., Th17 frequencies of ~1.0%, were measured. Therefore, it 
would seem that the conditions in the study by Leipe et al. were different to those in my study 
and others, and might account for their different conclusions.  
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My observation that PB IL-17+ T cell frequencies do not vary between RA patients and 
controls agrees with observations in other autoimmune conditions (Annunziato et al., 2007; 
Brucklacher-Waldert et al., 2009). Furthermore, for conditions where increased PB 
frequencies have been detected the levels in PB were generally still low (~1.0%) (Chen et al., 
2010; Shen et al., 2009). It is possible that chemokine signalling keeps reactive cells at the 
inflammatory site. In this regard, CCL20, the ligand for CCR6, which is expressed at high 
levels on both Th17 and TRegs, is elevated in synovial fluid (Hirota et al., 2007; Lim et al., 
2008; Nistala et al., 2008). Consistent with Th17 accumulation in the joint, I found enhanced 
IL-17+ T cell frequencies in SF relative to PB. Church et al. and Leipe et al. supported this 
finding although Yamada et al. showed a decline in total Th17 cells in SF relative to blood. In 
further support of increased Th17 frequencies at the inflammatory site, elevated Th17 
frequencies were found in the gut of Crohns patients and the CNS of MS patients when 
compared to PB (Annunziato et al., 2007; Brucklacher-Waldert et al., 2009). Strikingly, I 
observed that nearly all SF T cells expressed IFN. Although this finding contradicts the low 
IFN protein levels detected in RA SF (Firestein et al., 1990; Raza et al., 2005), most studies 
that analysed IFN expression at the single cell level observed significantly higher IFN+ T 
cell frequencies in SF or synovial tissue relative to PB (Church et al., 2010; Dolhain et al., 
1996; Leipe et al., 2010; Morita et al., 1998; Yamada et al., 2008). However, this discrepancy 
may be a consequence of the analysis method, as PMA and ionomycin re-stimulation used for 
intracellular cytokine staining could reveal „past histories‟ of gene expression recorded by 
chromatin remodelling. Indeed, IL-17 and IFN were not detected by intracellular staining in 
the absence of PMA and calcium signalling (Dolhain et al., 1996; Yamada et al., 2008). The 
fact that 99% of SF T cells were of the CD45-RO memory phenotype would support a 
previously established expression profile, which, although no longer active, could be re-
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instated by PMA and calcium signalling. Whether, re-stimulation through the T cell receptor 
would similarly drive IFN in T cells from the joint would be of interest and could address 
more physiologically the role of IFN in RA pathology. The possibility that IFN is expressed 
during the initial stages of disease is in keeping with the relatively low  frequencies of T17 
cells that I and others detected in SFMCs (Church et al., 2010; Leipe et al., 2010; Yamada et 
al., 2008), since IFN is inhibitory to Th17 differentiation (Harrington et al., 2005; Park et al., 
2005). However, additional inhibitory signals could contribute, such as the strength of co-
stimulation (Bouguermouh et al., 2009; Gomez-Rodriguez et al., 2009; Purvis et al., 2010) 
and IL-2 (Acosta-Rodriguez et al., 2007a; Laurence et al., 2007) although low IL-2 levels are 
reported in the RA joint (Firestein et al., 1990). 
 
My observation that TReg frequencies are not increased in the blood of synovitis patients 
compared to controls is likewise consistent with others findings (Cao et al., 2003a; Flores-
Borja et al., 2008; van Amelsfort et al., 2004). It is important to note, however, that not all 
studies included FoxP3 as a marker. Indeed, in one study where FoxP3 expression was 
assessed, fewer TRegs were found in the PB of RA patients versus controls and FoxP3 
expression was lower (Valencia et al., 2006). Decreased PB TReg frequencies are similarly 
described in other autoimmune conditions (Kukreja et al., 2002). Interestingly, my data 
suggest that TReg frequencies might increase as RA progresses. This could represent an 
attempt to restore regulation. More samples are needed however to strengthen these 
conclusions. I also observed a clear increase in the frequency of TRegs in SF compared to PB 
across disease outcomes. Such TReg enrichment in SF relative to PB has been reported by 
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others studying RA (Cao et al., 2003a; Jiao et al., 2007; van Amelsfort et al., 2004) and is 
described for childhood arthritis (de Kleer et al., 2004; Ruprecht et al., 2005). 
 
Given that both TRegs and T17 cells were enriched in SF, I was interested to compare the 
TReg/T17 ratio for SF and PB. Surprisingly, I found that the TReg/T17 ratio was balanced for 
the two sites. This could imply that inflammatory versus regulatory balance was equivalent in 
the two compartments. In contrast to the concept that Th17 and TReg are reciprocal fates 
(Bettelli et al., 2006; Quintana et al., 2008; Schambach et al., 2007; Veldhoen et al., 2008a), I 
did not observe an inverse relationship between T17 and TReg frequencies from PB or SF. This 
correlation has not been directly measured previously in RA but an inverse relationship 
between Th17 and TReg cells in SF was found in childhood arthritis (Nistala et al., 2008). It is 
possible that different mechanisms operate in the two conditions but data from other cohorts 
are needed to clarify my findings. 
 
Even if dysregulation of TReg and T17 frequencies does not contribute to RA pathogenesis, it 
is possible that excessive Th17 activity or loss of TReg function is responsible for the 
progression of RA. In this regard, Leipe et al. suggested that Th17 cell activity might become 
uncontrolled in RA pathogenesis through elevated RORC expression and acquired resistance 
to natural antagonists of their development (Leipe et al., 2010). However, in contrast to their 
findings and those by Colin et al. (2010), I did not observe enhanced propensity for T17 
development by PBMCs from synovitis patients. The possibility that FoxP3+CD25+ T cells in 
the joint are not effective TRegs might be supported by the need for multiple rounds of 
stimulation to induce regulatory activity within iTRegs (Horwitz et al., 2008b; Shevach et al., 
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2008). Possibly low CTLA-4 expression might contribute to this effect, since I showed in 
chapter five of this thesis that inflammatory conditions could suppress CTLA-4 and reduce 
the ability of T cells to down-regulate B7 expression by DCs. Thus, within an inflamed joint, 
TReg function could be compromised by low CTLA-4 expression. In agreement with defective 
TReg activity, Valencia et al. demonstrated that PB TRegs from RA patients had reduced ability 
to suppress responder T cell proliferation and IFN expression (Valencia et al., 2006). 
Counter to this, however, others showed that CD4+CD25+ cells from RA patients were 
anergic and able to suppress responder cell proliferation (Ehrenstein et al., 2004; van 
Amelsfort et al., 2004), although reduced ability to suppress TNF and IFN was observed. 
The latter might relate to low CTLA-4 expression by RA TRegs and abnormal CTLA-4 
biology, although how CTLA-4 contributes to such responses remains to be established 
(Flores-Borja et al., 2008). Loss of regulation within the joint could equally arise if 
CD4+CD25- T cells are less responsive to suppression. Consistent with this, CD4+CD25- T 
cells from SF were less responsive to suppression than those from PB (van Amelsfort et al., 
2004). Interestingly, Th17 cells in particular might be resistant to TRegs, since both healthy and 
RA TRegs did not suppress IL-17 production (Flores-Borja et al., 2008). Also, in the presence 
of TRegs, IL-17
+ cells were increased even though IFN+ frequencies decreased (Evans et al., 
2007). These effects might relate to high CTLA-4 expression by TRegs, since CTLA-4-Ig 
treatment could increase Th17 frequencies (Bouguermouh et al., 2009).  
 
In light of my finding that 1,25(OH)2D3 strongly promotes a TReg phenotype, whether disease 
outcome or TReg and T17 frequencies related to serum 25(OH)D3 level was also addressed in 
this study. No correlation of 25(OH)D3 level with disease outcome or T17 frequencies was 
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observed and in contrast to expectation, TReg frequencies correlated inversely with 25(OH)D3 
level. In support of this trend, early data suggests that CTLA-4 expression by PB 
CD4+FoxP3+ cells might also vary inversely with 25(OH)D3 level. However, more samples 
are needed to verify this trend statistically. It will also be important to perform the same 
analysis on SF samples once a sufficient sample size is available. In addition to analysing SF 
T17 and TReg frequencies against serum 25(OH)D3 levels it would be interesting to study their 
correlation against SF 25(OH)D3, since such data might provide a better indication of the 
relevance of vitamin D in the control of inflammation at a disease locus.  
 
My study has confirmed, that PBMCs and SFMCs from early synovitis patients are 
responsive to 1,25(OH)2D3 when cultured in-vitro, as IL-17 and IFN frequencies were 
suppressed when PBMC stimulations were supplemented with 1,25(OH)2D3. Consistent with 
observations throughout this thesis, the IFN+ subset of T17 cells was the most sensitive to 
1,25(OH)2D3 for both PBMCs and SFMCs. Interestingly though, PBMCs were more sensitive 
to 1,25(OH)2D3 than SFMCs. Given that all SFMC T cells, including CD4
+CD25- cells, 
displayed an activated surface marker profile, these data might support the hypothesis that 
repetitive activation reduces T cell plasticity (Grogan et al., 2001). Furthermore, the fact that 
1,25(OH)2D3 suppressed IL-17 but not IFN in SFMCs supports the concept that IL-17 is a 
more plastic cytokine than IFN (Zhou et al., 2009a). Whilst the lack of IFN suppression by 
SF T cells may question the potential effectiveness of 1,25(OH)2D3 supplementation in the 
treatment of RA, the fact that all patients could respond to 1,25(OH)2D3 implies that synovitis 
patients are not generally defective in VDR responses. Furthermore, given the associations of 
IL-17 with RA pathology (Firestein, 2003; Miossec et al., 2009), the ability of 1,25(OH)2D3 to 
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suppress IL-17 even in cells from SF, is encouraging. In support of the potential use of 
vitamin D in the control of RA, I observed negative correlations between 25(OH)D3 status 
and two measures of disease activity: DAS28 and ESR. However, rather than low 25(OH)D3 
being the cause of increased joint inflammation, it could be a consequence, since as disease 
severity increases, patients might spend less time outside, thus causing their 25(OH)D3 status 
to fall. Nonetheless, the involvement of vitamin D in the control of RA is supported by the 
finding that greater vitamin D intake through diet or supplement was inversely associated with 
RA risk (Merlino et al., 2004) and that 1-(OH)-D3, a vitamin D analogue could improve 
responses to standard DMARD therapy in active RA (Andjelkovic et al., 1999). However, in 
contrast to my observations, two other studies in RA did not show an association between 
25(OH)D3 and disease activity scores (Kroger et al., 1993; Oelzner et al., 1998). Since these 
studies involved patients with established disease, it is possible that other medications had 
confounding influence.  
 
As described above, the results presented in this chapter, as well as those of others, do not 
clearly demonstrate an association between aberrant T17 or TReg frequencies and RA 
pathogenesis. This is in contrast to the finding that RA is Th17 driven in the CIA mouse 
model. However, it is possible that the method of immunisation contributes to the pathogenic 
process in these mice as Mycobacterium tuberculosis, a potent Th17 inducer, is a component 
of Freund complete adjuvant, which is typically used in the immunisation procedure (Yamada 
et al., 2008). Further support for a non-Th17 dependent pathology in RA is the observation by 
FACS (Colin et al., 2010; Leipe et al., 2010; Yamada et al., 2008) and immunohistochemistry 
(Chabaud et al., 1999), that very few T cells within the synovium are IL-17+ (Chabaud et al., 
1999). Thus, even though IL-17 is a potent cytokine, it is difficult to imagine that T cell 
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derived IL-17 alone is sufficient to drive the inflammatory processes within the rheumatoid 
joint. It is now apparent that a variety of cells, besides CD4+ T cells express IL-17, including 
 T cells, NKT cells, NK cells, neutrophils, eosinophils, Lymphoid tissue inducer cells 
(LTis) and mast cells (Hueber et al., 2010). Interestingly, a very recent study revealed that 
mast cells might be a major source of IL-17 within the synovium, as the majority of IL-17A 
staining on RA synovium sections localised to mast cells. Furthermore, a range of factors, 
which could feature in the joint, were found to promote their IL-17 expression (Hueber et al., 
2010).  
 
Irrespective of the cellular source of IL-17, its ability to drive inflammation and bone erosion 
makes it an attractive candidate for biological therapy in RA. Clinical trials assessing the 
safety, tolerability and efficacy of monoclonal antibodies to IL-17 are promising (Genovese et 
al., 2010; Tak, 2009). In addition, the success of anti-IL-6 and anti-IL-1 therapies in 
childhood arthritis (Allantaz et al., 2007; Yokota et al., 2008) could involve their ability to 
suppress IL-17 expression. However, because IL-17 plays a major role in protection from 
certain pathogens (reviewed by (Miossec et al., 2009)), such therapies could leave patients at 
risk of infection. Thus, it will be important to characterise the dependency of RA pathology 
upon IL-17 and appropriately balance the benefits and disadvantages of its availability.
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8 GENERAL DISCUSSION 
The frequency of autoimmune diseases is increasing (Black, 2001), thus the identification of 
predisposing environmental and genetic factors is crucial. Dysregulation of the TReg/Th17 
balance is implicated in a number of autoimmune conditions and disease models. Therefore, 
factors that modulate this balance are of potential therapeutic and prophylactic benefit. Over 
the past 30 years, the importance of vitamin D in immune modulation has become 
increasingly recognised. Whilst in-vitro and in-vivo studies have pointed to its ability to 
suppress DC maturation and modulate CD4+ T cell differentiation away from Th1 and towards 
Th2 and TReg (reviewed in (Adams and Hewison, 2008; Adorini, 2002)) our understanding of 
the mechanisms by which vitamin D protects against autoimmunity is not complete. Indeed, 
the effect of 1,25(OH)2D3 upon novel CD4
+ T cell subsets, such as Th17, Tfh and Th22 cells 
had not been published prior to the start of work for this thesis. In addition, most studies that 
described an effect of 1,25(OH)2D3 upon T cell differentiation had used APC-containing 
systems (Adorini, 2002; Adorini et al., 2003; Penna and Adorini, 2000) or enriched or impure 
lymphocyte populations (Reichel et al., 1987b). Thus, the direct influence of 1,25(OH)2D3 
upon T cell differentiation was not well established. This thesis therefore set out to examine 
the influence of 1,25(OH)2D3 upon CD4
+ T cell differentiation and to investigate whether its 
effects were by direct action upon the T cell or indirect via the APC.  
 
A striking ability of 1,25(OH)2D3 to suppress CD4
+ T cell expression of pro-inflammatory 
cytokines IL-17, IFN, IL-21 and IL-22, even in the absence of APCs, was found. This 
indicates that 1,25(OH)2D3 can act directly upon T cells to modify their phenotype. Since 
these cytokines are the hallmark cytokines of Th17 (Harrington et al., 2005), Th1 (Mosmann 
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and Coffman, 1989), Tfh (Vogelzang et al., 2008) and Th22 (Trifari et al., 2009) effector 
classes respectively, it might further be concluded that 1,25(OH)2D3 has a broad ability to 
suppress pro-inflammatory effector classes. 1,25(OH)2D3 therefore has relevance in the 
control of immune responses to a wide range of bacterial and fungal pathogens as well as in 
autoimmune diseases and cancer.   
 
The work in this thesis also confirmed that 1,25(OH)2D3 can promote iTReg development as 
suggested by earlier studies (Barrat et al., 2002; Ghoreishi et al., 2009; Gregori et al., 2002; 
Urry et al., 2009), since its ability to dramatically increase CTLA-4 expression, and synergise 
with TGF to favour a CTLA-4+FoxP3+ population and IL-10 expression was striking. In 
addition, IL-2 was found to co-operate with 1,25(OH)2D3 for the induction of a TReg 
phenotype and suppression of IL-17.  
 
Studies within this thesis suggest that 1,25(OH)2D3 might be valuable in the treatment of 
active inflammatory diseases, especially those driven by an imbalance between TReg and Th17 
frequencies or activities. Firstly, anti-inflammatory effects of 1,25(OH)2D3 were maintained 
under Th17 polarising conditions, secondly stimulation of Th17 polarised cultures in the 
presence of 1,25(OH)2D3 and IL-2 shifted the bulk phenotype towards TReg. Thirdly 
1,25(OH)2D3 could  reduce IL-17
+ frequencies or the level of IL-17 expression by purified IL-
17+ cells, thus suggesting that 1,25(OH)2D3 can act upon previously committed Th17 cells as 
would be found at an inflammatory site.  
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To be effective therapeutically, it would be necessary, however, that patients can respond to 
1,25(OH)2D3. Response is primarily through the vitamin D Receptor (VDR). Allelic 
variations in VDR exist and associations have been made with susceptibility to autoimmune 
disease, although, in the main, results are conflicting and no functional consequence of the 
mutations has been found (reviewed by (Arnson et al., 2007; Mullin and Dobs, 2007)). In this 
study it was demonstrated that T cells from established and early synovitis patients respond 
efficiently to 1,25(OH)2D3, suggesting that response to 1,25(OH)2D3 is not impaired in RA. 
However, the highly activated T cells from SF were considerably less sensitive to 
1,25(OH)2D3 than those from PB, implying that repeat stimulation might „fix‟ a cytokine 
profile even in Th17 cells, which are generally regarded more plastic than Th1 or Th2 cells 
(Zhou et al., 2009a). This finding was in keeping with the seemingly lower sensitivity of 
purified IL-17+ cells to 1,25(OH)2D3 compared to CD4
+CD25-  T cells undergoing primary 
stimulation.  
 
Across all studies in this thesis, the suppressive effect of 1,25(OH)2D3 was most profound 
upon the IFN+ subset of IL-17+ cells. Interestingly, few cells in PB possessed this phenotype 
ex-vivo but it was detected in Th17 cells isolated from SF. Consistent with this finding, others 
have reported enrichment of IL-17+/IFN+ T cells at disease sites (Annunziato et al., 2008; 
Nistala et al., 2010; Nistala et al., 2008). Such enrichment suggests that they could be the 
most pathogenic species. Thus, the finding that 1,25(OH)2D3 most efficiently suppressed this 
population is encouraging when considering its therapeutic value. 
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In support of a therapeutic or prophylactic use for 1,25(OH)2D3 in the control of  autoimmune 
conditions, 1,25(OH)2D3 and its analogues have been able to suppress and prevent disease 
symptoms in mouse models of multiple sclerosis (MS), type 1 diabetes (TID), inflammatory 
bowel disease (IBD), uveitis, systemic lupus erythematosus (SLE) and rheumatoid arthritis 
(RA) (reviewed in (Adorini, 2002; Arnson et al., 2007; Mullin and Dobs, 2007; Smolders et 
al., 2008)). In addition, 1,25(OH)2D3 analogues are widely used topically in the treatment of 
human psoriasis (reviewed by (Adorini, 2002). Small-scale studies also show their possible 
benefit in RA (Andjelkovic et al., 1999) and steroid resistant asthma (Xystrakis et al., 2006). 
The primary concern with the systemic use of 1,25(OH)2D3 is its hypercalcaemic effect, 
although a trial in MS demonstrated overall safety at the dose used (Wingerchuk et al., 2005). 
Nonetheless, treatment with 1,25(OH)2D3 analogues that have reduced calcaemic effect and 
are more metabolically stable (Adorini et al., 2003), should improve the efficiency and reduce 
the risk of complications associated with systemic 1,25(OH)2D3 treatment.  
 
Given that the 25(OH)D3 converting enzyme, 25-hydroxyvitamin-D3-1-hydroxylase 
(CYP27B1), is expressed broadly throughout the body, including in immune cells (Hewison 
et al., 2007), 25(OH)D3 supplements could be given instead of 1,25(OH)2D3 for anti-
inflammatory therapy. In this thesis, whether locally generated 1,25(OH)2D3 could affect T 
cell phenotype was therefore addressed. It was found that in the presence of APCs, 25(OH)D3 
strongly induced CTLA-4 in a CYP27B1 dependent manner and suppressed IL-17 and IFN. 
Low CYP27B1 expression in T cells was also observed and was sufficient to support weak 
CTLA-4 induction and suppression of inflammatory cytokines in the presence of 25(OH)D3 
and absence of APC. By confirming that local 25(OH)D3 conversion can modulate T cell 
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phenotype, these data help to explain why low serum levels of 25(OH)D3 have been 
associated with autoimmune conditions even though 1,25(OH)2D3 levels remain relatively 
constant (Als et al., 1987; Andreassen et al., 1998; Andreassen et al., 1997; Holick, 2007; 
Kamen et al., 2006; Munger et al., 2006). These data also provide a cellular and molecular 
rationale for the use of inactive 25(OH)D3 in the treatment of autoimmune disease. Most 
studies to investigate the effect of 25(OH)D3 upon autoimmunity have centred around MS. In 
the main they have shown clinical benefit (reviewed by (Cantorna and Mahon, 2004). The 
success could, in part, be due to the effect of vitamin D within the nervous system, since VDR 
is expressed in the CNS and vitamin D derivatives can promote the expression of 
neurotrophins (Riaz et al., 1999) and suppress neurotoxic reactions (Kalueff et al., 2004). 
However, tolerogenic immune responses, including an increase in serum TGF, were 
observed in patients after 25(OH)D3 treatment (Mahon et al., 2003). The effect of vitamin D 
supplementation upon T1D risk and IBD has also been studied. However, whilst reduced risk 
or clinical benefit was observed, immunological effects were not assessed in these 
interventions (reviewed in (Cantorna and Mahon, 2004) and (Zella and DeLuca, 2003)). 
Therefore, more clinical studies are needed to assess the use of 25(OH)D3 for the control of a 
wider range of inflammatory diseases and to determine more definitively whether effects 
observed involve modulation of immune parameters. As such, trials are planned to assess the 
therapeutic and immune-modulatory effects of 25(OH)D3 upon patients with steroid resistant 
asthma, MS, RA and Crohn‟s disease (NIH, 2010). 
 
With reference to the above, it is important to consider, that 25(OH)D3 levels do not always 
correlate with disease risk or severity (Huisman et al., 2001; Kroger et al., 1993; Munger et 
al., 2006; Oelzner et al., 1998). Whilst this might relate to confounding factors such as the use 
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of other treatments, it could point to defects in the conversion and/or distribution of 25(OH)D3 
mediated by CYP27B1 and the vitamin D binding protein (VDBP) respectively. Indeed, 
polymorphisms in CYP27B1 (Bailey et al., 2007; Lopez et al., 2004) and VDBP (Papiha and 
Pal, 1985; Speeckaert et al., 2006) are associated with a range of autoimmune conditions, 
although, as for VDR (Arnson et al., 2007; Mullin and Dobs, 2007), results in different 
populations are conflicting. At extra-renal sites, a range of factors regulate the activity of 
CYP27B1, such as cytokines and growth factors (Leventis and Patel, 2008), and TLR ligand 
signalling appears to control CYP27B1 expression  in APCs (Adams and Hewison, 2008). A 
defect in any of these pathways could reduce 25(OH)D3 sensitivity and might account for the 
lack of correlation between 25(OH)D3 level and disease severity.  
 
The array of factors that contribute to extra-renal 25(OH)D3 conversion could also set the 
level of 25(OH)D3 required for optimal immune function much higher than the 80nM, 
currently recommended for optimal calcium regulation and bone strength (Hollis, 2005). 
Thus, the apparent lack of association between 25(OH)D3 and disease severity could be 
because most populations were deficient as far as immune regulation is concerned. In support 
of different serum 25(OH)D3 optimums for different body systems, it has been shown that 
insulin sensitivity in non-diabetic patients correlates positively with vitamin D status and that 
optimal glycaemic control requires a serum 25(OH)D3 level of 114nM (Heaney, 2005). This 
far exceeds the „normal‟ 25(OH)D3 level but might be reached by individuals who lead an 
outdoor lifestyle and are not overly clothed (Haddad and Chyu, 1971). Studies to determine 
tolerable 25(OH)D3 doses are ongoing but estimating the required level of 25(OH)D3 
supplement for efficient immune function necessitates the identification of efficient 
biomarkers of immune response. The recently published genome wide map of VDR binding 
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sites in lymphoblastic cell lines could aid identification of potential markers (Ramagopalan et 
al., 2010).  
 
In this thesis, CTLA-4 stood out as a very sensitive 1,25(OH)2D3 immune target. However, 
for PBMCs from early synovitis patients CTLA-4 expression by CD4+FoxP3+CTLA-4+ T 
cells did not appear to correlate positively with serum 25(OH)D3 level, although further 
samples would be needed to confirm this trend. A potential problem with CTLA-4 as a 
marker of vitamin D status might be its sensitivity to other factors. For example, suppression 
of CTLA-4 by Th17 polarising cytokines in the absence of 1,25(OH)2D3 was observed, whilst 
1,25(OH)2D3 synergised with these cytokines to promote very high levels of CTLA-4. IL-2 
was also found to synergise with 1,25(OH)2D3 to enhance CTLA-4. Data from ongoing work 
(not shown) further suggests that although 1,25(OH)2D3 is quite unique in its ability to greatly 
enhance CTLA-4 expression, the combined action of 1,25(OH)2D3 with other anti-
inflammatory agents can also influence levels. Therefore, particularly for individuals 
receiving anti-inflammatory treatment, CTLA-4 expression might not correlate closely with 
serum 25(OH)D3 level. 
 
CTLA-4 is highly expressed on TRegs and is induced in effector T cells upon activation. 
Mounting evidence supports its major role in the suppressive activity of TRegs (Friedline et al., 
2009; Kolar et al., 2009; Onishi et al., 2008; Read et al., 2006; Schmidt et al., 2009; Tivol et 
al., 1995; Waterhouse et al., 1995; Wing et al., 2008; Zheng et al., 2008b). Work in this thesis 
has demonstrated that the level of CTLA-4 is functionally important, at least as far as 
extrinsic regulation mechanisms are concerned. By its ability to dramatically up-regulate 
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CTLA-4 expression, 1,25(OH)2D3-enhanced CTLA-4-dependent removal of co-stimulatory 
ligands from APCs. This effect contributed greatly to 1,25(OH)2D3-mediated suppression of T 
cell proliferation observed when T cells were stimulated by APCs. However, it might also 
underlie the ability of 1,25(OH)2D3-conditioned stimulated T cells to suppress the division of 
CD4+CD25- responder T cells in DC driven stimulations. The fact that CTLA-4 blockade 
could not completely overcome CD86 down-regulation on primary APC driven  responses 
indicates, however, that additional, non-CTLA-4 dependent mechanisms of suppression might 
be employed by 1,25(OH)2D3-conditioned TRegs. It is likely that their cytokine profile is 
involved. This includes enhanced production of IL-10 and reduced IFN, both of which could 
decrease co-stimulatory molecule expression by DCs (Fujihara et al., 1996; Moore et al., 
2001). Future studies will examine in more detail the nature of the CTLA-4 dependent and 
independent mechanisms of suppression employed by 1,25(OH)2D3-conditioned T cells. 
 
In addition to its potential use as a medicinal supplement, 1,25(OH)2D3 in consort with TGF 
and IL-2 could be useful for the ex-vivo generation of TRegs for adoptive transfer to enhance 
tolerance. This approach has application in the treatment of autoimmune diseases, such as 
diabetes but also in short term immune suppression to prevent graft versus host disease or 
graft rejection in sold organ transplantation (Pahwa et al., 2010). However, because both 
FoxP3 and CTLA-4 showed transient patterns of expression in this study, even following 5-
aza-2-deoxycytidene treatment, the cells might not retain suppressive function long-term. 
Further work in this area is warranted to determine if altered culture conditions would 
improve stability of CTLA-4 and FoxP3 expression.  
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Others are using protocols to expand natural TRegs instead of generating iTRegs for transplant 
(Pahwa et al., 2010; Sheng et al., 2010). If 1,25(OH)2D3 could further enhance CTLA-4 
expression by nTRegs its supplementation might generate highly efficient nTRegs. Enhanced 
expression of CTLA-4 on TRegs in the skin following topical treatment with a 1,25(OH)2D3 
analogue, suggests this will be possible (Ghoreishi et al., 2009). One concern surrounding 
adoptive TReg  treatment strategies is the possibility that FoxP3
+ cells might differentiate into 
Th17 or Tfh cells in-vivo under appropriate pro-inflammatory conditions (Tsuji et al., 2009; 
Zhou et al., 2009b). Nonetheless, the report that TGF and IL-2 induced TRegs are resistant to 
Th17 conversion by IL-6 (Zheng et al., 2008a) maintains an element of doubt over the 
potential for iTRegs to switch phenotype. For nTRegs, there is suggestion that culturing under 
Th17 polarising conditions permits IL-17 expression whilst maintaining FoxP3 (Wei et al., 
2009). Data from this thesis suggest however, that if 1,25(OH)2D3 levels at the site of active 
disease can be sufficiently maintained, then the presence of pro-inflammatory cytokines might 
actually enhance the suppressive phenotype of the TRegs by favouring high levels of CTLA-4 
and permitting IL-10, whilst suppressing inflammatory cytokines. Since IL-2 supplementation 
was also found to enhance FoxP3 expression in this thesis, combined treatment with 
25(OH)D3 and IL-2 at the time of transfer could be particularly effective at maintaining the 
TReg phenotype in-vivo. In support of the beneficial effect of IL-2 in the treatment of 
autoimmune conditions, it was recently shown that low dose IL-2 can selectively promote 
TReg expansion in the Non-Obese Diabetic (NOD) mouse model of diabetes when 
administered at disease onset, leading to long-lasting remission of disease (Grinberg-Bleyer et 
al., 2010). In addition, a clinical trial involving IL-2 and rapamycin is currently ongoing for 
type 1 diabetes (NCT00525889).  
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In summary, the work in this thesis has provided further insight into the cellular and 
molecular basis of the association between low vitamin D status and autoimmune conditions, 
demonstrating in particular its strong ability to directly promote an anti-inflammatory 
phenotype in T cells. The findings are exciting, since they suggest that vitamin D 
supplementation could offer a simple and relatively inexpensive therapeutic method for the 
control of autoimmune conditions. Furthermore,  the antimicrobial properties of 1,25(OH)2D3 
in the innate immune system (Adams and Hewison, 2008) set it apart from other 
immunosuppressant strategies that compromise this line of defence.  
 
Work in this thesis has also investigated the balance of T17 and TReg cells in synovitis patients 
and analysed it with respect to outcome group. Since for PB no differences were observed 
between groups or with respect to healthy controls or established RA suffers, it is concluded 
that dysregulation of the TReg/Th17 balance is unlikely to contribute to disease outcome or 
play a major role in its pathogenesis. To strengthen conclusions for SF, more samples are 
needed and collection is ongoing. Nonetheless, the relatively low number of T17 cells 
measured in SF suggests that they are not central players. The observation that IL-17+ and 
IFN+ T cell frequencies did not correlate with serum 25(OH)D3 level might suggest a general 
25(OH)D3 deficiency as far as immune function is concerned. Nevertheless, the fact that all 
patients responded to 1,25(OH)2D3 in-vitro would support the use of 1,25(OH)2D3 analogues 
in RA therapy. In particular, it would be worth investigating whether vitamin D treatment 
within the therapeutic window of three months (Raza, 2010) could prevent RA onset or 
reduce disease severity. 
  
9 APPENDIX 
Table 9-1. Clinical data for synovitis patients. (Abbreviations: Disease activity score 28 (DAS28), C Reactive Protein (CRP), 
Erythrocyte sedimentation rate (ESR), rheumatoid factor (RF),  Cyclic Citrullinated Peptide Antibody (CCP), Disease modifying 
antirheumatic drug (DMARD), - indicates that data could not be collected or was not available).  
Patient 
code 
Disease  
outcome 
Gender Age Symptom 
Duration  
(wks) 
DAS28  
(CRP) 
score 
CRP ESR RF CCP DMARD / 
Biological 
drugs 
25(OH)D3 
ng/ml 
T08.109 RA m 55 6 6.93 11 19 0 - - 19.1 
T08.126 RA f 19 12 2.87 0 4 0 - - - 
T08.187 RA f 69 6 6.06 26 68 0 - - 13.7 
T08.200 RA f 51 8 4.39 6 21 21 - - 12.2 
T09.064 RA m 67 7 4.98 83 25 40 - - 39.2 
T09.090 RA f 48 2 3.46 102 4 0 - - 33.6 
T09.108 RA f 66 6 3.89 5 21 84 - - - 
T09.124 RA m 76 7 5.28 14 18 0 - - 19.6 
T09.145 RA m 66 8 4.97 20 31 0 - - 15.5 
T10.049 RA m 55 12 5.29 0 5 21 - - 11.8 
T10.058 RA m 54 4 3.03 45 58 0 - - 15.0 
T10.084 RA f 63 4 6.67 124 86 0 - - 21.3 
T10.118 RA f 48 12 3.87 10 10 339 - - 32.3 
T10.131 RA f 27 10 3.72 13 23 203 - - 25.9 
T08.179 Non-RA persistent f 67 5 6.46 20 47 20 - - 14.4 
T08.182 Non-RA persistent m 43 3 4.52 188 102 0 - - 17.8 
T08.203 Non-RA persistent m 24 3 2.59 0 5 0 - - 36.1 
T09.060 Non-RA persistent f 45 9 3.51 12 24 0 - - 6.1 
T09.136 Non-RA persistent  f 55 4 3.82 16 19 30 - - 18.6 
T10.126 Non-RA persistent f 43 2 6.45 70 97 0 - - 4.6 
  
Patient 
code 
Disease  
outcome 
Gender Age Symptom 
Duration  
(wks) 
DAS28  
(CRP) 
score 
CRP ESR RF CCP DMARD / 
Biological 
drugs 
25(OH)D3 
ng/ml 
T08.147 Self-limiting f 40 4 4.74 51 36 0 - - - 
T08.162 Self-limiting m 35 3 5.76 30 58 0 - - - 
T08.170 Self-limiting m 33 4 3.62 6 9 0 - - 26.5 
T08.183 Self-limiting m 45 2 4.68 103 97 0 - - 12.9 
T08.186 Self-limiting f 35 6 4.01 29 64 0 - - 19.9 
T09.103 Self-limiting m 74 4 3.38 0 17 0 - - 22.9 
T09.114 Self-limiting f 33 4 1.85 0 5 0 - - 40.3 
T09.133 Self-limiting m 57 4 NA NA NA 0 - - - 
T09.141 Self-limiting f 54 5 3.75 14 29 0 - - 17.3 
T09.146 Self-limiting m 32 8 2.95 10 10 0 - - 12.2 
T09.153 Self-limiting m 32 4 6.71 14 51 0 - - 7.5 
T09.160 Self-limiting m 74 6 4.77 13 45 0 - - 18.1 
T10.007 Self-limiting f 80 7 6.26 52 60 0 - - 15.6 
T10.027 Self-limiting f 53 4 3.34 0 13 0 - - 31.8 
T10.043 Self-limiting f 44 1 3.99 0 4 0 - - 20.6 
T10.113 Self-limiting m 34 2 4.06 7 51 0 - - 13.2 
T08.169 Not known m 27 7 3.54 9 19 0 - - 11.5 
T09.067 Not known - - - - - - - - - - 
T09.093 Not known m 62 4 3.13 12 7 85 - - 26.0 
T09.142 Not known f 43 5 3.48 6 18 0 - - 21.2 
T10.112 Not known f 23 9 5.85 40 26 0 - - 21.0 
T10.127 Not known f 44 2 3.01 0 14 0 - - 15.8 
T10.138 Not known m 55 11 3.52 6 2 0 - - 31.5 
T10.140 Not known - - - - - - - - - - 
T10.141 Not known f 24 11 3.80 66 79 0 - - 43.5 
T10.142 Not known f 39 8 4.73 15 27 0 - - 14.6 
T09.104 Established RA m 46 3 5.90 7 34 positive positive nil - 
  
Patient 
code 
Disease  
outcome 
Gender Age Symptom 
Duration  
(wks) 
DAS28  
(CRP) 
score 
CRP ESR RF CCP DMARD / 
Biological 
drugs 
25(OH)D3 
ng/ml 
T09.132 Established RA m 57 5 3.17 0 7 positive positive nil - 
T09.166 Established RA f 56  5.59 5 35 positive - nil - 
T10.010 Established RA f 35 2 1.67 0 9 positive positive Nil - 
T10.029 Established RA f 61 20 5.87 0 18 positive positive Nil - 
T10.033 Established RA m 21 <1 year 3.67 0 5 negative negative Nil - 
T10.114 Established RA f 75 40 4.49 49 55 negative positive methotrexate,  
sulfasalazine 
- 
T10.128 Established RA f 43 1 3.91 0 4 positive positive Nil - 
T10.139 Established RA f 57 1 7.91 59 91 positive positive Nil - 
T10.146 Established RA f 55 5 7.08 221 124 positive positive methotrexate - 
 
 
  
Table 9-2. Ex-vivo data for peripheral blood T cells from synovitis patients and controls. (- indicates that data could not be 
collected). 
Patient 
code 
Disease  
outcome 
CD3
+ 
(%)  
CD4
+
 
(% of 
CD3
+
) 
CD45-RO
+
  
(% of  
CD3
+
) 
IL17
+ 
IFN- 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
+
 
total 
(%) 
IFN+ 
total 
(%) 
TReg 
(%)  
TReg 
/T17 
ratio 
CTLA4 
MFI 
T08.187 RA 63.0 71.0 34.8 0.4 0.0 27.6 0.4 27.6 - - - 
T08.200 RA 59.6 70.9 36.3 0.8 0.2 17.4 0.9 17.6 2.9 3.2 - 
T09.064 RA 60.3 52.9 51.2 0.4 0.0 23.4 0.4 23.4 4.6 12.0 - 
T09.090 RA 63.2 74.8 49.2 1.0 0.4 14.8 1.4 15.2 5.5 4.0 - 
T09.108 RA 61.7 81.5 70.8 0.7 0.1 34.5 0.8 34.6 3.4 4.3 - 
T09.124 RA 55.1 72.3 60.8 0.6 0.0 20.6 0.6 20.6 6.2 10.2 - 
T09.145 RA 63.0 77.8 31.3 0.3 0.0 10.1 0.3 10.1 5.4 16.1 - 
T10.049 RA 54.1 73.5 63.6 0.8 0.1 26.6 0.9 26.7 6.3 7.3 - 
T10.058 RA 57.7 86.0 51.4 0.6 0.0 11.7 0.6 11.7 4.1 6.9 - 
T10.084 RA 58.2 85.1 45.6 1.9 0.5 15.7 2.3 16.2 3.9 1.7 29.9 
T10.118 RA 61.5 60.5 63.1 0.3 0.0 26.2 0.3 26.2 4.4 14.6 - 
T10.131 RA 67.5 60.9 36.5 0.1 0.0 10.4 0.2 10.4 2.4 13.1 20.2 
T08.179 Non-RA persistent 59.5 80.6 42.6 0.3 0.1 26.8 0.3 26.9 - - - 
T08.182 Non-RA persistent 44.8 54.9 50.4 0.8 0.3 24.1 1.1 24.4 - - - 
T08.203 Non-RA persistent 68.1 66.4 38.4 1.5 0.4 20.0 1.9 20.4 4.1 2.2 - 
T09.060 Non-RA persistent 63.7 63.6 58.9 0.2 0.0 5.1 0.2 5.1 6.9 33.9 - 
T09.136 Non-RA persistent 52.0 73.9 63.5 0.6 0.1 28.6 0.7 28.7 8.4 11.5 - 
T10.126 Non-RA persistent 38.6 58.8 49.4 0.5 0.1 22.0 0.6 22.1 11.3 19.8 56.8 
T08.147 Self-limiting 67.3 62.9 37.6 0.5 0.1 20.5 0.6 20.6 - - - 
T08.162 Self-limiting 66.8 66.5 33.5 0.3 0.1 12.8 0.4 12.9 - - - 
T08.170 Self-limiting 74.3 56.3 55.5 0.5 0.1 28.2 0.7 28.3 - - - 
T08.183 Self-limiting 58.5 71.4 50.2 1.8 0.5 23.1 2.4 23.6 - - - 
  
Patient 
code 
Disease  
outcome 
CD3
+ 
(%)  
CD4
+
 
(% of 
CD3
+
) 
CD45-RO
+
  
(% of  
CD3
+
) 
IL17
+ 
IFN- 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
+
 
total 
(%) 
IFN+ 
total 
(%) 
TReg 
(%)  
TReg 
/T17 
ratio 
CTLA4 
MFI 
T08.186 Self-limiting 82.2 77.2 38.0 0.6 0.1 19.0 0.7 19.1 - - - 
T09.103 Self-limiting 57.1 69.7 70.8 1.1 0.2 22.7 1.2 22.9 5.3 4.3 - 
T09.114 Self-limiting 56.6 67.2 52.8 0.5 0.1 21.8 0.6 21.9 2.8 4.8 - 
T09.133 Self-limiting 57.7 58.7 57.8 0.7 0.1 24.8 0.7 24.9 11.5 15.8 - 
T09.141 Self-limiting 56.5 66.5 82.2 0.4 0.0 31.1 0.5 31.1 7.2 15.1 - 
T09.146 Self-limiting 59.3 65.4 40.5 1.1 0.2 15.1 1.3 15.3 5.2 4.0 - 
T09.153 Self-limiting 69.0 57.0 66.9 1.0 0.2 27.5 1.3 27.7 6.8 5.3 - 
T09.160 Self-limiting 76.0 85.2 14.8 0.9 0.1 14.0 1.1 14.1 4.5 4.3 - 
T10.007 Self-limiting 56.7 55.6 53.7 1.1 0.2 28.5 1.3 28.7 5.4 4.1 - 
T10.027 Self-limiting 72.2 62.1 53.1 1.2 0.2 24.5 1.4 24.7 5.8 4.2 25.3 
T10.043 Self-limiting 61.3 79.5 50.9 0.6 0.1 19.4 0.7 19.5 3.8 5.3 40.1 
T10.113 Self-limiting 53.4 72.8 49.4 1.1 0.3 21.6 1.4 21.9 3.8 2.8 35.7 
T08.169 Not known 66.1 53.2 38.1 0.6 0.1 33.2 0.7 33.3 - - - 
T09.067 Not known 80.5 78.9 34.9 1.2 0.2 14.9 1.4 15.1 1.4 1.0 - 
T09.093 Not known 48.2 68.1 45.7 0.3 0.0 23.0 0.3 23.0 3.4 10.9 - 
T09.142 Not known 58.3 59.6 65.3 1.4 0.8 24.2 2.3 25.0 5.0 2.2 - 
T10.112 Not known 55.1 66.7 38.6 0.5 0.3 18.2 0.8 18.5 3.7 4.6 34.8 
T10.127 Not known 70.9 72.2 27.4 0.2 0.0 11.3 0.3 11.3 3.5 13.1 36.7 
T10.138 Not known 60.8 69.4 48.8 0.4 0.0 12.4 0.4 12.4 4.3 10.1 60.7 
T10.140 Not known 29.6 74.9 54.0 1.2 0.2 17.8 1.4 18.0 13.6 9.9 37.0 
T10.141 Not known 64.2 77.7 27.6 1.0 0.2 11.7 1.1 11.9 - - - 
T10.142 Not known 68.1 74.0 80.5 0.9 0.3 34.7 1.2 35.0 - - - 
T09.104 Established RA 50.7 67.2 89.1 0.8 0.3 28.6 1.1 28.9 11.5 10.7 - 
T09.132 Established RA 55.7 53.7 85.7 0.5 0.1 32.3 0.6 32.4 14.8 23.1 - 
T09.166 Established RA 67.3 68.8 44.1 0.5 0.1 25.5 0.6 25.6 5.6 9.4 - 
T10.010 Established RA 50.6 73.0 52.6 0.5 0.2 17.5 0.7 17.7 4.5 6.8 - 
T10.029 Established RA 63.7 63.8 62.4 0.7 0.1 28.2 0.8 28.3 4.9 6.0 31.7 
  
Patient 
code 
Disease  
outcome 
CD3
+ 
(%)  
CD4
+
 
(% of 
CD3
+
) 
CD45-RO
+
  
(% of  
CD3
+
) 
IL17
+ 
IFN- 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
+
 
total 
(%) 
IFN+ 
total 
(%) 
TReg 
(%)  
TReg 
/T17 
ratio 
CTLA4 
MFI 
T10.033 Established RA 68.9 58.5 48.9 0.6 0.3 22.1 0.9 22.4 3.8 4.3 41.0 
T10.114 Established RA 52.0 70.1 54.0 0.2 0.0 22.9 0.2 22.9 4.9 20.1 28.4 
T10.128 Established RA 78.6 64.9 45.8 0.4 0.0 22.4 0.5 22.4 4.4 9.4 41.3 
T10.139 Established RA 72.4 79.8 35.7 0.7 0.2 35.1 0.8 35.3 - - - 
T10.146 Established RA 49.9 50.0 68.4 0.3 0.1 38.9 0.4 39.0 13.3 35.0 24.8 
T09.137 Healthy control 55.9 48.9 59.3 0.7 0.2 29.0 0.9 29.2 9.5 10.1 - 
T09.138 Healthy control 60.7 67.0 58.0 0.6 0.1 27.5 0.8 27.6 3.1 4.1 - 
T09.139 Healthy control 56.1 56.0 54.2 0.4 0.1 23.0 0.6 23.1 4.4 7.7 - 
 
 
 
 
  
Table 9-3. IL-17 and IFN expression by peripheral blood T cells from synovitis patients and controls post seven-day stimulation in 
the presence or absence of 1,25(OH)2D3 (D3). (- indicates that data could not be collected). 
Patient  
code 
Disease  
outcome 
IL-17
+ 
IFN- 
(%) 
IL-17
+ 
IFN- 
(D3) 
(%) 
IL-17
+ 
IFN+ 
(%) 
IL-17
+ 
IFN+  
(D3) 
(%) 
IL-17 
IFN+ 
(%) 
IL-17
- 
IFN+ 
(D3) 
(%) 
IL-17
+
  
total 
(%) 
IL-17
+
  
total 
(D3) 
(%) 
IFN+ 
total 
(%) 
IFN+  
total 
(D3) 
(%) 
T08.187 RA 4.0 2.0 7.0 1.9 39.6 19.1 11.0 4.0 46.6 21.0 
T08.200 RA 22.3 4.1 9.9 1.6 12.1 12.9 32.2 5.6 22.0 14.5 
T09.064  RA 3.7 1.9 2.1 0.1 37.2 11.3 5.8 2.0 39.3 11.4 
T09.090  RA 14.6 2.4 11.5 0.7 12.9 11.5 26.1 3.2 24.4 12.2 
T09.108 RA 6.5 1.0 6.2 0.2 35.3 18.9 12.7 1.2 41.5 19.1 
T09.124 RA - - - - - - - - - - 
T09.145 RA 10.0 0.5 2.6 0.0 7.9 2.9 12.6 0.5 10.5 2.9 
T10.049 RA 12.6 0.2 4.9 0.0 28.1 15.2 17.5 0.2 33.0 15.2 
T10.058 RA 18.1 2.0 7.1 0.1 14.5 7.2 25.2 2.1 21.6 7.3 
T10.084 RA 21.4 0.9 11.6 0.1 10.4 14.3 33.0 1.1 22.0 14.4 
T10.118 RA 4.9 1.8 5.0 0.8 29.5 27.4 9.9 2.6 34.5 28.2 
T10.131 RA - - - - - - - - - - 
T08.179 Non-RA persistent 8.7 1.1 6.8 0.2 33.7 19.8 15.5 1.4 40.5 20.0 
T08.182 Non-RA persistent 4.2 14.4 10.6 21.1 48.9 16.3 14.8 35.5 59.5 37.4 
T08.203 Non-RA persistent 21.1 11.7 26.2 7.1 23.3 19.4 47.3 18.8 49.5 26.5 
T09.060 Non-RA persistent 22.3 7.3 17.8 2.5 22.1 16.2 40.1 9.8 39.9 18.7 
T09.136 Non-RA persistent  7.5 3.0 10.6 1.5 36.7 32.8 18.1 4.5 47.3 34.3 
T10.126 Non-RA persistent 11.3 1.4 2.5 0.2 11.1 13.9 13.8 1.5 13.6 14.1 
T08.147 Self-limiting 2.7 0.1 2.1 0.0 13.6 17.0 4.8 0.1 15.7 17.0 
T08.162 Self-limiting 10.1 0.7 10.0 0.2 17.0 8.8 20.1 0.9 27.0 9.0 
T08.170 Self-limiting 8.7 8.7 6.4 4.3 40.6 27.2 15.1 12.9 47.0 31.5 
T08.183 Self-limiting 5.5 5.0 6.6 4.1 30.4 26.7 12.1 9.1 37.0 30.8 
  
Patient  
code 
Disease  
outcome 
IL-17
+ 
IFN- 
(%) 
IL-17
+ 
IFN- 
(D3) 
(%) 
IL-17
+ 
IFN+ 
(%) 
IL-17
+ 
IFN+  
(D3) 
(%) 
IL-17 
IFN+ 
(%) 
IL-17
- 
IFN+ 
(D3) 
(%) 
IL-17
+
  
total 
(%) 
IL-17
+
  
total 
(D3) 
(%) 
IFN+ 
total 
(%) 
IFN+  
total 
(D3) 
(%) 
T08.186 Self-limiting - - - - - - - - - - 
T09.103  Self-limiting 16.2 2.2 13.1 0.4 26.4 19.3 29.3 2.6 39.5 19.7 
T09.114 Self-limiting 12.6 0.5 10.2 0.1 17.8 22.9 22.8 0.7 28.0 23.0 
T09.133 Self-limiting 16.2 1.7 8.3 0.4 16.9 10.2 24.5 2.2 25.2 10.6 
T09.141 Self-limiting 6.1 4.9 6.9 1.9 43.8 24.8 13.0 6.7 50.7 26.7 
T09.146 Self-limiting 15.9 0.6 7.8 0.1 9.7 11.0 23.7 0.8 17.5 11.1 
T09.153 Self-limiting - - - - - - - - - - 
T09.160 Self-limiting 10.2 5.7 8.5 2.1 25.2 13.4 18.7 7.8 33.7 15.5 
T10.007 Self-limiting 8.9 4.9 2.6 1.1 20.2 17.2 11.5 6.0 22.8 18.3 
T10.027 Self-limiting 7.3 1.9 6.1 0.9 22.5 13.4 13.4 2.8 28.6 14.3 
T10.043 Self-limiting 7.5 1.0 10.4 0.1 31.8 12.8 17.9 1.1 42.2 12.9 
T10.113 Self-limiting 11.4 1.6 18.4 1.1 22.5 21.2 29.8 2.7 40.9 22.3 
T08.169 Not known - - - - - - - - - - 
T09.067 Not known - - - - - - - - - - 
T09.093 Not known 2.1 0.8 4.8 0.4 69.6 39.6 6.9 1.2 74.4 40.0 
T09.142 Not known 16.6 2.1 17.3 0.8 12.5 16.1 33.9 2.9 29.8 16.9 
T10.112 Not known 1.0 0.0 0.8 0.0 9.3 8.4 1.8 0.0 10.1 8.4 
T10.127 Not known 1.0 0.2 0.9 0.0 19.4 4.3 1.9 0.2 20.3 4.3 
T10.138 Not known 2.5 0.9 4.5 0.5 28.0 11.8 7.0 1.4 32.5 12.3 
T10.140 Not known 12.2 1.3 6.7 0.3 13.6 11.3 18.9 1.6 20.3 11.6 
T10.141 Not known 13.0 5.0 15.5 2.6 17.7 17.0 28.5 7.6 33.2 19.6 
T10.142 Not known 2.4 2.9 4.3 1.8 36.6 25.6 6.7 4.7 40.9 27.4 
T09.104  Established RA 8.2 0.4 3.8 0.0 23.7 21.9 12.0 0.4 27.5 21.9 
T09.132 Established RA 18.2 3.3 13.2 0.8 28.5 28.8 31.4 4.0 41.7 29.6 
T09.166 Established RA 8.1 4.0 12.4 3.0 21.3 18.0 20.5 7.0 33.7 21.0 
T10.010 Established RA 10.7 0.6 12.7 0.3 17.8 21.7 23.4 0.9 30.5 22.0 
  
Patient  
code 
Disease  
outcome 
IL-17
+ 
IFN- 
(%) 
IL-17
+ 
IFN- 
(D3) 
(%) 
IL-17
+ 
IFN+ 
(%) 
IL-17
+ 
IFN+  
(D3) 
(%) 
IL-17 
IFN+ 
(%) 
IL-17
- 
IFN+ 
(D3) 
(%) 
IL-17
+
  
total 
(%) 
IL-17
+
  
total 
(D3) 
(%) 
IFN+ 
total 
(%) 
IFN+  
total 
(D3) 
(%) 
T10.029 Established RA 0.4 0.3 1.6 0.3 43.7 23.4 1.9 0.6 45.3 23.7 
T10.033 Established RA 3.1 1.7 12.0 2.6 37.4 24.3 15.1 4.4 49.4 26.9 
T10.114 Established RA - - - - - - - - - - 
T10.128 Established RA 0.9 0.5 3.0 0.5 22.6 17.5 3.9 1.0 25.6 18.0 
T10.139 Established RA 6.1 1.1 6.7 0.4 27.7 13.7 12.8 1.5 34.4 14.1 
T10.146 Established RA 0.9 0.8 0.9 0.3 23.3 19.4 1.8 1.1 24.2 19.7 
T09.137 Healthy control 7.3 0.4 6.1 0.1 26.5 25.9 13.4 0.5 32.6 26.0 
T09.138 Healthy control 6.4 0.3 9.8 0.1 34.4 30.1 16.2 0.3 44.2 30.2 
T09.139 Healthy control - - - - - - - - - - 
 
  
Table 9-4. Ex-vivo data for synovial fluid T cells from the joints of synovitis patients. (- indicates that data could not be collected).  
Patient 
code 
Disease 
outcome 
CD3
+
  
(%) 
CD4
+
   
(% of 
CD3
+
) 
CD45-RO
+
  
(% of 
CD3
+
) 
IL-17
+ 
IFN- 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
-
IFN+ 
(%) 
IL-17
+
 
total 
(%) 
IFN+ 
total 
(%) 
TReg 
(%) 
TReg/T17 
T08.187 RA - - - 0.1 0.3 82.2 0.4 82.5 - - 
T09.065 RA - - - 0.3 0.4 78.3 0.7 78.7 12.0 17.1 
T09.092 RA 64.4 62.6 98.4 0.8 0.8 61.5 1.6 62.3 13.7 8.5 
T10.084 RA - - - 1.9 1.2 44.5 3.1 45.7 27.6 9.0 
T08.203 Non-RA 
persistent 
87.3 54.4 100.0 1.6 3.8 78.7 5.3 82.5 9.4 1.8 
T10.126 Non-RA 
persistent 
58.7 55.3 99.3 0.9 3.1 74.5 4.0 77.6 9.5 2.4 
T08.162 Self-limiting - - - 0.2 0.4 67.6 0.6 68.0 - - 
T08.170 Self-limiting 73.3 33.8 97.8 0.1 0.8 79.2 0.9 80.0 - - 
T08.183 Self-limiting - - - 1.0 11.8 62.1 12.8 73.9 - - 
T09.106 Self-limiting - - - 3.2 3.6 81.2 6.8 84.8 20.8 3.1 
T09.141 Self-limiting - - - - - - - - - - 
T09.146 Self-limiting - - - 1.3 0.7 59.5 2.0 60.2 14.7 7.4 
T10.007 Self-limiting 79.6 42.5 99.6 0.6 0.7 76.7 1.4 77.4 10.7 7.9 
T10.113 Self-limiting 52.8 41.7 98.8 1.9 3.7 80.7 5.5 84.4 3.9 0.7 
T10.114 Established RA 45.7 54.6 97.7 0.2 0.0 57.8 0.2 57.8 13.0 59.1 
T10.146 Established RA 86.7 48.5 99.6 0.5 1.0 76.6 1.5 77.6 9.7 6.5 
 
  
Table 9-5. IL-17 and IFN expression by synovial fluid T cells from the joints of synovitis patients post  
seven-day stimulation in the presence or absence of 1,25(OH)2D3 (D3). (- indicates that data could not be collected) 
Patient  
code 
Disease  
outcome 
IL-17
+
 
IFN- 
(%) 
IL-17
+
 
IFN-  
(D3) 
(%) 
IL-17
+
 
IFN+ 
(%) 
IL-17
+
 
IFN+ 
(D3) 
(%) 
IL-17
- 
IFN+ 
(%) 
IL-17
-
 
IFN+ 
(D3) 
(%) 
IL-17
+
 
Total 
(%) 
IL-17
+
 
total  
(D3) 
(%) 
IFN+ 
total 
(%) 
IFN+ 
total  
(D3) 
(%) 
T08.187 RA - - - - - - - - - - 
T09.065 RA - - - - - - - - - - 
T09.092 RA 2.5 2.0 11.0 5.3 75.1 72.5 13.5 7.3 86.1 77.8 
T10.084 RA 1.8 1.2 3.4 1.1 65.0 57.1 5.2 2.3 68.4 58.2 
T08.203 Non-RA persistent 4.7 2.8 34.5 15.9 55.0 73.0 39.2 18.7 89.5 88.9 
T10.126 Non-RA persistent 1.1 1.0 2.2 1.3 55.2 60.1 3.4 2.3 57.4 61.4 
T08.162 Self-limiting - - - - - - - - - - 
T08.170 Self-limiting 0.3 0.4 4.4 1.9 78.6 90.1 4.7 2.4 83.0 92.0 
T08.183 Self-limiting           
T09.106 Self-limiting 11.4  19.3  55.9  30.7  75.2  
T09.141 Self-limiting - - - - - - - - - - 
T09.146 Self-limiting - - - - - - - - - - 
T10.007 Self-limiting - - - - - - - - - - 
T10.113 Self-limiting 5.9 5.0 24.9 11.1 55.6 64.2 30.8 16.1 80.5 75.3 
T10.114 Established RA - - - - - - - - - - 
T10.146 Established RA 2.9 2.2 7.2 3.8 55.0 62.1 10.0 6.0 62.2 65.9 
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